0001356576-22-000076.txt : 20221109 0001356576-22-000076.hdr.sgml : 20221109 20221109170704 ACCESSION NUMBER: 0001356576-22-000076 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 221373622 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 10-Q 1 supn-20220930.htm 10-Q supn-20220930
0001356576false12-312022Q3http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member0.0168545http://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent00013565762022-01-012022-09-3000013565762022-10-31xbrli:shares00013565762022-09-30iso4217:USD00013565762021-12-31iso4217:USDxbrli:shares0001356576us-gaap:ProductMember2022-07-012022-09-300001356576us-gaap:ProductMember2021-07-012021-09-300001356576us-gaap:ProductMember2022-01-012022-09-300001356576us-gaap:ProductMember2021-01-012021-09-300001356576us-gaap:RoyaltyMember2022-07-012022-09-300001356576us-gaap:RoyaltyMember2021-07-012021-09-300001356576us-gaap:RoyaltyMember2022-01-012022-09-300001356576us-gaap:RoyaltyMember2021-01-012021-09-3000013565762022-07-012022-09-3000013565762021-07-012021-09-3000013565762021-01-012021-09-300001356576us-gaap:CommonStockMember2021-12-310001356576us-gaap:AdditionalPaidInCapitalMember2021-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001356576us-gaap:RetainedEarningsMember2021-12-3100013565762022-01-012022-03-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001356576us-gaap:CommonStockMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001356576us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001356576srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001356576us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001356576us-gaap:CommonStockMember2022-01-012022-03-310001356576us-gaap:RetainedEarningsMember2022-01-012022-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001356576us-gaap:CommonStockMember2022-03-310001356576us-gaap:AdditionalPaidInCapitalMember2022-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001356576us-gaap:RetainedEarningsMember2022-03-3100013565762022-03-310001356576us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000013565762022-04-012022-06-300001356576us-gaap:CommonStockMember2022-04-012022-06-300001356576us-gaap:RetainedEarningsMember2022-04-012022-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001356576us-gaap:CommonStockMember2022-06-300001356576us-gaap:AdditionalPaidInCapitalMember2022-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001356576us-gaap:RetainedEarningsMember2022-06-3000013565762022-06-300001356576us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001356576us-gaap:CommonStockMember2022-07-012022-09-300001356576us-gaap:RetainedEarningsMember2022-07-012022-09-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001356576us-gaap:CommonStockMember2022-09-300001356576us-gaap:AdditionalPaidInCapitalMember2022-09-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001356576us-gaap:RetainedEarningsMember2022-09-300001356576us-gaap:CommonStockMember2020-12-310001356576us-gaap:AdditionalPaidInCapitalMember2020-12-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001356576us-gaap:RetainedEarningsMember2020-12-3100013565762020-12-310001356576us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100013565762021-01-012021-03-310001356576us-gaap:CommonStockMember2021-01-012021-03-310001356576us-gaap:RetainedEarningsMember2021-01-012021-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001356576us-gaap:CommonStockMember2021-03-310001356576us-gaap:AdditionalPaidInCapitalMember2021-03-310001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001356576us-gaap:RetainedEarningsMember2021-03-3100013565762021-03-310001356576us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000013565762021-04-012021-06-300001356576us-gaap:CommonStockMember2021-04-012021-06-300001356576us-gaap:RetainedEarningsMember2021-04-012021-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001356576us-gaap:CommonStockMember2021-06-300001356576us-gaap:AdditionalPaidInCapitalMember2021-06-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001356576us-gaap:RetainedEarningsMember2021-06-3000013565762021-06-300001356576us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001356576us-gaap:CommonStockMember2021-07-012021-09-300001356576us-gaap:RetainedEarningsMember2021-07-012021-09-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001356576us-gaap:CommonStockMember2021-09-300001356576us-gaap:AdditionalPaidInCapitalMember2021-09-300001356576us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001356576us-gaap:RetainedEarningsMember2021-09-3000013565762021-09-300001356576supn:AdamasPharmaceuticalsMember2021-11-242021-11-24supn:marketedProductsupn:segment0001356576us-gaap:AccountingStandardsUpdate202006Member2022-01-010001356576srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate202006Member2022-01-010001356576srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006Memberus-gaap:AdditionalPaidInCapitalMember2022-01-010001356576us-gaap:ConvertibleDebtMemberus-gaap:AccountingStandardsUpdate202006Member2022-01-012022-01-010001356576supn:AdamasPharmaceuticalsMember2021-11-24supn:right0001356576supn:AdamasPharmaceuticalsMembersrt:ScenarioPreviouslyReportedMember2021-11-240001356576supn:AdamasPharmaceuticalsMember2021-11-242022-06-300001356576supn:AdamasPharmaceuticalsMembersrt:ScenarioPreviouslyReportedMember2021-11-242021-11-240001356576supn:AdamasPharmaceuticalsMemberus-gaap:DevelopedTechnologyRightsMember2021-11-240001356576srt:MinimumMembersupn:AdamasPharmaceuticalsMemberus-gaap:DevelopedTechnologyRightsMember2020-01-012020-01-010001356576supn:AdamasPharmaceuticalsMembersrt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember2020-01-012020-01-010001356576supn:AdamasPharmaceuticalsMember2021-07-012021-09-300001356576supn:AdamasPharmaceuticalsMember2021-01-012021-09-300001356576supn:TrokendiXrMember2022-07-012022-09-300001356576supn:TrokendiXrMember2021-07-012021-09-300001356576supn:TrokendiXrMember2022-01-012022-09-300001356576supn:TrokendiXrMember2021-01-012021-09-300001356576supn:OxtellarXRMember2022-07-012022-09-300001356576supn:OxtellarXRMember2021-07-012021-09-300001356576supn:OxtellarXRMember2022-01-012022-09-300001356576supn:OxtellarXRMember2021-01-012021-09-300001356576supn:GOCOVRIMember2022-07-012022-09-300001356576supn:GOCOVRIMember2021-07-012021-09-300001356576supn:GOCOVRIMember2022-01-012022-09-300001356576supn:GOCOVRIMember2021-01-012021-09-300001356576supn:QelbreeMember2022-07-012022-09-300001356576supn:QelbreeMember2021-07-012021-09-300001356576supn:QelbreeMember2022-01-012022-09-300001356576supn:QelbreeMember2021-01-012021-09-300001356576supn:APOKYNMember2022-07-012022-09-300001356576supn:APOKYNMember2021-07-012021-09-300001356576supn:APOKYNMember2022-01-012022-09-300001356576supn:APOKYNMember2021-01-012021-09-300001356576us-gaap:ManufacturedProductOtherMember2022-07-012022-09-300001356576us-gaap:ManufacturedProductOtherMember2021-07-012021-09-300001356576us-gaap:ManufacturedProductOtherMember2022-01-012022-09-300001356576us-gaap:ManufacturedProductOtherMember2021-01-012021-09-300001356576supn:TrokendiXrMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-07-012022-09-30xbrli:pure0001356576supn:TrokendiXrMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012021-09-300001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembersupn:CardinalHealthMember2021-01-012021-09-300001356576supn:AmerisourceBergenDrugCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-09-300001356576supn:McKessonMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-09-300001356576supn:AmerisourceBergenDrugCorporationMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001356576us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembersupn:CardinalHealthMember2022-01-012022-09-300001356576supn:McKessonMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001356576supn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-09-300001356576supn:ThreeMajorCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001356576supn:NavitorPharmaceuticalsIncMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-04-012020-04-300001356576supn:NavitorPharmaceuticalsIncMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2020-04-300001356576supn:NavitorPharmaceuticalsIncMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2021-03-3100013565762021-12-012021-12-310001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:FairValueInputsLevel3Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2022-09-300001356576us-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2022-09-300001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2022-09-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2022-09-300001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2022-09-300001356576us-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001356576us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-12-310001356576us-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembersupn:CorporateAndMunicipalDebtSecuritiesMember2021-12-310001356576us-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001356576us-gaap:FairValueInputsLevel2Member2022-09-300001356576us-gaap:FairValueInputsLevel2Member2021-12-3100013565762020-06-092020-06-090001356576supn:SPN830RegulatoryAndCommercialActivitiesMember2020-06-092020-06-090001356576supn:SPN830FDAAcceptanceMilestoneMember2020-06-092020-06-090001356576supn:SPN830NDAApprovalMilestoneMember2020-06-092020-06-090001356576supn:SPN830NDAApprovalMilestoneTimeBasedMember2020-06-092020-06-090001356576supn:SPN830NDAApprovalMilestoneApprovalBasedMember2022-01-012022-09-300001356576supn:SPN830FutureSalesPerformanceMember2020-06-092020-06-090001356576supn:SPN830FirstCommercialAndSaleMember2020-06-092020-06-090001356576supn:APOKYNMember2020-06-092020-06-090001356576supn:APOKYNAndSPN830Member2020-06-092020-06-090001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-07-012022-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-01-012022-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-07-012021-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-01-012021-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-04-012021-06-300001356576supn:AdamasPharmaceuticalsMember2022-07-012022-09-300001356576supn:AdamasPharmaceuticalsMember2022-01-012022-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2021-12-310001356576supn:AdamasMember2021-12-310001356576supn:AdamasMember2022-01-012022-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember2022-09-300001356576supn:AdamasMember2022-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMembersupn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2022-09-300001356576supn:AdamasMembersupn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2022-09-300001356576supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember2022-09-300001356576supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMembersupn:SalesBasedContingentConsiderationLiabilityMember2022-09-300001356576supn:SalesBasedContingentConsiderationLiabilityMembersupn:AdamasMember2022-09-300001356576supn:SalesBasedContingentConsiderationLiabilityMember2022-09-300001356576us-gaap:InProcessResearchAndDevelopmentMember2022-09-300001356576us-gaap:InProcessResearchAndDevelopmentMember2021-12-310001356576us-gaap:DevelopedTechnologyRightsMember2022-01-012022-09-300001356576us-gaap:DevelopedTechnologyRightsMember2022-09-300001356576us-gaap:DevelopedTechnologyRightsMember2021-12-310001356576supn:PatentDefenseCostsMember2022-01-012022-09-300001356576supn:PatentDefenseCostsMember2022-09-300001356576supn:PatentDefenseCostsMember2021-12-310001356576supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember2022-07-012022-09-300001356576supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember2022-01-012022-09-300001356576supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember2021-07-012021-09-300001356576supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember2021-01-012021-09-300001356576us-gaap:ConvertibleDebtMember2018-03-310001356576us-gaap:ConvertibleDebtMember2022-09-300001356576supn:ConversionCircumstanceOneMemberus-gaap:ConvertibleDebtMember2018-03-012018-03-31supn:day0001356576us-gaap:ConvertibleDebtMembersupn:ConversionCircumstanceTwoMember2018-03-012018-03-31utr:Rate0001356576us-gaap:ConvertibleDebtMember2018-03-012018-03-3100013565762018-03-310001356576us-gaap:ConvertibleDebtMember2021-12-310001356576us-gaap:ConvertibleDebtMember2021-12-312021-12-310001356576us-gaap:ConvertibleDebtMember2022-09-302022-09-300001356576us-gaap:ConvertibleDebtMember2022-01-012022-09-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001356576us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001356576us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300001356576supn:StockOptionStockAppreciationRightsMember2021-12-310001356576supn:StockOptionStockAppreciationRightsMember2021-01-012021-12-310001356576supn:StockOptionStockAppreciationRightsMember2022-01-012022-09-300001356576supn:StockOptionStockAppreciationRightsMember2022-09-300001356576us-gaap:RestrictedStockUnitsRSUMember2021-12-310001356576us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001356576us-gaap:RestrictedStockUnitsRSUMember2022-09-300001356576supn:PerformanceBasedUnitsMember2021-12-310001356576supn:MarketBasedUnitsMember2021-12-310001356576us-gaap:PerformanceSharesMember2021-12-310001356576supn:PerformanceBasedUnitsMember2022-01-012022-09-300001356576supn:MarketBasedUnitsMember2022-01-012022-09-300001356576us-gaap:PerformanceSharesMember2022-01-012022-09-300001356576supn:PerformanceBasedUnitsMember2022-09-300001356576supn:MarketBasedUnitsMember2022-09-300001356576us-gaap:PerformanceSharesMember2022-09-300001356576us-gaap:ConvertibleDebtSecuritiesMember2022-07-012022-09-300001356576us-gaap:ConvertibleDebtSecuritiesMember2021-07-012021-09-300001356576us-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-09-300001356576us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-09-300001356576us-gaap:StockCompensationPlanMember2022-07-012022-09-300001356576us-gaap:StockCompensationPlanMember2021-07-012021-09-300001356576us-gaap:StockCompensationPlanMember2022-01-012022-09-300001356576us-gaap:StockCompensationPlanMember2021-01-012021-09-300001356576us-gaap:ConvertibleDebtMemberus-gaap:AccountingStandardsUpdate202006Member2022-01-012022-09-3000013565762019-02-0100013565762021-11-24supn:renewalOption0001356576supn:AdamasPharmaceuticalsMember2022-01-012022-03-310001356576supn:LabEquipmentAndFurnitureMember2022-09-300001356576supn:LabEquipmentAndFurnitureMember2021-12-310001356576us-gaap:LeaseholdImprovementsMember2022-09-300001356576us-gaap:LeaseholdImprovementsMember2021-12-310001356576us-gaap:ComputerSoftwareIntangibleAssetMember2022-09-300001356576us-gaap:ComputerSoftwareIntangibleAssetMember2021-12-310001356576us-gaap:ComputerEquipmentMember2022-09-300001356576us-gaap:ComputerEquipmentMember2021-12-310001356576us-gaap:ConstructionInProgressMember2022-09-300001356576us-gaap:ConstructionInProgressMember2021-12-3100013565762014-09-30iso4217:EUR0001356576supn:MDDSubsidiariesMember2019-03-012019-03-310001356576supn:NAMENDAXRNamzaricQuiTamLitigationMember2019-04-012019-04-01
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                 to              
Commission File Number: 001-35518
SUPERNUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware20-2590184
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
9715 Key West Avenue
Rockville MD20850
(Address of principal executive offices)(Zip Code)
(301) 838-2500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  ☒ Yes  ☐ No
Indicate by check mark whether the registrant has submitted electronically pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒
Accelerated filer ☐
Non-accelerated filer ☐Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  ☐ Yes  ☒ No
Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each classOutstanding at October 31, 2022Trading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per share54,058,138SUPNThe Nasdaq Global Market
1
SUPERNUS PHARMACEUTICALS, INC.
FORM 10-Q — QUARTERLY REPORT
FOR THE QUARTERLY PERIOD ENDED September 30, 2022
Page No.
2
PART I — FINANCIAL INFORMATION

Supernus Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)
September 30,December 31,
20222021
(unaudited)
Assets
Current assets
Cash and cash equivalents$111,492 $203,434 
Marketable securities280,297 136,246 
Accounts receivable, net164,086 148,932 
Inventories, net83,165 85,959 
Prepaid expenses and other current assets24,846 27,019 
Total current assets663,886 601,590 
Long-term marketable securities131,937 119,166 
Property and equipment, net15,872 16,955 
Intangible assets, net722,761 784,693 
Goodwill117,383 117,516 
Other assets41,290 49,232 
Total assets$1,693,129 $1,689,152 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable and accrued liabilities$110,302 $117,683 
Accrued product returns and rebates158,470 132,724 
Contingent consideration, current portion47,590 44,840 
Convertible notes, net401,438 — 
Other current liabilities8,187 20,132 
Total current liabilities725,987 315,379 
Convertible notes, net— 379,252 
Contingent consideration, long-term9,781 35,637 
Operating lease liabilities, long-term36,028 41,298 
Deferred income tax liabilities58,164 85,355 
Other liabilities10,371 16,380 
Total liabilities840,331 873,301 
Stockholders’ equity
Common stock, $0.001 par value; 130,000,000 shares authorized; 54,053,513 and 53,256,094 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively
54 53 
Additional paid-in capital401,026 434,337 
Accumulated other comprehensive earnings (loss), net of tax(4,046)1,539 
Retained earnings455,764 379,922 
Total stockholders’ equity852,798 815,851 
Total liabilities and stockholders’ equity$1,693,129 $1,689,152 



See accompanying notes.
3
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Earnings
(in thousands, except share and per share data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
(unaudited)(unaudited)
Revenues
Net product sales$172,724 $145,532 $485,647 $412,541 
Royalty revenues4,629 2,932 14,263 8,184 
Total revenues177,353 148,464 499,910 420,725 
Costs and expenses
Cost of goods sold (a)
25,878 18,085 64,267 58,067 
Research and development19,554 19,654 56,778 69,389 
Selling, general and administrative112,314 72,032 303,249 203,024 
Amortization of intangible assets20,644 6,009 61,932 17,964 
Contingent consideration expense (gain)486 80 1,894 (7,650)
Total costs and expenses178,876 115,860 488,120 340,794 
Operating earnings (loss)(1,523)32,604 11,790 79,931 
Other income (expense)
Interest expense(1,724)(5,925)(5,476)(17,489)
Interest and other income, net2,803 2,281 19,289 8,682 
Total other income (expense)1,079 (3,644)13,813 (8,807)
Earnings (Loss) before income taxes(444)28,960 25,603 71,124 
Income tax (benefit) expense(2,193)7,398 (9,627)20,142 
Net earnings$1,749 $21,562 $35,230 $50,982 
Earnings per share
Basic$0.03 $0.41 $0.66 $0.96 
Diluted$0.03 $0.40 $0.62 $0.94 
Weighted average shares outstanding
Basic53,789,674 53,187,764 53,517,838 53,053,441 
Diluted55,034,838 54,334,794 61,543,121 54,301,461 
______________________________
(a) Excludes amortization of acquired intangible assets




See accompanying notes.
4
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Comprehensive Earnings (Loss)
(in thousands)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
(unaudited)(unaudited)
Net earnings$1,749 $21,562 $35,230 $50,982 
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax(1,826)(1,224)(5,585)(4,766)
Other comprehensive loss(1,826)(1,224)(5,585)(4,766)
Comprehensive earnings (loss)$(77)$20,338 $29,645 $46,216 























See accompanying notes.
5
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(unaudited, in thousands, except share data)
jCommon StockAdditional 
Paid-in Capital		Accumulated Other
Comprehensive
Earnings (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmount
Balance, December 31, 202153,256,094 $53 $434,337 $1,539 $379,922 $815,851 
Cumulative effect of adoption of ASU 2020-06— — (56,212)— 40,612 (15,600)
Balance, January 1, 202253,256,094 53 378,125 1,539 420,534 800,251 
Share-based compensation— — 4,025 — — 4,025 
Issuance of common stock in connection with the Company’s equity award plans130,211 — 866 — — 866 
Net earnings— — — — 25,616 25,616 
Unrealized loss on marketable securities, net of tax— — — (2,312)— (2,312)
Balance, March 31, 202253,386,305 53 383,016 (773)446,150 828,446 
Share-based compensation— — 4,297 — — 4,297 
Issuance of common stock in connection with the Company’s equity award plans106,081 — 2,273 — — 2,273 
Net earnings— — — — 7,865 7,865 
Unrealized loss on marketable securities, net of tax— — — (1,447)— (1,447)
Balance, June 30, 202253,492,386 $53 $389,586 $(2,220)$454,015 $841,434 
Share-based compensation— — 4,985 — — 4,985 
Issuance of common stock in connection with the Company’s equity award plans561,127 1 6,455 — — 6,456 
Net earnings— — — — 1,749 1,749 
Unrealized loss on marketable securities, net of tax — — — (1,826)— (1,826)
Balance, September 30, 202254,053,513 $54 $401,026 $(4,046)$455,764 $852,798 























6
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(unaudited, in thousands, except share data)
Common StockAdditional 
Paid-in Capital		Accumulated Other
Comprehensive
Earnings (Loss)		Retained
Earnings		Total
Stockholders’
Equity
SharesAmount
Balance, December 31, 202052,868,482 $53 $409,332 $8,975 $326,498 $744,858 
Share-based compensation— — 4,371 — — 4,371 
Issuance of common stock in connection with the Company’s equity award plans125,655 — 2,247 — — 2,247 
Net earnings— — — — 5,694 5,694 
Unrealized loss on marketable securities, net of tax— — — (2,726)— (2,726)
Balance, March 31, 202152,994,137 53 415,950 6,249 332,192 754,444 
Share-based compensation— — 5,476 — — 5,476 
Issuance of common stock in connection with the Company’s equity award plans150,622 — 2,749 — — 2,749 
Net earnings— — — — 23,726 23,726 
Unrealized loss on marketable securities, net of tax— — — (816)— (816)
Balance, June 30, 202153,144,759 $53 $424,175 $5,433 $355,918 $785,579 
Share-based compensation— $— $4,027 $— $— $4,027 
Issuance of common stock in connection with the Company’s equity award plans35,884 $— $524 $— $— $524 
Net earnings— $— $— $— $21,562 $21,562 
Unrealized loss on marketable securities, net of tax— $— $— $(1,224)$— $(1,224)
Balance, September 30, 202153,180,643 $53 $428,726 $4,209 $377,480 $810,468 













See accompanying notes.
7
Supernus Pharmaceuticals, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
Nine Months Ended September 30,
20222021
(unaudited)
Cash flows from operating activities
Net earnings$35,230 $50,982 
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization64,694 19,888 
Navitor investment R&D expense (see Note 5)— 15,000 
Other income from Navitor (see Note 5)(12,888)— 
Amortization of deferred financing costs and debt discount1,582 13,037 
Realized gains from sales of marketable securities(14)(221)
Amortization of premium/discount on marketable securities3,215 (845)
Change in fair value of contingent consideration1,894 (7,650)
Other noncash adjustments, net7,983 (22)
Share-based compensation expense13,307 13,874 
Deferred income tax provision(18,564)(479)
Changes in operating assets and liabilities:
Accounts receivable(14,958)7,352 
Inventories(6,304)(9,331)
Prepaid expenses and other assets3,098 (13,351)
Accrued product returns and rebates25,746 5,856 
Accounts payable and other liabilities(12,659)(15,726)
Contingent consideration(2,100)— 
Net cash provided by operating activities89,262 78,364 
Cash flows from investing activities
Purchases of marketable securities(340,665)(307,634)
Sales and maturities of marketable securities173,189 152,546 
Purchase of property and equipment and deferred legal fees paid(422)(2,005)
Acquisition of USWM, net of cash acquired— (950)
Net cash used in investing activities(167,898)(158,043)
Cash flows from financing activities
Payment of contingent consideration(22,900)— 
Proceeds from issuance of common stock9,594 5,520 
Proceeds from governmental loan and grant— 800 
Net cash (used in) provided by financing activities(13,306)6,320 
Net change in cash and cash equivalents(91,942)(73,359)
Cash and cash equivalents at beginning of year203,434 288,640 
Cash and cash equivalents at end of period$111,492 $215,281 
Supplemental cash flow information
Cash paid for interest on convertible notes$2,516 $1,887 
Cash paid for income taxes14,558 25,111 
Cash paid for operating leases9,547 7,613 
Noncash investing and financing activities
Lease assets obtained for new operating leases$973 $4,120 
Deferred legal fees and fixed assets included in accounts payable and accrued expenses144 186 
Property and equipment additions from utilization of tenant improvement allowance580 — 
See accompanying notes.
8
Supernus Pharmaceuticals, Inc.
Notes to Condensed Consolidated Financial Statements (unaudited)
1.    Business Organization
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•Qelbree® (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company launched Qelbree for adult patients in May 2022.
•GOCOVRI® (amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
•Osmolex ER® (amantadine) extended-release is a once-daily product for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
Product Candidates
The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following:
•SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. In October 2022, the FDA issued a Complete Response Letter (CRL) regarding the NDA for SPN-830. Refer to Note 17, Subsequent Events.
•SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).
•SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development.
9
Adamas Acquisition and Reorganization
On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas, pursuant to the Adamas Agreement dated October 10, 2021, and the Purchaser was merged with and into Adamas (the Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and Osmolex ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.
In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, Income Tax (Benefit) Expense.)
COVID-19 Impact
The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of September 30, 2022.
Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.
2.    Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Consolidation
The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.
The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to
10
liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the fair values of financial instruments and the recoverability of intangible assets, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as television, print media, digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $52.0 million and $112.8 million in advertising expense for the three and nine months ended September 30, 2022, respectively, and approximately $22.6 million and $59.7 million for the three and nine months ended September 30, 2021, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
Accounting Standards Update (ASU) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.
The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method.
ASU 2021-10, Government Assistance (Topic 832) - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific U.S. GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.
11
3. Acquisition
Adamas Acquisition
In connection with the Adamas Acquisition (see Note 1), the Company paid the Adamas shareholders $400.8 million and transferred two non-tradable contingent value rights (CVRs). Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once.
In connection with the two CVRs, the Company recorded contingent consideration liabilities of $10.3 million as of the date of the acquisition, to reflect the estimated fair value of the contingent consideration. The estimated fair values of the contingent consideration liabilities were determined using Monte Carlo simulations. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs and thus represent Level 3 fair value measurements. The key assumptions considered include the estimated amount and timing of projected revenues, volatility, estimated discount rates and the risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liabilities and will record increases or decreases in the fair value of the liabilities in its consolidated statements of earnings. Changes in fair value will result from actual milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but they reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.
The acquisition was accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill, have been included in the Company's consolidated financial statements since the acquisition Closing Date.
The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed. The activities the Company is currently undertaking include review and evaluation of the tax positions, and other tax-related matters. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date are subject to change.
12
The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):
As Initially Reported
Measurement Period Adjustments (1)
As Adjusted
(unaudited)(unaudited)
Cash and cash equivalents$90,064 $— $90,064 
Accounts receivable11,156 — 11,156 
Inventories20,200 — 20,200 
Prepaid expenses and other current assets5,077 — 5,077 
Property and equipment1,254 — 1,254 
Intangibles450,100 — 450,100 
Other assets(2)
6,442 (1,620)4,822 
Total fair value of assets acquired584,293 (1,620)582,673 
Accounts payable(4,592)— (4,592)
Accrued expenses and other current liabilities(8,014)— (8,014)
Current debt(138,315)— (138,315)
Operating lease liabilities, long-term(5,224)— (5,224)
Deferred income tax liabilities(2)(3)
(56,588)1,753 (54,835)
Total fair value of liabilities assumed(212,733)1,753 (210,980)
Total identifiable net assets371,560 133 371,693 
Goodwill39,553 (133)39,420 
Total purchase price$411,113 $— $411,113 
Cash consideration paid$400,806 $— $400,806 
Fair value of contingent consideration10,307 — 10,307 
Total purchase price$411,113 $— $411,113 
______________________________
(1) Measurement period adjustments reflect changes for the nine months ended September 30, 2022 based on information related to the facts and circumstances that existed as of the Closing Date.
(2) Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease recorded in the first quarter of 2022. Refer to Note 13, Leases.
(3) Represents tax impact for the changes in fair value estimate of the right of use asset and changes made to finalize the accounting of certain state tax attributes which existed at the opening balance sheet date.
Acquired Inventory
The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or dispose of the inventory, as well as a profit on the sale.
Acquired Intangible Assets
The acquired intangible assets include the acquired developed technology and product rights to GOCOVRI and Osmolex ER, as well as the right to receive royalties from Allergan plc for sales of Namzaric. The Company determined the estimated fair values for the acquired intangible assets as of the Closing Date using the income approach. This is a valuation technique that provides an estimate of fair value of the assets, based on the market participant's expectations of the cash flows that the assets are forecasted to generate. The cash flows were discounted at a rate commensurate with the level of risk associated with its projected cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value.
13
The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and thus represent Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation includes: the estimated future cash flows from product sales, the timing and projection of costs and expenses, discount rates and tax rates.
Acquired intangible assets consist of developed technology and product rights and are amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation and the average remaining useful lives for identifiable intangible assets (dollars in thousands):
Estimated Fair ValueEstimated Useful Life as of Closing Date (in years)
Acquired developed technology and product rights$450,100 
3.1 - 8.1
Goodwill
Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is primarily attributable to the anticipated cost synergies, additional growth platforms, and an expanded revenue base with the addition of the assets from the Adamas Acquisition. The goodwill is not expected to be deductible for tax purposes.
Acquired Deferred Income Tax Liabilities, net
The deferred income tax liabilities, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. The acquired federal and state net operating loss carryforwards are reduced by a valuation allowance for amounts that are not expected to be realizable in the future. The reported measurement period adjustment of $1.8 million for the nine months ended September 30, 2022 consisted of a reduction to deferred tax liabilities of $3.7 million recorded in the first quarter of 2022 and an increase to deferred tax liabilities of $1.9 million recorded in the third quarter of 2022.
Revenue and Net Earnings of Adamas
The operations of Adamas and its subsidiaries have been included in the Company's consolidated statements of earnings for the periods subsequent to the Closing Date.
Pro Forma Information
The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
20212021
Pro forma total revenues$174,360 $487,904 
Pro forma net loss(10,405)(30,905)
The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition on January 1, 2020, the unaudited pro forma combined financial information reflects the recognition of additional amortization expense on intangible assets and estimated additional cost of products sold related to the inventory step-up adjustment; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Adamas Acquisition, and the estimated tax impact of the pro forma adjustments.
The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.
14
4. Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):
Three Months Ended
September 30,		 Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Net product sales
Trokendi XR$69,599 $80,935 $204,033 $231,531 
Oxtellar XR30,528 29,728 88,007 82,120 
GOCOVRI27,878 — 75,179 — 
Qelbree18,326 2,370 37,708 2,685 
APOKYN$18,261 $24,627 $57,156 $73,338 
Other(1)
8,132 7,872 23,564 22,867 
Total net product sales$172,724 $145,532 $485,647 $412,541 
Royalty revenues4,629 2,932 14,263 8,184 
Total revenues$177,353 $148,464 $499,910 $420,725 
______________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
Trokendi XR accounted for more than 40% of the Company’s total net product sales for both the three and nine months ended September 30, 2022, and 56% of the Company's total net product sales for both the three and nine months ended September 30, 2021, respectively.
Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales for both the nine months ended September 30, 2022 and 2021, and collectively accounted for more than 80% and 85% of our total net product sales for the nine months ended September 30, 2022 and 2021, respectively.
Royalty revenues include noncash royalty revenues. The Company recognized noncash royalty revenue of $2.5 million and $7.2 million, for the three and nine months ended September 30, 2022, respectively. The Company recognized noncash royalty revenue of $2.4 million and $6.8 million, for the three and nine months ended September 30, 2021, respectively. Refer to Note 16, Commitments and Contingencies.
5. Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):
September 30,
2022		December 31,
2021
(unaudited)
Corporate and U.S. government agency and municipal debt securities
Amortized cost$417,576 $253,301 
Gross unrealized gains— 2,349 
Gross unrealized losses(5,342)(238)
Total fair value$412,234 $255,412 
15
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
September 30,
2022
(unaudited)
Less than 1 year$280,297 
1 year to 2 years104,346 
2 years to 3 years27,591 
3 years to 4 years— 
Greater than 4 years— 
Total$412,234 
As of September 30, 2022, there was no impairment due to credit loss on any available-for-sale marketable securities.
Investment in Navitor
Development Agreement
In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required.
Equity investment
In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc.
In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals LLC (Navitor LLC), and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Units in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.
The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance.
Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company's ability to exert significant influence over but not control the financial and operating decisions of Navitor LLC. As a result of the change from a cost method investment to an equity method investment, the Company was required to measure its investment initially in accordance with the guidance in ASC 805. The majority of the assets and liabilities recorded in Navitor LLC's financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company's investment in Navitor LLC, which created a significant basis difference for the Company's investment in the underlying net assets. The Company determined that substantially all of the fair value of the investment was attributable to a single in-process research and development (IPR&D) asset. As a result, Navitor LLC was not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in Other assets in the condensed consolidated balance sheets, was expensed and recorded in Research and development expense in the condensed consolidated statements of earnings.
16
The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. In December 2021, Navitor LLC sold one of its subsidiaries and distributed cash to its members in accordance with each member's share of the proceeds from the sale. The Company received $12.9 million in December 2021 from Navitor LLC in connection with this sale. As the Company's policy is to record its share of the results in its equity method investment on a quarter lag as previously indicated, the Company recorded the cash amount received in Other current liabilities in the consolidated balance sheets as of December 31, 2021. In the first quarter of 2022, the Company determined its estimated share of Navitor LLC's year-end 2021 earnings and recorded a gain of $12.9 million in Interest and other income, net in the condensed consolidated statement of earnings.
The maximum exposure to losses related to Navitor LLC is approximately $50 million for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.
Subsequent to the Development Agreement entered into in 2020, no additional equity investment has been made or financing has been provided to Navitor LLC.
6.    Fair Value of Financial Instruments
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. The fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
The fair value of the restricted marketable securities which are classified as Level 2 financial assets are recorded in Other assets on the condensed consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
17
Financial Assets and Liabilities Recorded at Fair Value on a Recurring Basis
The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements at September 30, 2022 (unaudited)
Total Fair Value at September 30,
2022		Level 1Level 2Level 3
Assets:(unaudited)
Cash and cash equivalents
Cash$111,087 $111,087 $— $— 
Money market funds405 405 — — 
Marketable securities
Corporate and municipal debt securities280,297 — 280,297 — 
Long term marketable securities
Corporate and municipal debt securities131,937 — 131,937 — 
Other noncurrent assets
Marketable securities - restricted (SERP)464 9 455 — 
Total assets at fair value$524,190 $111,501 $412,689 $— 
Liabilities:
Contingent consideration $57,371 $— $— $57,371 
Total liabilities at fair value$57,371 $— $— $57,371 
Fair Value Measurements at December 31, 2021
Total Fair Value at December 31,
2021		Level 1Level 2Level 3
Assets:
Cash and cash equivalents
Cash$148,863 $148,863 $— $— 
Money market funds54,571 54,571 — — 
Marketable securities
Corporate and municipal debt securities136,246 251 135,995 — 
Long term marketable securities
Corporate and municipal debt securities119,166 — 119,166 — 
Other noncurrent assets
Marketable securities - restricted (SERP)630 7 623 — 
Total assets at fair value$459,476 $203,692 $255,784 $— 
Liabilities:
Contingent consideration$80,477 $— $— $80,477 
Total liabilities at fair value$80,477 $— $— $80,477 
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities.
Financial Liabilities Recorded at Carrying Value
The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands):
18
September 30, 2022December 31, 2021
(unaudited)
Carrying ValueFair Value (Level 2)Carrying ValueFair Value (Level 2)
2023 Notes$401,438 $392,438 $379,252 $400,236 
The fair value has been estimated based on actual trading information, and quoted prices, both provided by bond traders. As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption.
7.    Contingent Consideration
The Company's contingent consideration liabilities are related to the USWM Acquisition (as defined below) and the Adamas Acquisition. The contingent consideration liabilities are measured at fair value on a recurring basis using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement.
USWM Contingent Consideration
On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments of up to $230 million comprised of the following:
•Regulatory and developmental milestones - gross contingent consideration of up to $130 million contingent upon achievement of regulatory and developmental milestones.
This includes a $25 million milestone due upon the FDA acceptance of the SPN-830 NDA for review, which was paid in the first quarter of 2022. This milestone payment is reported under both financing and operating activities in the condensed consolidated statements of cash flows. Of the $25 million payment, $22.9 million represents the acquisition date fair value of the contingent consideration liability and was reported under cash flows from financing activities. The remaining $2.1 million represents the excess of the acquisition date fair value and was reported under cash flows from operating activities.
The remaining $105 million is comprised of amounts due upon achievement of certain FDA's regulatory approval and commercial launch of SPN-830. This includes a $50 million milestone which has a time-based mechanism for full or partial payment. As of September 30, 2022, the achievement of this milestone is remote. The remaining $55 million, which does not have a time-based mechanism for payment, relates to the FDA's approval of the SPN-830 NDA and the subsequent commercial product launch. Refer to Note 1, Business Organization and Note 17, Subsequent Events.
•Sales-based milestones consist of gross contingent consideration payments of up to $100 million related to future sales performance of the acquired USWM products. Of the $100 million sales-based contingent consideration, a $35 million milestone due upon the achievement of certain U.S. net product sales of APOKYN in 2021 was not achieved. The remaining $65 million relates to the achievement of certain net product sales of the acquired USWM products in 2022 and 2023. As of September 30, 2022, the Company assessed that the remaining sales-based milestones will not be achieved based on net sales projections.
The change in fair value is reported on the condensed consolidated statement of earnings in Contingent consideration expense (gain). The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, discount rate, the estimated revenue volatility and the estimated amount and timing of projected revenues from the acquired USWM products.
The Company recorded a $0.4 million expense and a $2.4 million expense due to the change in fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2022, respectively. The change in the fair value of contingent consideration for USWM milestones was primarily driven by the increase in estimated fair value of regulatory and developmental milestones due to passage of time and the accretion to the payout amount related to the milestone achieved in the first quarter of 2022.
19
The Company recorded a $0.1 million expense and a $7.7 million gain due to the change in fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2021, respectively. In the second quarter of 2021, the Company recorded a change in fair value of $7.7 million, which was primarily due to the write-down of the sales-based contingent consideration. The Company assessed that the sales-based milestones will not be achieved based on the revised net sales projections.
Adamas Contingent Consideration
As discussed in Note 3, Acquisition, the Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI.
During the measurement period, changes in the fair value of contingent consideration related to the Adamas Acquisition are recorded against goodwill if such changes are related to facts and circumstances that existed at the acquisition date. In each reporting period after the acquisition, the Company remeasures the fair value of contingent consideration liabilities and records in its consolidated statements of earnings the increases or decreases in the fair value of the liabilities. The Company recorded a $0.1 million expense and a $0.5 million gain due to the change in fair value of the contingent consideration liabilities for the three and nine months ended September 30, 2022, respectively. The change in fair value was reported on the condensed consolidated statement of earnings in Contingent consideration expense (gain).
The change in estimated fair value of contingent consideration for the sales-based Adamas milestones was primarily due to changes in market data and the passage of time. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated amount and timing of projected revenues, volatility, estimated discount rates and risk-free interest rate. Refer to Note 3, Acquisition, for further discussion of significant inputs and assumptions used in the valuation of the contingent consideration for the Adamas Acquisition.
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2021$70,170 $10,307 $80,477 
Milestone payments(25,000)— (25,000)
Change in fair value recognized in earnings2,420 (526)1,894 
Balance at September 30, 2022 (unaudited)$47,590 $9,781 $57,371 
Regulatory and developmental contingent consideration liabilities$47,590 $— $47,590 
Sales-based contingent consideration liabilities— 9,781 9,781 
Balance at September 30, 2022 (unaudited)$47,590 $9,781 $57,371 
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
September 30,
2022		December 31,
2021
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$47,590 $44,840 
Contingent consideration, long-term9,781 35,637 
Total$57,371 $80,477 
20
8.    Goodwill and Intangible Assets, Net
Goodwill
The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):
Balance as of December 31, 2021
$117,516 
Measurement period adjustments related to the acquisition of Adamas (see Note 3)(133)
Balance as of September 30, 2022 (unaudited)
$117,383 
Intangible Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets and goodwill (dollars in thousands):
September 30, 2022December 31, 2021
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights8.02681,100 (93,642)587,458 681,100 (35,550)645,550 
Capitalized patent defense costs4.2443,820 (32,517)11,303 43,820 (28,677)15,143 
Total intangible assets7.95$848,920 $(126,159)$722,761 $848,920 $(64,227)$784,693 
Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regards to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances.
Amortization expense for intangible assets was approximately $20.6 million and $61.9 million for the three and nine months ended September 30, 2022, respectively, and approximately $6.0 million and $18.0 million for the three and nine months ended September 30, 2021, respectively. The increase in expense is primarily due to amortization of the acquired developed technology and product rights from the Adamas Acquisition.
Anticipated annual amortization expense for intangible assets is estimated at $79.8 million each in both 2023 and 2024, $75.1 million in 2025, $74.9 million in 2026, and $73.2 million in 2027.
9.    Convertible Senior Notes Due 2023
The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million. We have reclassified the debt from long-term to current liabilities on our Condensed Consolidated Balance Sheet, as the debt matures in less than twelve months as of September 30, 2022.
The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar
21
quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date.
At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.
If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.
Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.
Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.91 per share of the Company’s common stock, and is subject to adjustment.
The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be.
The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.
The liability component of the 2023 Notes consists of the following (dollars in thousands):
September 30,
2022		December 31,
2021
(unaudited) 
2023 Notes$402,500 $402,500 
Unamortized debt discount and deferred financing costs(1,062)(23,248)
Total carrying value$401,438 $379,252 
As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption. No 2023 Notes were converted as of September 30, 2022 or December 31, 2021.
22
10.    Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
(unaudited)(unaudited)
Research and development$825 $615 $2,284 $1,909 
Selling, general and administrative4,160 3,412 11,023 11,965 
Total$4,985 $4,027 $13,307 $13,874 
Stock Option and Stock Appreciation Rights
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options & SARs		Weighted
Average
Exercise Price
(per share)		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20215,774,076 $24.15 5.95
Granted 1,046,785 $31.95 
Exercised (673,120)$12.79 
Forfeited (145,473)$30.06 
Outstanding, September 30, 2022 (unaudited)6,002,268 $26.64 6.29
As of December 31, 2021:
Vested and expected to vest5,774,076 $24.15 5.95
Exercisable3,651,824 $21.29 4.53
As of September 30, 2022 (unaudited):
Vested and expected to vest6,002,268 $26.64 6.29
Exercisable 3,682,170 $24.61 4.83
Restricted Stock Units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 202121,110 $29.61 
Granted134,460 $32.17 
Vested(21,110)$29.61 
Nonvested, September 30, 2022 (unaudited)134,460 $32.17 
There were no forfeited RSU awards during the nine months ended September 30, 2022.
23
Performance Share Units

The following table summarizes performance share unit (PSU) activities:

Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 202153,500 $29.82 35,625 $26.34 89,125 $28.43 
Granted155,000$28.93 ——155,000$28.93 
Vested(22,250)$29.69 ——(22,250)$29.69 
Forfeited(1,500)$30.45 ——(1,500)$30.45 
Nonvested, September 30, 2022 (unaudited)184,750$29.08 35,625$26.34 220,375$28.64 
11.    Earnings per Share
The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, whereas the Company previously calculated diluted earnings per share under the treasury stock method. Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock option grants, SARs, RSUs, employee stock purchase plan (ESPP) awards, and the 2023 Notes, as determined per the if-converted method for the three and nine months ended September 30, 2022 in connection with the adoption of ASU 2020-06 and the treasury stock method for the three and nine months ended September 30, 2021.
Effect of Convertible Notes and Related Convertible Note Hedges and Warrants
In connection with the issuance of the 2023 Notes, the Company entered into Convertible Note Hedge and Warrant Transactions as described further in Note 9, Convertible Senior Notes Due 2023. The expected collective impact of the Convertible Note Hedge and Warrant Transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $59.33 per share and the strike price of the warrants of $80.91 per share.
Diluted EPS related to the 2023 Notes in the current year is calculated using the if-converted method. The number of dilutive shares is based on the initial conversion rate associated with the 2023 Notes. The Convertible Note Hedge and Warrant Transactions are excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $80.91 per share. Prior to actual conversion, the Convertible Note Hedge Transactions are not considered in calculating diluted earnings per share, as their impact would be anti-dilutive.
In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards and shares associated with the conversion of the 2023 Notes in the calculation of diluted EPS, because their inclusion would be anti-dilutive:
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
2023 Notes6,783,936 — — — 
Stock options, RSUs, PSUs792,904 1,654,816 470,822 1,397,424 

24
As mentioned in Note 2, as a result of the adoption of ASU 2020-06 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are not included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended September 30, 2022 because their inclusion would be anti-dilutive. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.
The following table sets forth the computation of basic and diluted net earnings per share for the three and nine months ended September 30, 2022 under the if-converted method and for the three and nine months ended September 30, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Numerator:
Net earnings $1,749 $21,562 $35,230 $50,982 
After-tax interest expense for 2023 Notes— — 2,664 — 
Numerator for dilutive earnings per share$1,749 $21,562 $37,894 $50,982 
Denominator:
Weighted average shares outstanding, basic53,789,674 53,187,764 53,517,838 53,053,441 
Effect of dilutive securities:
Stock options, RSUs and SARs1,245,164 1,147,030 1,241,347 1,248,020 
Convertible notes— — 6,783,936 — 
Weighted average shares outstanding, diluted55,034,838 54,334,794 61,543,121 54,301,461 
Earnings per share, basic$0.03 $0.41 $0.66 $0.96 
Earnings per share, diluted$0.03 $0.40 $0.62 $0.94 
    
12.    Income Tax (Benefit) Expense
The following table provides information regarding the Company’s income tax (benefit) expense for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Income tax (benefit) expense$(2,193)$7,398 $(9,627)$20,142 
Effective tax rate493.9 %25.5 %(37.6)%28.3 %

The decrease in income tax expense for the three months ended September 30, 2022 compared to the same period in prior year was primarily due to lower earnings before income taxes. The change in effective tax rate for the three months ended September 30, 2022 compared to the same period in prior year was primarily due to larger excess tax benefits of stock-based awards in 2022.

The change in income tax (benefit) expense and effective tax rate for the nine months ended September 30, 2022 compared to the same period in the prior year was primarily due to tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022.
25
13.    Leases
Office Space and Fleet Vehicle Leases
The Company has operating leases for its headquarters lease, certain other office space, and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company also elected to combine the lease and non-lease components for the fleet vehicles and headquarters leases.
The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless earlier terminated in accordance with the terms of the lease. The lease includes options to extend the lease for up to 10 years.
As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term will continue until April 30, 2025. The lease contains an option to extend the term for one additional five-year period.
During a measurement period, changes in fair value due to measurement period adjustments are recorded against goodwill. The Company recorded in the first quarter of 2022 a measurement period adjustment associated with the valuation of the acquired Adamas lease which decreased the fair value estimate of the operating lease right of use asset by $1.6 million. Refer to Note 3, Acquisition.
Contract Manufacturing Lease
The Company has a contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience.
Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounts for as an embedded lease.
The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classifies and accounts for the embedded lease as an operating lease.
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationSeptember 30, 2022December 31, 2021
(unaudited)
Assets
Operating lease assetsOther assets$29,663 $35,365 
Total lease assets$29,663 $35,365 
Liabilities
Lease liabilities, current
Operating lease liabilities, current portionAccounts payable and accrued liabilities$6,757 $6,477 
Lease liabilities, long-term
Operating lease liabilities, long-termOperating lease liabilities, long-term36,028 41,298 
Total lease liabilities$42,785 $47,775 

26
14.    Composition of Other Balance Sheet Items
The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):
Accounts Receivables, Net
As of September 30, 2022 and December 31, 2021, the Company has recorded allowances reducing accounts receivable by approximately $12.8 million and $13.5 million, respectively. These allowances represent prompt pay discounts and contractual service fees, which were originally recorded as a reduction to revenues, representing estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.
Inventories, Net
September 30,
2022		December 31,
2021
(unaudited)
Raw materials$11,012 $7,325 
Work in process25,461 45,711 
Finished goods46,692 32,923 
Total$83,165 $85,959 
Inventories as of September 30, 2022 include acquired inventory from the Adamas Acquisition. Refer to Note 3, Acquisition, for further discussion of the acquisition.
Property and Equipment, Net
September 30,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,207 $12,287 
Leasehold improvements14,023 14,369 
Software1,007 4,776 
Computer equipment1,282 1,944 
Construction-in-progress291 33 
28,810 33,409 
Less accumulated depreciation and amortization(12,938)(16,454)
Property and equipment, net$15,872 $16,955 
Depreciation and amortization expense on property and equipment was approximately $0.8 million and $2.2 million for the three and nine months ended September 30, 2022, respectively, and approximately $0.6 million and $1.9 million for the three and nine months ended September 30, 2021, respectively. The Company retired certain fully depreciated property and equipment in the nine months ended September 30, 2022.
27
Accounts Payable and Accrued Liabilities
September 30,
2022		December 31,
2021
(unaudited)
Accounts payable$16,015 $9,331 
Accrued professional & marketing fees31,269 26,728 
Accrued compensation16,748 28,068 
Accrued product costs11,129 18,460 
Accrued royalties (1)
11,671 13,821 
Accrued clinical trial costs (2)
6,823 9,125 
Operating lease liabilities, current portion (3)
6,757 6,477 
Other accrued expenses9,890 5,673 
Total$110,302 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Accrued Product Returns and Rebates
September 30,
2022		December 31,
2021
(unaudited)
Accrued product rebates$119,162 $97,597 
Accrued product returns39,308 35,127 
Total$158,470 $132,724 
Other Liabilities
September 30,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$— $5,977 
Other liabilities10,371 10,403 
Total$10,371 $16,380 
28
15.    Interest Expense
The following details the composition of interest expense (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Interest expense$(1,158)$(5,033)$(3,488)$(14,593)
Interest expense on nonrecourse liability related to sale of future royalties(566)(892)(1,988)(2,896)
Total$(1,724)$(5,925)$(5,476)$(17,489)
For the three and nine months ended September 30, 2022, interest expense includes noncash interest expense related to amortization of deferred financing costs of $0.5 million and $1.6 million. For the three and nine months ended September 30, 2021, interest expense includes noncash interest expense related to amortization of deferred financing costs and amortization of the debt discount on the 2023 Notes of $4.4 million and $13.0 million. As discussed in Note 2, Summary of Significant Accounting Policies, the Company adopted ASU 2020-06 on January 1, 2022. As a result, interest expense for the three and nine months ended September 30, 2022 significantly decreased compared to the three and nine months ended September 30, 2021 due to the Company no longer recording interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes.
16.    Commitments and Contingencies
Product Licenses
The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.
Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings.
Royalty Agreement
In the third quarter of 2014, the Company received $30 million pursuant to a Royalty Interest Acquisition Agreement related to the purchase by HC Royalty of certain of the Company's rights under the Company's agreement with United Therapeutics related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets. Full ownership of the royalty rights will revert to the Company if and when a certain cumulative payment threshold is reached (see Note 4, Note 14, and Note 15).
USWM Enterprises Commitments Assumed
As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below.
The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. Refer to Note 13, Leases for further discussion related to the Merz Agreement in connection with the MYOBLOC annual minimum purchase requirement.
In addition, USWM Enterprises had an existing license and distribution agreement for XADAGO. This included an annual minimum promotional spend to support the marketing of XADAGO for the first five years of the agreement which will end in 2022. As of September 30, 2022, there is no remaining contractual commitment.
In March 2019, MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector
29
General of the U.S. Department of Health and Human Services. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to maintain a broad array of processes, policies and procedures necessary to comply with the CIA through March 2024.
Data Breach-related Contingency
On November 24, 2021, the Company announced that it was the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on its internal investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from the Company's systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to the Company's systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. In the fourth quarter of 2021, the Company had successfully recovered the impacted files and took additional steps designed to further protect its networks and files.
Furthermore, while the Company has not been the subject of any legal proceedings involving the attack, the likelihood that the Company could be the subject of claims from persons alleging they suffered damages from the incident or actions by governmental authorities is possible, but the amount of such fines, penalties or costs, if any, cannot be estimated at this time. The Company continues to monitor the situation.
Claims and Litigation
From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.
NAMENDA XR/Namzaric Qui Tam Litigation
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit. The petition remains pending. No decision has been reached as of the date of this filing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.
30
17.    Subsequent Events

SPN-830 Regulatory Development
In December 2021, we resubmitted the NDA for SPN-830 to the FDA. In February 2022, we received a notice from the FDA that the resubmission of the NDA for SPN-830 is considered as a Standard Review, thereby was assigned a PDUFA target action date in early October 2022. In October 2022, the FDA issued a CRL regarding the NDA for SPN-830. The CRL requires additional information and analysis related to the infusion device and drug product across several areas of the NDA including, but not limited to, labeling, product quality and manufacturing, device performance and risk analysis. In addition, the FDA mentions that approval of the NDA requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. The CRL does not request additional efficacy and safety clinical studies. The FDA has made an initial determination that the amendment to the Company’s application in response to the CRL will be subject to a Class 2, or six-month, review timeline.
The Company is in the process of analyzing the CRL and determining next steps for the resubmission of the NDA. While it is too early to ascertain the full impact to our financial statements, we anticipate that we may identify indicators of impairment for the IPR&D asset that represents an estimate of the fair value of SPN-830, the product candidate, that could result from the non-approval of the NDA. The potential adjustment to the IPR&D asset that may be necessary as a result of any required interim impairment analysis may be material. Additionally, the Company also expects to assess adjustments to the fair value of the contingent consideration arrangements which includes milestones payments due upon achievement of certain FDA's regulatory approval and commercial launch of SPN-830. While we are unable to estimate the anticipated financial impact at this time, we expect potential adjustments, which may be material, will be recognized and reported within the fourth quarter of 2022. These adjustments could impact the Company’s future results of operations and financial condition.
APOKYN Litigation
     On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware (Case No. 22-cv-1302) alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN. The Company is currently reviewing the details of the complaint and will respond as appropriate.
31
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to help the reader understand the results of operations and the financial condition of Supernus Pharmaceuticals, Inc. (the Company, we, us, or our). The interim condensed consolidated financial statements included in this report and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2021 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 13, 2022.
In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. These forward-looking statements may include declarations regarding the Company’s belief or current expectations of management, such as statements including the words “budgeted,” “anticipate,” “project,” “forecast,” “estimate,” “expect,” “may,” “believe,” “potential,” and similar statements or expressions, which are intended to be among the statements that are forward-looking statements, as such statements reflect the reality of risk and uncertainty that is inherent in our business. Actual results may differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date this report was filed with the Securities and Exchange Commission. Our actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K, our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022 and elsewhere in this report as well as in other reports and documents we file with the Securities and Exchange Commission from time to time. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q.
Solely for convenience, in this Quarterly Report on Form 10-Q, the trade names are referred to without the TM symbols and the trademark registrations are referred to without the circled R, but such references should not be construed as any indicator that the Company will not assert, to the fullest extent under applicable law, our rights thereto.
32
Overview
We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
We have a portfolio of commercial products and product candidates.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•Qelbree® (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company launched Qelbree for adult patients in May 2022.
•GOCOVRI® (amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
•Osmolex ER® (amantadine) extended-release is a once-daily product for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
33
Research and Development
We are developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The table below summarizes our product candidates in clinical development.
Product CandidateIndicationDevelopmentNDA
SPN-830
Continuous treatment of motor fluctuations ("off" episodes) in PD patients
Complete Response Letter (CRL) received from FDA in October 2022
SPN-820Treatment-resistant depressionPhase II
SPN-817Treatment-resistant seizuresPhase I
SPN-443CNSPreclinical
SPN-446CNSPreclinical
SPN-830 (apomorphine infusion device)
SPN-830 is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. If approved, it would be the only continuous infusion of apomorphine available in the U.S. and an important step for PD patients that would have otherwise been candidates for potentially invasive surgical procedures, such as deep brain stimulation. Continuous slow infusion may also limit some of the side effects of a bolus injection of apomorphine.
In December 2021, we resubmitted the NDA to the FDA. In February 2022, we received a notice from the FDA that the resubmission of the NDA for SPN-830 is considered as a Standard Review, thereby was assigned a PDUFA target action date in early October 2022. In October 2022, the FDA issued a CRL regarding the NDA for SPN-830. The CRL requires additional information and analysis related to the infusion device and drug product across several areas of the NDA including, but not limited to, labeling, product quality and manufacturing, device performance and risk analysis. In addition, the FDA mentions that approval of the NDA requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. The CRL does not request additional efficacy and safety clinical studies. The FDA has made an initial determination that the amendment to the Company’s application in response to the CRL will be subject to a Class 2, or six-month, review timeline.
SPN-820 (NV-5138)
SPN-820 is a first-in-class, orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1), a gatekeeper of cellular metabolism and renewal. SPN-820 binds to and modulates sestrin, which senses amino acid availability in the brain, a potent natural activator of mTORC1.
SPN-817 (huperzine A)
SPN-817 represents a novel mechanism of action (MOA) for an anticonvulsant. SPN-817 is a novel synthetic form of
huperzine A, whose MOA includes potent acetylcholinesterase inhibition, with pharmacological activities in CNS conditions such as epilepsy. The development will initially focus on the drug's anticonvulsant activity, which has been shown in preclinical models to be effective for the treatment of partial seizures and Dravet Syndrome. SPN-817 is in clinical development and has received Orphan Drug designation for several epilepsy indications from the FDA.
Adamas Reorganization
In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, Income Tax (Benefit) Expense).
34
COVID-19 Impact
While the impact of the ongoing COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the three months and nine months ended September 30, 2022, we continue to closely monitor the events and circumstances surrounding the COVID-19 pandemic and its impact on all aspects of our business operations. Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on our business operations and financial position cannot be reasonably estimated at this time. See “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K and "Risk Factors" in Part II, Item 1A of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022 for additional information on risk factors that could impact our business and our results.
Operational Highlights
Qelbree Launch Update
•Total IQVIA prescriptions were 94,328 in the third quarter of 2022, an increase of 50% compared to total prescriptions of 62,938 in the second quarter of 2022. In September 2022, the most recent month available, total prescriptions reached 34,633.
•Qelbree continues to expand its base of prescribers, with approximately 14,265 prescribers in the third quarter of 2022, up from 9,276 prescribers from the second quarter of 2022.
Product Pipeline Update
SPN-830 (apomorphine infusion device) - Continuous treatment of motor fluctuations (“off” episodes) in Parkinson's disease (PD)
•In October 2022, the Company announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the SPN-830 New Drug Application (NDA). The CRL does not request additional efficacy and safety clinical studies but rather requires additional information and analysis related to the infusion device and drug product across several areas of the NDA, including labeling, product quality and manufacturing, device performance and risk analysis. In addition, the FDA mentions that approval of the NDA requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. Supernus will continue to work closely with the FDA to address all questions, and when possible, to provide clarity regarding the potential timing of a resubmission of the NDA. The FDA has made an initial determination that the amendment to the Company’s application in response to the CRL will be subject to a Class 2, or six-month, review timeline.
SPN-820 - Novel first-in-class activator of mTORC1
•The Phase II multi-center, randomized double-blind placebo-controlled parallel design study of SPN-820 in adults with treatment-resistant depression is ongoing. The study will examine the efficacy and safety of SPN-820 over a course of five weeks of treatment in approximately 270 patients. The primary outcome measure is the change from baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score, a standard depression rating scale.
SPN-817 – A novel product candidate for the treatment of epilepsy
•An open-label Phase II clinical study of SPN-817 in patients with treatment-resistant seizures is expected to start in the fourth quarter of 2022.
Critical Accounting Policies and the Use of Estimates
A summary of our significant accounting policies is included in Note 2, Summary of Significant Accounting Policies of our audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2021. There were no significant changes to the disclosures with respect to our critical accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2021.
35
Results of Operations
Comparison of the Three and Nine Months Ended September 30, 2022 and 2021
Revenues
Revenues consist primarily of net product sales of our commercial products in the U.S., supplemented by royalty revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20222021AmountPercent20222021AmountPercent
Net product sales
Trokendi XR$69,599 $80,935 $(11,336)(14)%$204,033 $231,531 $(27,498)(12)%
Oxtellar XR30,528 29,728 800 3%88,007 82,120 5,887 7%
GOCOVRI27,878 — 27,878 **75,179 — 75,179 **
Qelbree18,326 2,370 15,956 **37,708 2,685 35,023 **
APOKYN18,261 24,627 (6,366)(26)%57,156 73,338 (16,182)(22)%
Other(1)
8,132 7,872 260 3%23,564 22,867 697 3%
Total net product sales$172,724 $145,532 $27,192 19%$485,647 $412,541 $73,106 18%
Royalty revenues4,629 2,932 1,697 58%14,263 8,184 6,079 74%
Total revenues$177,353 $148,464 $28,889 19%$499,910 $420,725 $79,185 19%
______________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
The $27.2 million and 19% increase in net product sales for the three months ended September 30, 2022, as compared to the same period in 2021, was primarily due to the inclusion of $27.9 million in net product sales of GOCOVRI, subsequent to the completion of the Adamas Acquisition in November 2021, as well as a $16.0 million increase in net product sales of Qelbree, which was launched in May 2021. Partially offsetting this increase was a $11.3 million decrease in net product sales of Trokendi XR and a $6.4 million decrease in net product sales of APOKYN primarily attributable to the decline in unit demand due to competitive headwinds.
The $73.1 million and 18% increase in net product sales for the nine months ended September 30, 2022, as compared to the same period in 2021, was primarily due to the inclusion of $75.2 million in net product sales of GOCOVRI, subsequent to the completion of the Adamas Acquisition in November 2021, the increase of $5.9 million in net product sales of Oxtellar, as well as a $35.0 million increase in net product sales of Qelbree, which was launched in May 2021 for pediatric patients and in May 2022 for adult patients. Partially offsetting this increase was a $27.5 million decrease in net product sales of Trokendi XR and a $16.2 million decrease in net product sales of APOKYN primarily attributable to the decline in unit demand due to competitive headwinds.
Sales Deductions and Related Accruals
We record accrued product returns and accrued product rebates as current liabilities in Accrued product returns and rebates, on our condensed consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable, net on the condensed consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.




36
The following table provides a summary of activity with respect to sales deductions and related accruals during the periods indicated (dollars in thousands):
Accrued Product Returns and Rebates
Product
Returns		Product
Rebates		Reduction to Accounts Receivable for
Sales Discounts		Total
Balance at December 31, 2021$35,127 $97,597 $13,537 $146,261 
Provision
Provision for current year sales13,846 321,860 55,693 391,399 
Adjustments relating to prior year sales(3,225)31 (3)(3,197)
Total provision$10,621 $321,891 $55,690 $388,202 
Less: Actual payments/credits(6,440)(300,326)(56,447)(363,213)
Balance at September 30, 2022$39,308 $119,162 $12,780 $171,250 
Balance at December 31, 2020$29,603 $96,589 $11,404 $137,596 
Provision
Provision for current year sales9,945 275,352 51,472 336,769 
Adjustments relating to prior year sales(1,525)1,334 19 (172)
Total provision$8,420 $276,686 $51,491 $336,597 
Less: Actual payments/credits(4,611)(274,639)(51,677)(330,927)
Balance at September 30, 2021$33,412 $98,636 $11,218 $143,266 
Accrued Product Returns and Rebates Balances
The accrued product returns balance increased from $33.4 million as of September 30, 2021 to $39.3 million as of September 30, 2022 principally due to the timing of related return activity and an increase in provision for product returns primarily for Qelbree.
The accrued product rebates balance increased from $98.6 million as of September 30, 2021 to $119.2 million as of September 30, 2022 due to timing of payments which more than offsets the increase in the provision.
Provision for Product Returns and Rebates
The provision for product returns increased from $8.4 million for the nine month period ended September 30, 2021 to $10.6 million for the nine month period ended September 30, 2022. The change was primarily attributable to an increase in volume of products sold with the launch of Qelbree for pediatric patients in the second quarter of 2021 and for adults in second quarter of 2022, partially offset by lower sales of Trokendi XR.
The provision for product rebates increased from $276.7 million for the nine month period ended September 30, 2021 to $321.9 million for the nine month period ended September 30, 2022. The increase was primarily attributable to higher sales volume, as well as higher per patient payments under both government and commercial managed care programs.
Royalty Revenues
Royalty revenues include a royalty from net product sales of Mydayis, a product of Takeda Pharmaceuticals Company Ltd., Namzaric royalties, and noncash royalty revenue pursuant to our agreement with Healthcare Royalty Partners III, L.P. (HC Royalty). HC Royalty receives royalty payments from United Therapeutics Corporation (United Therapeutics) based on net product sales of United Therapeutics’ product Orenitram.
Royalty revenues were $4.6 million and $2.9 million for the three months ended September 30, 2022 and 2021, respectively. Royalty revenues were $14.3 million and $8.2 million for the nine months ended September 30, 2022 and 2021, respectively. The increase was primarily due to the Namzaric royalties for the three and nine months ended September 30, 2022. Namzaric royalty rights were acquired in connection with the Adamas Acquisition.
37
Cost of Goods Sold
Cost of goods sold was $25.9 million and $18.1 million for the three months ended September 30, 2022 and 2021, respectively. The increase was primarily due to higher Qelbree sales, offset by lower royalty expense compared to the same period in the prior year.
Cost of goods sold was $64.3 million and $58.1 million for the nine months ended September 30, 2022 and 2021, respectively. The increase was primarily due to higher Qelbree sales, offset by lower royalty expense compared to the same period in the prior year.
Royalty expense associated with the acquired commercial products, APOKYN and XADAGO, made up the majority of cost of goods sold. Royalty expense declined $2.4 million for the three months ended September 30, 2022 and $5.7 million for the nine months ended September 30, 2022 primarily due to the decline in APOKYN sales in 2022.
Research and Development Expenses
R&D expenses were $19.6 million and $19.7 million for the three months ended September 30, 2022 and 2021, respectively. R&D expenses were $56.8 million and $69.4 million for the nine months ended September 30, 2022 and 2021. The $12.6 million decrease for the nine months ended September 30, 2022 was primarily due to the write-down of the $15.0 million investment in Navitor LLC which was attributable to a single in-process research and development (IPR&D) asset and recorded in R&D expense in the first quarter of 2021, offset by a $2.0 million increase in costs associated with regulatory activities mainly related to acquired products.
Selling, General and Administrative Expenses
The following table provides information regarding our selling, general and administrative (SG&A) expenses during the periods indicated (dollars in thousands):
Three Months Ended September 30,ChangeNine Months Ended September 30,Change
20222021AmountPercent20222021AmountPercent
 Selling and marketing $85,704 $50,704 $35,000 69%$219,798 $137,531 $82,267 60%
 General and administrative 26,610 21,328 5,282 25%83,451 65,493 $17,958 27%
 Total $112,314 $72,032 $40,282 56%$303,249 $203,024 $100,225 49%
Selling, general and administrative expenses increased by 56% to $112.3 million for the three months ended September 30, 2022. The increase was primarily due to increased marketing expenditures of approximately $30.5 million primarily for activities to support the launch of Qelbree to the adult population and the Qelbree direct-to-consumer campaign, which substantially occurred in the third quarter of 2022, as well as the acquired commercial products from Adamas Acquisition. In addition, general and administrative expenses increased $3.3 million due to higher professional and consulting costs and increased employee-related costs mainly to support IT and finance operations related to the ransomware incident, financial reporting and Adamas integration in 2022.
Selling, general and administrative expenses increased by 49% to $303.2 million for the nine months ended September 30, 2022. The increase was primarily due to increased marketing expenditures of (i) approximately $46.1 million primarily for activities to support the launch of Qelbree to the adult population and the Qelbree direct-to-consumer campaign, which substantially occurred in the third quarter of 2022, as well as (ii) approximately $8.0 million related to the commercial products acquired from the Adamas Acquisition. In addition, general and administrative expenses increased $10.7 million due to higher professional and consulting costs and increased employee-related costs mainly to support IT and finance operations related to the ransomware incident, financial reporting and Adamas integration in 2022.
Amortization of Intangible Assets
Amortization of intangible assets was $20.6 million and $6.0 million for the three months ended September 30, 2022 and 2021, respectively. Amortization of intangible assets was $61.9 million and $18.0 million for the nine months ended September 30, 2022 and 2021, respectively. The increase was due to amortization of the definite-lived intangible assets acquired in the Adamas Acquisition.
Contingent Consideration Expense (Gain)
38
The change in fair value of the contingent consideration liabilities was an expense of $0.5 million and $0.1 million for the three months ended September 30, 2022 and 2021, respectively. The contingent consideration expense was primarily due to an increase in the estimated fair value of regulatory and developmental milestones due to the passage of time.

The change in fair value of the contingent consideration liabilities was an expense of $1.9 million and a gain of $7.7 million for the nine months ended September 30, 2022 and 2021, respectively. The contingent consideration gain was primarily due to a reduction of the sales based contingent consideration liabilities associated with the USWM Acquisition recorded in the second quarter of 2021, offset by an increase in the estimated fair value of regulatory and developmental milestones due to the passage of time and the accretion to the payout amount related to the milestone achieved in the first quarter of 2022.
Other Income (Expense)
Other income (expense) was income of $1.1 million and an expense of $3.6 million for the three months ended September 30, 2022 and 2021, respectively. The increase in other income was principally due to a decrease of $4.2 million in interest expense. The decrease in interest expense was primarily related to the Company's adoption of ASU 2020-06 on January 1, 2022. As a result of the adoption, the Company no longer records interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes.
Other income (expense) was income of $13.8 million and an expense of $8.8 million for the nine months ended September 30, 2022 and 2021, respectively. The increase in other income was primarily due to $12.9 million recognized in connection with the gain associated with the Navitor investment and a decrease in interest expense of $12.0 million primarily related to the Company's adoption of ASU 2020-06.
Income Tax (Benefit) Expense
Income tax benefit was $2.2 million and income tax expense was $7.4 million for the three months ended September 30, 2022 and 2021, respectively. The decrease was mainly due to lower earnings before income taxes. The effective income tax rate was 493.9% and 25.5% for the three months ended September 30, 2022 and 2021, respectively. The change in effective income tax rate was primarily due to larger excess tax benefits of stock-based awards in 2022.
Income tax benefit was $9.6 million and income tax expense was $20.1 million for the nine months ended September 30, 2022 and 2021, respectively. The effective income tax rate was (37.6)% and 28.3% for the nine months ended September 30, 2022 and 2021, respectively. The change in income tax (benefit) expense and effective income tax rate was primarily due to tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022.
Liquidity and Capital Resources
We have financed our operations primarily with cash generated from product sales, supplemented by revenues from royalty and licensing arrangements, as well as proceeds from the sale of equity and debt securities. Continued cash generation is highly dependent on the success of our commercial products, as well as the success of our product candidates if approved by the FDA. While we expect continued profitability in future years, we anticipate there may be significant variability from year to year in the level of our profits particularly due to the commercial launch of Qelbree and the future commercial launch of SPN-830 (apomorphine infusion device), if approved by the FDA; continued market and payor pressures for our commercial products; and the likely unfavorable impact of the upcoming loss of patent exclusivity for Trokendi XR in January 2023, or sooner under certain conditions.
The Company believes its balances of cash, cash equivalents and unrestricted marketable securities, which totaled $523.7 million as of September 30, 2022, along with cash generated from ongoing operations and continued access to debt markets, will be sufficient to satisfy its cash requirements over the next 12 months and beyond.
We may, from time to time, consider raising additional capital through: new collaborative arrangements; strategic alliances; additional equity and/or debt financings; or financing from other sources, especially in conjunction with opportunistic business development initiatives. We will continue to actively manage our capital structure and to consider all financing opportunities that could strengthen our long-term financial profile. Any such capital raises may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
39
Financial Condition
Cash and cash equivalents, marketable securities, and long-term marketable securities as of the periods presented below, are as follows (dollars in thousands):
September 30,December 31,Change
20222021AmountPercent
Cash and cash equivalents$111,492 $203,434 $(91,942)(45)%
Marketable securities280,297 136,246 144,051 106%
Long-term marketable securities131,937 119,166 12,771 11%
Total$523,726 $458,846 $64,880 14%
Total cash and cash equivalents, marketable securities and long-term marketable securities increased by $64.9 million in the first nine months of 2022, primarily due to cash generated from ongoing operations.
As of September 30, 2022 and December 31, 2021, the outstanding principal on our 0.625% Convertible Senior Notes Due 2023 (2023 Notes) was $402.5 million. No 2023 Notes have been converted as of September 30, 2022. We have reclassified the debt from long-term to current liabilities on our Condensed Consolidated Balance Sheet, as the debt matures in less than twelve months as of September 30, 2022. There were no changes to the separate convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) and separate warrant transactions (the Warrant Transactions). Refer to Part I, Item 1, Unaudited Condensed Financial Statements, Note 9, Convertible Senior Notes Due 2023, in the Notes to the Condensed Consolidated Financial Statements, for further discussion of the 2023 Notes and our other indebtedness.
Summary of Cash Flows
The following table summarizes the major sources and uses of cash for the periods set forth below (dollars in thousands):
Nine Months Ended September 30, 2022Change
20222021Amount
Net cash provided by (used in):
Operating activities $89,262 $78,364 $10,898 
Investing activities (167,898)(158,043)(9,855)
Financing activities (13,306)6,320 (19,626)
Net change in cash and cash equivalents $(91,942)$(73,359)$(18,583)
Operating Activities
Net cash provided by operating activities was $89.3 million and $78.4 million for the nine months ended September 30, 2022, and 2021, respectively. The increase in cash flows provided by operating activities was primarily due to changes in working capital which reflects the timing impacts of cash collections on receivables and settlement of payables.
Investing Activities
Net cash used in investing activities was $167.9 million for the nine months ended September 30, 2022, as compared to $158.0 million for the same period in 2021. Net cash used in investing activities primarily reflect cash flows from purchase, sale and maturities of marketable securities.
Financing Activities
Net cash used in financing activities was $13.3 million for the nine months ended September 30, 2022 compared to net cash provided by financing activities of $6.3 million for the same period in prior year. The change was primarily due to the payment of a contingent consideration milestone associated with the USWM Acquisition, offset by proceeds from the issuance of common stock.
Material Cash Requirements
Refer to “Part II, Item 7 — Management’s Discussion and Analysis of Liquidity and Capital Resources”, of our Annual Report on Form 10-K for the year ended December 31, 2021, and Note 16, Commitments and Contingencies, in the Notes to the
40
Condensed Consolidated Financial Statements in Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this Quarterly Report on Form 10-Q for the discussion of our contractual obligations.
Recently Issued Accounting Pronouncements
For a discussion of new accounting pronouncements, see Note 2 in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, Unaudited Condensed Consolidated Financial Statements, of this Quarterly Report on Form 10-Q.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
The primary objective of our investment activities is to preserve our capital to fund operations and to facilitate business development activities. We also seek to maximize income from our investments without assuming significant interest rate risk, liquidity risk, or risk of default by investing in investment grade securities with maturities of four years or less. Our exposure to market risk is confined to investments in cash, cash equivalents, marketable securities, and long-term marketable securities. As of September 30, 2022, we had unrestricted cash, cash equivalents, marketable securities, and long-term marketable securities of $523.7 million.
In connection with the 2023 Notes, we have separately entered into Convertible Note Hedge Transactions and Warrant Transactions to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and to partially offset the cost to purchase the Convertible Note Hedge Transactions, respectively.
Our cash and cash equivalents consist primarily of cash held at banks and investments in highly liquid financial instruments with an original maturity of three months or less. Our marketable securities as of September 30, 2022, which are reported at fair value, consist of money market funds; corporate and municipal debt securities; and other fixed income securities. All our investments in marketable securities are in the form of debt securities issued by governmental, corporate, and financial institutions whose debt is rated as investment grade and have maturities of one to four years. Because of the relatively short period that we hold our investments and because we generally hold these securities to maturity, we do not believe that a change in interest rates would have any significant impact on the realizable value of our investments. We do not have any currency or other derivative financial instruments other than outstanding warrants to purchase common stock and the convertible note hedges.
We may contract with clinical research organizations (CROs), investigational sites and contract manufacturing organizations (CMOs) globally. Currently, we have ongoing clinical trials for certain product candidates outside the U.S. We do not hedge our foreign currency exchange rate risk. Transactions denominated in currencies other than the U.S. dollar are recorded based on exchange rates at the time such transactions arise. As of September 30, 2022 and December 31, 2021, substantially all of our liabilities were denominated in the U.S. dollar.
Inflation generally affects us by increasing our cost of labor, cost of purchased goods, and the cost of services provided by our vendors. We do not believe that inflation and changing prices over the nine months ended September 30, 2022 and 2021 had a significant impact on our consolidated results of operations. However, in the future, inflation may have an effect on our consolidated results of operations.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures required by Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act has been appropriately recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our CEO and CFO, to allow timely decisions regarding required disclosure. We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2022, the end of the period covered by this report. Based on that evaluation, under the supervision and with the participation of our management, including our CEO and CFO, we concluded that our disclosure controls and procedures were not effective as of September 30, 2022 due to the continued material weaknesses in our internal control over financial reporting as described in our Annual Report on Form 10-K as of December 31, 2021, (the "Form 10-K") and our Quarterly Reports on Form 10-Q as of March 31, 2022 and June 30, 2022 (the "Form 10-Q").
In light of the identified material weaknesses, we performed additional analyses and other procedures to ensure that the condensed consolidated financial statements included in this quarterly report on Form 10-Q present fairly, in all material respects,
41
the Company's financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. generally accepted accounting principles (U.S. GAAP).
As discussed in Note 3 in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1, of this report, the Company completed its acquisition of Adamas Pharmaceuticals, Inc. (Adamas), a publicly traded biopharmaceutical company (Adamas Acquisition) on November 24, 2021. We are in the process of integrating Adamas with our controls over financial reporting. As such, the scope of our assessment of the effectiveness of our disclosure control and procedures as of September 30, 2022 did not include the internal control over financial reporting of Adamas, as permitted by the guidance of the Office of the Chief Accountant of the SEC (not to extend more than one year beyond the date of acquisition or for more than one annual reporting period).
Remediation of Material Weaknesses
Management is actively remediating the identified material weaknesses, and is committed to remediating the material weaknesses in a timely manner. As of September 30, 2022, we have taken steps to remediate the material weaknesses. These include the following:
•implementation of a new ERP system which went live during the second quarter of 2022
•performance of risk assessment procedures and reevaluation of control design and control procedures, both are ongoing
•active recruitment of key finance and IT personnel. Management identified those roles deemed critical to the remediation of the material weakness and are in the process of actively recruiting for those roles
•conducted training on internal control over financial reporting to employees and contractors
While we believe the steps we have undertaken so far will improve our internal control environment, the design and implementation of our remediation is ongoing and will require validation and testing of the design and operating effectiveness of our internal control over financial reporting for a sustained period of financial reporting cycles.
While the audit committee of our board of directors and senior management are closely monitoring the remediation efforts, until the remediation efforts discussed in this section, including any additional remediation efforts that our senior management identifies as necessary, are completed, tested and determined effective, we will not be able to conclude that the material weaknesses have been remediated. In addition, we will continue to incur incremental costs associated with this remediation, primarily due to the hiring and training of additional personnel, and the improvements in our IT infrastructure. The material weaknesses will not be considered remediated until the above system, controls and personnel are in place for a period of time, the applicable controls operate for a sufficient period of time and management concludes based on its testing and evaluation that these controls are properly designed and operating effectively.
Changes in Internal Control over Financial Reporting
Our management, including our CEO and CFO, evaluated changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2022.
As the integration of Adamas as well as the remediation of the material weaknesses continues in 2022, we are implementing certain changes to our processes and procedures, which may result in changes to our internal control over financial reporting. Management has expanded its oversight of our internal control over financial reporting during this period,
Except for: 1) the above noted and previously reported material weaknesses and the related ongoing remediation activities described above, and 2) the ongoing integration of Adamas, there were no other changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 that occurred during the quarter ended September 30, 2022 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.
42
PART II — OTHER INFORMATION
Item 1.    Legal Proceedings
From time to time and in the ordinary course of business, Supernus Pharmaceuticals, Inc. ("Company") and any of its subsidiaries may be subject to various claims, charges and litigation. Parent and any of its subsidiaries may be required to file infringement claims against third parties for the infringement of our patents.
Oxtellar XR®
Supernus Pharmaceuticals, Inc. v. Apotex Inc., et al., C.A. No. 20-cv-7870 (FLW)(TJB) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug makers Apotex Inc. and Apotex Corp. (collectively, “Apotex”) dated May 13, 2020 directed to nine of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278; and 10,220,042 generally cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists all nine of the Company’s Oxtellar XR® patents as expiring on April 13, 2027. On June 26, 2020, the Company filed a lawsuit against Apotex alleging infringement of the Company’s nine patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Apotex infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of the Company’s patents. Filing its June 26, 2020 Complaint within 45 days of receiving Apotex’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Apotex’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On September 4, 2020, Apotex answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Apotex also asserted Counterclaims seeking declaratory judgments of non-infringement for the nine Oxtellar XR® Orange Book patents. On October 30, 2020, the Company filed its Reply, denying the substantive allegations of Apotex’s Counterclaims. On January 27, 2022, the Court issued an Order staying all litigation proceedings and administratively terminated the action. The Court lifted the stay on July 1, 2022. Pursuant to the Court’s January 27, 2022 and July 1, 2022 Orders, the 30-month Stay was extended by 152 days from November 14, 2022 to April 15, 2023. On August 1, 2022, the Court issued an Order consolidating this lawsuit with another pending lawsuit against Apotex, C.A. No. 22-cv-322, discussed below. The Court issued a revised Scheduling Order on October 11, 2022 that (i) provides for a final pre-trial conference and trial for May 2023; and (ii) further extends the 30-month stay. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Apotex Inc., et al., C.A. No. 22-cv-322 (FLW)(TJB) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug makers Apotex Inc. and Apotex Corp. (collectively, “Apotex”) dated December 10, 2021 directed to one of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent No. 11,166,960 generally covers once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists U.S. Patent No. 11,166,960 as expiring on April 13, 2027. On January 24, 2022, the Company filed a lawsuit against Apotex alleging infringement of U.S. Patent No. 11,166,960. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Apotex infringed U.S. Patent No. 11,166,960 by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of U.S. Patent No. 11,166,960. On January 27, 2022, in related Civil Action No. 20-cv-7870 (FLW)(TJB) (D.N.J.), the Court issued an Order staying all litigation proceedings and administratively terminated that related action. That Order further indicated that this action, i.e., Civil Action No. 22-cv-322 (FLW)(TJB) (D.N.J.), will also be stayed. The Court lifted the stay of both actions on July 1, 2022. Pursuant to the Court’s January 27, 2022 and July 1, 2022 Orders, the 30-month Stay was extended by 152 days from November 14, 2022 to April 15, 2023. On August 1, 2022, the Court issued an Order consolidating this lawsuit with another pending lawsuit against Apotex C.A. No. 20-cv-7870 and administratively terminated C.A. No. 22-cv-322, discussed above. As of the date of this submission, C.A. No. 22+-ca-322 remains administratively terminated.
Supernus Pharmaceuticals, Inc. v. RiconPharma LLC, et al., C.A. No. 21-cv-12133 (KM)(MAH) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker RiconPharma LLC dated April 20, 2021 directed to nine of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent Nos. 7,722,898; 7,910,131; 8,617,600; 8,821,930; 9,119,791; 9,351,975; 9,370,525; 9,855,278; and 10,220,042 generally cover once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists all nine of the Company’s Oxtellar XR® patents as expiring on April 13, 2027. On June 3, 2021, the Company filed a lawsuit against RiconPharma LLC and Ingenus Pharmaceuticals, LLC (collectively, “Ricon”) alleging infringement of the Company’s nine Oxtellar XR® patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ricon infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic
43
version of Oxtellar XR® prior to the expiration of the Company’s patents. Filing its June 3, 2021 Complaint within 45 days of receiving Ricon’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ricon’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On August 30, 2021, Ricon answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Ricon also asserted Counterclaims seeking declaratory judgments of non‑infringement for the nine Oxtellar XR® Orange Book patents. Supernus filed a motion to strike the jury demand in Ricon’s answer. On December 6, 2021, the Court signed an Order withdrawing the Jury demand from Ricon’s answer. On December 13, 2021, Ricon filed an amended Answer to Supernus’s Complaint. On December 15, 2021, the Company filed its reply, denying the substantive allegations of Ricon’s Counterclaims. On September 19, 2022, the Court issued an amended scheduling order that, among other things, moved the Final Pretrial Order deadline to June 30, 2023 (trial is still scheduled to commence in July 2023). Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. RiconPharma LLC, et al., C.A. No. 22-cv-6340 (KM)(MAH) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker RiconPharma, LLC (“Ricon”) dated October 7, 2022 directed to one of its Oxtellar XR® Orange Book patents. Supernus’s U.S. Patent No. 11,166,960 generally covers once-a-day oxcarbazepine formulations and methods of treating seizures using those formulations. The FDA Orange Book lists U.S. Patent No. 11,166,960 as expiring on April 13, 2027. On October 28, 2022, the Company filed a lawsuit against Ricon alleging infringement of U.S. Patent No. 11,166,960. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ricon infringed U.S. Patent No. 11,166,960 by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of U.S. Patent No. 11,166,960. As of the date of this submission, Ricon has not answered the Complaint.
Trokendi XR®
Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, et al., C.A. No. 21-cv-6964 (GC)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Ajanta Pharma Limited dated February 10, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On March 26, 2021, the Company filed a lawsuit against Ajanta Pharma Limited and Ajanta Pharma USA Inc. (collectively “Ajanta”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Ajanta infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its March 26, 2021 Complaint within 45 days of receiving Ajanta’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ajanta’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On June 7, 2021, Ajanta answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Ajanta also asserted Counterclaims seeking declaratory judgments of non‑infringement and invalidity for the Trokendi XR® Orange Book patents. On June 28, 2021, the Company filed its reply, denying the substantive allegations of Ajanta’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule. On December 17, 2021, the Court issued an order consolidating this lawsuit with the lawsuit against Torrent, discussed below. The consolidation order extended the 30-month stay preventing the FDA from approving Ajanta’s ANDA to December 16, 2023. On August 17, 2022, the Court amended the scheduling order. Under the amended scheduling order, the Final Pretrial Conference is set for May 24, 2023. The amended scheduling order states that trial will commence in July 2023. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Torrent Pharmaceuticals Ltd., et al., C.A. No. 21-cv-14268 (GC)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Torrent Pharmaceuticals Ltd. dated June 15, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On July 28, 2021, the Company filed a lawsuit against Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc. (collectively,
44
“Torrent”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Torrent infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its July 28, 2021 Complaint within 45 days of receiving Torrent’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Torrent’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On September 29, 2021, Torrent answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Torrent also asserted Counterclaims seeking declaratory judgments of non‑infringement for the Trokendi XR® Orange Book patents. On November 3, 2021, the Company filed its reply, denying the substantive allegations of Torrent’s Counterclaims. Following the initial Rule 16 Scheduling Conference, the Court issued a case schedule. On December 17, 2021, the Court issued an order consolidating this lawsuit with the lawsuit against Ajanta, discussed above. On August 17, 2022, the Court amended scheduling order. Under the amended scheduling order, the Final Pretrial Conference is set for May 24, 2023. The amended scheduling order states that trial will commence in July 2023. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Lupin Limited, et al., C.A. No. 21-cv-1293 (MN) (D. Del.)
The Company received a Paragraph IV Notice Letter from generic drug maker Lupin Limited dated July 29, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On September 10, 2021, the Company filed a lawsuit against Lupin Limited, Lupin Atlantis Holdings S.A., Nanomi B.V., Lupin Inc., and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of Delaware—alleges, inter alia, that Lupin infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its September 10, 2021 Complaint within 45 days of receiving Lupin’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Lupin’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On December 20, 2021, Lupin answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. Lupin also asserted Counterclaims seeking declaratory judgments of non infringement and invalidity for the Trokendi XR® Orange Book patents. On January 10, 2022, the Company filed its reply, denying the substantive allegations of Lupin’s Counterclaims. On February 25, 2022, the Court issued a scheduling order that provides for the Final Pretrial Order being submitted on June 6, 2023, and a trial beginning on June 20, 2023. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., et al., C.A. No. 21-cv-17104 (GC)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug maker Zydus Pharmaceuticals (USA) Inc. dated August 5, 2021 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On September 17, 2021, the Company filed a lawsuit against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (collectively, “Zydus”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that Zydus infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its September 17, 2021 Complaint within 45 days of receiving Zydus’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Zydus’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. The August 5, 2021 Paragraph IV Notice Letter from Zydus Pharmaceuticals (USA) Inc. concerns Zydus’s proposed generic equivalent of the 200 mg
45
strength of Trokendi XR®.[1] The August 5, 2021 Paragraph IV Notice Letter referenced herein does not concern the same ANDA as the one that was at issue in the previous lawsuit. On December 28, 2021, Zydus answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. On April 29, 2022, the Court issued a scheduling order that provides for the Final Pretrial Order being submitted on October 5, 2023, and a trial beginning on November 7, 2023. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., C.A. No. 22-cv-3511 (EEB)(SRH) (N.D. Ill.)
The Company received a Paragraph IV Notice Letter from generic drug maker Alkem Laboratories Ltd. dated May 25, 2022 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On July 6, 2022, the Company filed a lawsuit against Alkem Laboratories Ltd. (“Alkem”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the Northern District of Illinois—alleges, inter alia, that Alkem infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its July 6, 2022 Complaint within 45 days of receiving Alkem’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Alkem’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On October 3, 2022, Alkem answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. On October 26, 2022, the Court issued a scheduling order. The scheduling order states that the Pretrial Conference will be in May 2024 and that trial will commence in June 2024. Pretrial discovery is ongoing as of the date of this submission.
Supernus Pharmaceuticals, Inc. v. Dr. Reddy's Laboratories, Ltd., et al., C.A. No. 22-cv-4705 (GC)(LHG) (D.N.J.)
The Company received a Paragraph IV Notice Letter from generic drug makers Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. dated June 9, 2022 directed to ten of its Trokendi XR® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 generally cover once-a-day topiramate formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent No. 8,298,576 as expiring on April 4, 2028 and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; and 10,314,790 as expiring on November 16, 2027. On July 22, 2022, the Company filed a lawsuit against Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. (“DRL”) alleging infringement of the Company’s Trokendi XR® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, inter alia, that DRL infringed the Company’s Trokendi XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Trokendi XR® prior to the expiration of the Company’s patents. Filing its July 22, 2022 Complaint within 45 days of receiving DRL’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving DRL’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. On October 7, 2022, DRL answered the Compliant and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. As of the date of this submission, the Court has not issued a case schedule.
Sage Chemical, Inc., et al. v. Supernus Pharmaceuticals, Inc., et al., C.A. No. 22-cv-1302 (CFC) (D. Del.)
On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN® (apomorphine HCl). The Company is currently reviewing the details of the Complaint and will respond as appropriate.
Supernus Pharmaceuticals, Inc. v. Ajanta Pharma Limited, C.A. No. 22-cv-1431 (D. Del.)
The Company received a Paragraph IV Notice Letter from Ajanta Pharma Limited (“Ajanta”) on or around September 21, 2022, advising the Company of the filing by Ajanta of an Abbreviated New Drug Application with the U.S. Food and Drug
[1] Previously, the Company was in a lawsuit against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited concerning an Abbreviated New Drug Application (“ANDA”) for Zydus’s proposed generic equivalents of the 25 mg, 50 mg, and 100 mg strengths of Trokendi XR®. A settlement agreement was entered into between the Company and Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited concerning the previous lawsuit. See https://www.sec.gov/Archives/edgar/data/1356576/000110465917031191/a17-10293_1ex10d1.htm.
46
Administration (“FDA”) seeking approval for Oxcarbazepine Extended-Release Tablets, 150 mg, 300 mg, and 600 mg. The Notice Letter is directed to the Oxtellar XR® Orange Book patents, namely United States Patent Nos. 7,722,898, 7,910,131, 8,617,600, 8,821,930, 9,119,791, 9,351,975, 9,370,525, 9,855,278, 10,220,042, and 11,166,960. The FDA Orange Book currently lists all ten of the Oxtellar XR® Orange Book patents as expiring on April 13, 2027. On October 28, 2022, the Company filed a lawsuit against Ajanta alleging infringement of the Company’s Oxtellar XR® patents. The Complaint—filed in the U.S. District Court for the District of Delaware—alleges, inter alia, that Ajanta infringed the Company’s Oxtellar XR® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) seeking to market a generic version of Oxtellar XR® prior to the expiration of the Company’s patents. Filing its October 28, 2022 Complaint within 45 days of receiving Ajanta’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ajanta’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. As of the date of this submission, Ajanta has not answered the Complaint.
XADAGO®
On June 10, 2021, Newron Pharmaceuticals S.p.A. ("Newron"), Zambon S.p.A. ("Zambon") and Supernus Pharmaceuticals, Inc. (the "Company"), through its subsidiary MDD US Operations, LLC (collectively, "Plaintiffs"), initiated litigation against generic drug makers Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., MSN Laboratories Private Limited ("MSN"), Optimus Pharma Pvt Ltd, Prinston Pharmaceutical, Inc., RK Pharma, Inc. and Zenara Pharma Private Limited (collectively, "Defendants") for infringement of three FDA Orange Book patents covering XADAGO®, the Company's once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's Disease experiencing "off" episodes. U.S. Patent Nos. 8,076,515, 8,278,485 and 8,283,380 (collectively, the "XADAGO Patents") cover the pharmaceutical formulation of and methods of treatment with safinamide. The XADAGO Patents expire between June 2027 and March 2031. The Company has a license agreement with Zambon, Newron's partner, related to the XADAGO Patents, and as a new chemical entity, XADAGO was under the 5-year FDA exclusivity period that expired on March 21, 2022. The Complaint - filed in the U.S. District Court for the District of Delaware - alleges that the Defendants infringed the XADAGO Patents by submitting to the U.S. Food and Drug Administration (FDA) Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of XADAGO prior to the expiration of the patents. Filing the Complaint within 45 days of receiving each of the Defendants' Paragraph IV notice letters entitles the Plaintiffs to an automatic stay preventing the FDA from approving the Defendants' ANDAs for 30 months from the date of the Plaintiffs' receipt of the Paragraph IV Notice Letters. The parties agreed on a case schedule. A trial has been set for January 8, 2024. On March 22, 2022, defendant Optimus Pharma Pvt Ltd. was dismissed from the case without prejudice. Fact discovery is ongoing with the remaining defendants. A claim construction hearing originally scheduled for August 22, 2022 has been rescheduled for December 1, 2022.
Adamas Litigation
In November 2012, Adamas Pharmaceuticals, Inc. (Adamas) granted Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc (Forest), an exclusive license to certain of Adamas's intellectual property rights relating to human therapeutics containing memantine in the United States. Under the terms of that license agreement, Forest has the right to enforce such intellectual property rights which are related to its right to market and sell Namzaric and NAMENDA XR for the treatment of moderate to severe dementia related to Alzheimer's disease. Adamas has a right to participate in, but not control, such enforcement actions by Forest.
Since 2018 multiple generic companies have launched generic versions of NAMENDA XR. A number of companies have submitted ANDAs including one or more certifications to the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(iv), requesting approval to manufacture and market generic versions of Namzaric, on which Adamas became entitled to receive royalties from Forest beginning in May 2020.
Adamas and Forest have settled with all such Namzaric ANDA filers, including all first filers on all the available dosage forms of Namzaric. Subject to those agreements, the earliest date on which any of these agreements grant a license to market a Namzaric ANDA filer's generic version of Namzaric is January 1, 2025 (or earlier in certain circumstances). Alternatively, the Namzaric ANDA filers with the earliest date have the option to launch an authorized generic version of Namzaric beginning on January 1, 2026 instead of launching their own generic version of Namzaric on January 1, 2025. Adamas and Forest intend to continue to enforce the patents associated with Namzaric.
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (Case No. 3:18-cv-03018-JCS) against it and several Forest and Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by a named individual, Zachary Silbersher, asserting rights of the Federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit
47
when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high prices being charged to government payors.
Adamas's patents in question were licensed exclusively to Forest. The complaint includes a claim for damages of “potentially more than $2.5 billion dollars,” treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motions to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit. The petition remains pending.
On December 10, 2019, a putative class action lawsuit alleging violations of the federal securities laws was filed by Ali Zaidi against Adamas and certain of Adamas's former directors and officers in federal court in the Northern District of California (Case No. 4:19-cv-08051). This lawsuit alleges violations of the Securities Exchange Act of 1934 by Adamas and certain of Adamas's former directors and officers. On October 8, 2021, the presiding judge dismissed the litigation, and granted Plaintiffs leave to amend their complaint. On November 5, 2021, Plaintiffs filed their second amended class action complaint. On December 10, 2021, Adamas filed a motion to dismiss the Second Amended Complaint. Plaintiffs opposed the motion to dismiss. The motion to dismiss remains pending.
On March 16, 2020, a shareholder derivative lawsuit was filed by Patrick Van Camp in federal court in the Northern District of California (Case No. 4:20-cv-01815) naming Adamas and certain of Adamas's former directors and officers as defendants. This lawsuit alleges certain of Adamas's former directors and officers breached fiduciary duties and violated the Securities Exchange Act of 1934. Adamas is named as a nominal defendant only. On April 6, 2020, another, virtually identical, shareholder derivative lawsuit was filed by James Druzbik in federal court in the Northern District of California (Case No. 4:20- cv-02320) naming Adamas and certain of Adamas's former directors and officers as defendants. This lawsuit contains the same allegations, claims, and defendants as the first derivative action. Adamas is named as a nominal defendant only. In both actions, Plaintiffs seek unspecified monetary damages and other relief. These actions have been consolidated and are stayed pending resolution of the Zaidi class action.
Adamas believes it has strong factual and legal defenses to all actions and intends to defend itself vigorously.
Item 1A. Risk Factors
Any investment in our business involves a high degree of risk. Before making an investment decision, you should carefully consider the information we include in this Quarterly Report on Form 10-Q, including our condensed consolidated financial statements and related notes; the additional information in the other reports we file with the Securities and Exchange Commission; and the risks described in our Annual Report on Form 10-K for the year ended December 31, 2021, on Form 10-Q for the period ended June 30, 2022, and on this Quarterly Report on Form 10-Q for the period ended September 30, 2022. These risks may result in material harm to our business and our financial condition and results of operations. If a material, adverse event was to occur, the market price of our common stock may decline, and you could lose part or all of your investment.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
(a)     Sales of Unregistered Securities.
During the nine months ended September 30, 2022, all of the Company’s grants of equity awards occurred pursuant to its 2021 Equity Incentive Plan (the “2021 Plan”). Securities issued under the 2021 Plan are registered on the Company’s Form S-8 filed on June 25, 2021.
Item 3.    Defaults Upon Senior Securities
None
Item 4.    Mine Safety Disclosures
None
48
Item 5.    Other Information
None
49
Item 6.    Exhibits
The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:
31.1
31.2
32.1
32.2
101
The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL: (i) Cover Page, (ii) Condensed Consolidated Statements of Earnings, (iii) Condensed Consolidated Statements of Comprehensive Earnings, (iv) Condensed Consolidated Balance Sheets, (v) Condensed Consolidated Statements of Changes in Stockholders' Equity, (vi) Condensed Consolidated Statements of Cash Flows, and (vii) the Notes to Condensed Consolidated Financial Statements, tagged in summary and detail.
104
The cover page of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL (included with the Exhibit 101 attachments).
50
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
SUPERNUS PHARMACEUTICALS, INC.
DATED: November 9, 2022By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer
DATED: November 9, 2022By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer
51
 EX-31.1 2 supn-20220930x10qxex311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION
I, Jack A. Khattar, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Supernus Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 9, 2022By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer


 EX-31.2 3 supn-20220930x10qxex312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION
I, Timothy C. Dec, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Supernus Pharmaceuticals, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 9, 2022By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer


 EX-32.1 4 supn-20220930x10qxex321.htm EX-32.1 Document

EXHIBIT 32.1
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jack A. Khattar, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2022By:/s/ Jack A. Khattar
Jack A. Khattar
President and Chief Executive Officer


 EX-32.2 5 supn-20220930x10qxex322.htm EX-32.2 Document

EXHIBIT 32.2
SUPERNUS PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. sec. 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Timothy C. Dec, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2022By:/s/ Timothy C. Dec
Timothy C. Dec
Senior Vice President and Chief Financial Officer


 EX-101.SCH 6 supn-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Earnings link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Business Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Disaggregated Revenues link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Contingent Consideration link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Convertible Senior Notes Due 2023 link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Share-Based Payments link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Tax (Benefit) Expense link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Composition of Other Balance Sheet Items link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Interest Expense link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Acquisition (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Disaggregated Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Contingent Consideration (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Convertible Senior Notes Due 2023 (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Income Tax (Benefit) Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Composition of Other Balance Sheet Items (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Interest Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Business Organization (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Acquisition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Acquisition - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Disaggregated Revenues - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Investments - Unrestricted Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Investments - Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Fair Value of Financial Instruments - Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Fair Value of Financial Instruments- Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Contingent Consideration - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Convertible Senior Notes Due 2023 - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Share-Based Payments - SAR Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Share-Based Payments - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Share-Based Payments - Performance Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Income Tax (Benefit) Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Leases - Leases Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Composition of Other Balance Sheet Items - Accounts Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Composition of Other Balance Sheet Items - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Composition of Other Balance Sheet Items - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Composition of Other Balance Sheet Items - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Composition of Other Balance Sheet Items - Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 supn-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 supn-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 supn-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Less than 1 year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Business Acquisition [Axis] Business Acquisition [Axis] Agreement termination notice period Variable Interest Entity, Agreement Termination Notice, Period Variable Interest Entity, Agreement Termination Notice, Period Restatement [Axis] Revision of Prior Period [Axis] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Unrealized loss on marketable securities, net of tax Unrealized loss on marketable securities, net of tax Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Additional cash payments upon milestone achievements maximum Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two Consecutive trading day period (in days) Debt Instrument, Convertible, Threshold Consecutive Trading Days Property and equipment, gross Property, Plant and Equipment, Gross APOKYN and SPN-830 APOKYN And SPN-830 [Member] APOKYN And SPN-830 Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Additional paid-in capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Finite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Interest rate Debt Instrument, Interest Rate, Stated Percentage Sales and maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Income tax expense (benefit), adjustment of deferred tax (asset) liability Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Other noncash adjustments, net Other Noncash Income (Expense) Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization 3 years to 4 years Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value Fair value of available-for-sale debt securities maturing in the third fiscal year through the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Net earnings Net earnings Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Conversion Circumstance Two Conversion Circumstance Two [Member] Conversion Circumstance Two Income per share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock equivalents excluded in the calculation of diluted income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Equity Component [Domain] Equity Component [Domain] SPN-830 First Commercial And Sale SPN-830 First Commercial And Sale [Member] SPN-830 First Commercial And Sale Total fair value of assets acquired Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired Total assets at fair value Total assets at fair value Assets, Fair Value Disclosure Investment, Name [Domain] Investment, Name [Domain] Leases Lessee, Operating Leases [Text Block] Leases Lessee, Lease, Description [Line Items] NAMENDA XR/Namzaric Qui Tam Litigation NAMENDA XR/Namzaric Qui Tam Litigation [Member] NAMENDA XR/Namzaric Qui Tam Litigation Conversion option stock price trigger (in dollars per share) Debt Instrument, Convertible, Stock Price Trigger Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Supplemental cash flow information Supplemental Cash Flow Information [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Convertible notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Outstanding at the end of the period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Denominator: Weighted Average Number of Shares Outstanding, Basic [Abstract] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating lease liabilities, current portion Operating Lease, Liability, Current Accrued product returns Accrued Product Returns Represents the amount of accrued product returns. Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Summary of restricted stock units Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Acquired in-process research and development In Process Research and Development [Member] Milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses Costs and Expenses [Abstract] Long term marketable securities Debt Securities, Noncurrent [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Legal Entity [Axis] Legal Entity [Axis] Deferred legal fees and fixed assets included in accounts payable and accrued expenses Deferred Legal Fees and Fixed Assets Included in Accounts Payable and Accrued Expenses Deferred Legal Fees and Fixed Assets Included in Accounts Payable and Accrued Expenses Convertible notes, net Long-Term Debt, Excluding Current Maturities Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Total liabilities Liabilities Share-Based Payments Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Goodwill, adjustments Goodwill, Purchase Accounting Adjustments Finite-lived and indefinite-lived intangible assets acquired as part of business combination Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of premium/discount on marketable securities Investment Income, Net, Amortization of Discount and Premium Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Issuance of common stock in connection with the Company’s equity award plans Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Corporate and municipal debt securities Debt Securities, Available-for-Sale, Current Document Type Document Type Weighted Average Exercise Price (per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Convertible Senior Notes Due 2023 Long-Term Debt [Text Block] Number of RSUs Number of PSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Adamas Pharmaceuticals Adamas Pharmaceuticals [Member] Adamas Pharmaceuticals Assets: Assets, Fair Value Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Additional cash payments upon milestone achievements minimum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Nonvested, beginning balance (in dollars per share) Nonvested, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Purchase of property and equipment and deferred legal fees paid Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees Raw materials Inventory, Work in Process and Raw Materials, Net of Reserves 1 year to 2 years Available For Sale Securities Debt Maturities After One Through Two Years Fair Value Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred income tax provision Deferred Income Tax Expense (Benefit) Accrued clinical trial costs Accrued Clinical Trial and Clinical Supply Costs Current Represents the amount of clinical trial and clinical supply costs accrued. Marketable securities - restricted (SERP) Assets for Plan Benefits, Defined Benefit Plan Lease liabilities, current Lease Liabilities, Current [Abstract] Lease Liabilities, Current Financial Instrument [Axis] Financial Instrument [Axis] Acquired developed technology and product rights Developed Technology Rights [Member] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] APOKYN APOKYN [Member] APOKYN Document Period End Date Document Period End Date Schedule of financial liabilities that are not carried at fair value Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total PSUs Performance Shares [Member] Total Accrued Liabilities, Current Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Convertible notes, net Long-Term Debt, Current Maturities Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Interest expense Interest Expense, Debt Accrued compensation Employee-related Liabilities, Current Earnings (Loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Amortization of deferred financing costs and debt discount Amortization of Debt Issuance Costs and Discounts Earnings per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Sales-based contingent consideration liabilities Sales-Based Contingent Consideration Liability [Member] Sales-Based Contingent Consideration Liability Composition of Other Balance Sheet Items Supplemental Balance Sheet Disclosures [Text Block] Award Type [Domain] Award Type [Domain] Accrued product rebates Accrued Rebates Represents the amount of accrued rebates. Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Computer equipment Computer Equipment [Member] SPN-830 NDA Approval Milestone SPN-830 NDA Approval Milestone [Member] SPN-830 NDA Approval Milestone Cash consideration paid Payments to Acquire Businesses, Gross Other Manufactured Product, Other [Member] Entity Registrant Name Entity Registrant Name Issuance of common stock in connection with the Company’s equity award plans (in shares) Stock Issued During Period, Shares, New Issues Subsequent Events Subsequent Events [Text Block] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory USWM Enterprises MDD US Enterprises LLC (Formerly USWM Enterprises) [Member] MDD US Enterprises LLC (Formerly USWM Enterprises) Regulatory and developmental contingent consideration liabilities Regulatory And Developmental Contingent Consideration Liability [Member] Regulatory And Developmental Contingent Consideration Liability Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Consolidation Consolidation, Policy [Policy Text Block] Market-Based Units Market Based Units [Member] Market Based Units Minimum Minimum [Member] Conversion rate for the notes (in shares per $1,000 principal amount) Debt Instrument, Convertible, Conversion Ratio Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Royalty revenues Royalty [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Intangibles Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Investment, Name [Axis] Investment, Name [Axis] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Fair Value of Financial Instruments and Contingent Consideration Fair Value Disclosures [Text Block] Accrued product returns and rebates Total Accrued Product Returns and Rebates. Carrying value as of the balance sheet date of accrued product returns and rebates. Trading Symbol Trading Symbol Entity File Number Entity File Number 2023 Notes Convertible Debt Securities [Member] Lease liabilities, long-term Lease Liabilities, Noncurrent [Abstract] Lease Liabilities, Noncurrent 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense Accrued product costs Accrued Product Costs, Current Accrued Product Costs, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period RSUs Restricted Stock Units (RSUs) [Member] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Money market funds Cash and Cash Equivalents, Fair Value Disclosure Acquisition Business Combination Disclosure [Text Block] Other income (expense) Other Nonoperating Income (Expense) [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Accrued product returns and rebates Increase (Decrease) In Accrued Product Returns And Rebates Amount of increase (decrease) in product returns and rebates. SPN-830 FDA Acceptance Milestone SPN-830 FDA Acceptance Milestone [Member] SPN-830 FDA Acceptance Milestone Total purchase price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Balance at December 31, 2021 Balance at September 30, 2022 (unaudited) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Concentration risk percentage (more than) Concentration Risk, Percentage Subsequent Events [Abstract] Pro forma net loss Business Acquisition, Pro Forma Net Income (Loss) Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Tax (Benefit) Expense Income Tax Disclosure [Text Block] Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities Finished goods Inventory, Finished Goods, Net of Reserves Total intangible assets, carrying amount, gross Intangible Assets, Gross (Excluding Goodwill) Amortization of intangible assets Amortization of intangible assets Amortization of Intangible Assets Strike price of the warrant transactions (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Goodwill Schedule of Goodwill [Table Text Block] Cash paid for interest on convertible notes Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in dollars per share) Earnings per share, basic (in dollars per share) Earnings Per Share, Basic Operating lease liabilities, long-term Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Concentration Risk Type [Domain] Concentration Risk Type [Domain] Other income from Navitor (see Note 5) Payments For (Proceeds From) Collaborative Arrangement, Investment Payments For (Proceeds From) Collaborative Arrangement, Investment Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total stockholders’ equity Balance Balance Stockholders' equity attributable to parent Stockholders' Equity Attributable to Parent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Deferred income tax liabilities adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Reconciliation of the beginning and ending balances related to the contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Nonrecourse liability related to sale of future royalties, long-term Non-Recourse Liability, Noncurrent Non-Recourse Liability, Noncurrent Money market funds Money Market Funds [Member] Threshold for development costs payments Collaborative Arrangement, Threshold For Development Costs Payments Collaborative Arrangement, Threshold For Development Costs Payments Retained Earnings Retained Earnings [Member] Common Stock Common Stock [Member] Schedule of share-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Contingent consideration Contingent consideration Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] 2 years to 3 years Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value Fair value of available-for-sale debt securities maturing in the second fiscal year through the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Optional lease renewal term (in years) Lessee, Operating Lease, Renewal Term Long-term marketable securities Marketable Securities, Noncurrent Document Quarterly Report Document Quarterly Report Current assets Assets, Current [Abstract] Operating lease liabilities, long-term Operating lease liabilities, long-term Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Payment of contingent consideration Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Capitalized patent defense costs Patent Defense Costs [Member] Represents information concerning the capitalized patent defense costs related to the Watson litigation. Acquired in-process research and development Indefinite-Lived Intangible Assets (Excluding Goodwill) Leasehold improvements Leasehold Improvements [Member] SPN-830 NDA Approval Milestone, Time-Based SPN-830 NDA Approval Milestone, Time-Based [Member] SPN-830 NDA Approval Milestone, Time-Based Retained earnings Retained Earnings (Accumulated Deficit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchases of marketable securities Payments to Acquire Marketable Securities Fair Value (Level 2) Convertible Debt, Fair Value Disclosures Equity Components [Axis] Equity Components [Axis] Cardinal Health Cardinal Health [Member] Cardinal Health Recurring Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Business acquisition, pro forma information Business Acquisition, Pro Forma Information [Table Text Block] Restatement [Domain] Revision of Prior Period [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement Statement [Line Items] Contingent Consideration Disclosure Contingent Consideration Disclosure [Text Block] Contingent Consideration Disclosure Nonvested, beginning balance (in shares) Nonvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Contingent consideration, current portion Business Combination, Contingent Consideration, Liability, Current Total other income (expense) Nonoperating Income (Expense) Carrying Amount, Gross Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense SPN-830 NDA Approval Milestone, Approval-Based SPN-830 NDA Approval Milestone, Approval-Based [Member] SPN-830 NDA Approval Milestone, Approval-Based Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Contingent consideration expense (gain) Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Accrued royalties Accrued Royalties, Current Operating lease assets Operating Lease, Right-of-Use Asset Gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Net product sales Product [Member] Accumulated Other Comprehensive Earnings (Loss) AOCI Attributable to Parent [Member] Change in fair value of operating lease acquired Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets Additional cash payments upon milestone achievements minimum Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One Proceeds from governmental loan and grant Proceeds from Governmental Loan and Grant Proceeds from Governmental Loan and Grant Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Schedule of balance sheet information related to leases Lessee, Operating and Finance Lease, Balance Sheet Disclosure [Table Text Block] Lessee, Operating and Finance Lease, Balance Sheet Disclosure Document Transition Report Document Transition Report Local Phone Number Local Phone Number Summary of stock options and SAR activities Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating earnings (loss) Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Common stock issued upon conversion of notes (in shares) Debt Conversion, Converted Instrument, Shares Issued Total identifiable net assets, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets (Liabilities), Net Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets (Liabilities), Net Other liabilities Other Sundry Liabilities, Noncurrent Corporate and Municipal Debt Securities Corporate And Municipal Debt Securities [Member] Corporate And Municipal Debt Securities Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock shares outstanding (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill Balance as of December 31, 2021 Balance as of September 30, 2022 (unaudited) Goodwill Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Total liabilities at fair value Liabilities, Fair Value Disclosure MDD Subsidiaries MDD Subsidiaries [Member] MDD Subsidiaries Adjustments to reconcile net earnings to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Trokendi XR Trokendi Xr [Member] Represents information pertaining to Trokendi XR patent litigation. Income tax (benefit) expense Income Tax Expense (Benefit) Deferred income tax liabilities Deferred Income Tax Liabilities, Net Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional  Paid-in Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Balance, January 1, 2022 Cumulative Effect, Period of Adoption, Adjusted Balance [Member] Cost of goods sold Cost of Goods and Services Sold Debt securities, available-for-sale, excluding accrued interest, allowance for credit loss, not previously recorded Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded Diluted (in shares) Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of inventories Schedule of Inventory, Current [Table Text Block] Current debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt Schedule of unrestricted available-for-sale marketable securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Weighted Average Remaining Contractual Term (in years) Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract] Common Stock, Value, Issued Common Stock, Value, Issued Conversion of debt to equity Debt Conversion, Original Debt, Amount Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Granted (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Conversion price, per share of common stock (in dollars per share) Debt Instrument, Convertible, Conversion Price Schedule of common stock equivalents excluded in the calculation of diluted earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Convertible Debt Convertible Debt [Member] Product Concentration Risk Product Concentration Risk [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Cash and cash equivalents at beginning of year Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Three Major Customers Three Major Customers [Member] Three Major Customers Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities Liabilities, Current [Abstract] Numerator for dilutive earnings per share Net Income (Loss) Available to Common Stockholders, Basic Common stock shares issued (in shares) Common Stock, Shares, Issued Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Cash distributions received Proceeds from Divestiture of Businesses and Interests in Affiliates Property and equipment additions from utilization of tenant improvement allowance Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] Interest expense on nonrecourse liability related to sale of future royalties Interest Expense, Other Carrying Value Convertible Notes Payable, Noncurrent Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Principal amount of debt 2023 Notes Debt Instrument, Face Amount Remaining Weighted Average Life (Years) Finite-Lived Intangible Assets, Remaining Amortization Period After-tax interest expense for 2023 Notes Interest on Convertible Debt, Net of Tax Lab equipment and furniture Lab Equipment And Furniture [Member] Represents information pertaining to lab equipment and furniture. Comprehensive earnings (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Lease assets obtained for new operating leases Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability Pro forma total revenues Business Acquisition, Pro Forma Revenue Total fair value of liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Construction-in-progress Construction in Progress [Member] Gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other current liabilities Other Liabilities, Current Fair value of excess of the acquisition Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value Other assets Other Assets, Noncurrent Earnings per share EPS Basic And Diluted [Abstract] EPS Basic And Diluted Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total fair value Total Debt Securities, Available-for-Sale, Excluding Accrued Interest McKesson McKesson [Member] McKesson Schedule of recognized identified assets acquired and liabilities assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Unamortized debt discount and deferred financing costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Schedule of interest expense Interest Income and Interest Expense Disclosure [Table Text Block] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Number of shares per warrant entitled to holder (in shares) Class of Warrant or Right, Number of Shares in Which Holder Can be Entitled per Warrants at Strike Price Represents the information pertaining to the shares per warrant entitled to holders at strike price. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Allowance for expected sales discounts and allowances Allowance for Expected Sales deductions Represents the allowance for sales discounts related to prompt-pay discounts and contractual fee for service arrangements to wholesalers and distributors. Contingent consideration Increase (Decrease) In Contingent Consideration Increase (Decrease) In Contingent Consideration Property and equipment, net Property, Plant and Equipment, Net Liabilities Liabilities [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Contingents value rights Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share Cash and cash equivalents Cash and Cash Equivalents [Abstract] Cash paid for operating leases Operating Lease, Payments Change in fair value recognized in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Additional cash payments upon milestone achievements maximum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Measurement Period Adjustments Prior Period Adjustment [Abstract] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt Total carrying value Long-Term Debt Interest and other income, net Other Nonoperating Income (Expense) Common stock shares authorized (in shares) Common Stock, Shares Authorized Contingent consideration, long-term Business Combination, Contingent Consideration, Liability, Noncurrent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Accumulated other comprehensive earnings (loss), net of tax Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of accrued product returns and rebates Schedule of Accrued Product Returns and Rebates [Table Text Block] Tabular disclosure of the accrued product returns and rebates. Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Stock options, RSUs, PSUs Share-Based Payment Arrangement [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Schedule of fair value of the financial assets and liabilities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Total current assets Assets, Current Cash paid for income taxes Income Taxes Paid, Net Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Balance (in shares) Balance (in shares) Shares, Outstanding Measurement Frequency [Domain] Measurement Frequency [Domain] Revenues Revenues [Abstract] Carrying Amount, Net Finite-Lived Intangible Assets, Net Accrued expenses and other current liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Threshold trading days (whether or not consecutive) Debt Instrument, Convertible, Threshold Trading Days Software Computer Software, Intangible Asset [Member] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Number of Options & SARs Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Summary of performance stock unit Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Convertible note hedge options issued (in shares) Debt Conversion, Converted Instrument, Warrants or Options Issued Other liabilities Other Noncurrent Liabilities [Table Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security Consolidated Entities [Axis] Consolidated Entities [Axis] Total costs and expenses Costs and Expenses Realized gains from sales of marketable securities Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Conversion Circumstance One Conversion Circumstance One [Member] Conversion Circumstance One Marketable securities Debt Securities, Current [Abstract] Selling, general and administrative Selling, General and Administrative Expenses [Member] Schedule of intangible assets and goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Investments, Debt and Equity Securities [Abstract] As Initially Reported Previously Reported [Member] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Deferred tax liabilities, net Deferred Tax Liabilities, Net Number of established marketed products Number Of Established Marketed Products Number Of Established Marketed Products Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Payment to resolve U.S. Department of Justice allegations Litigation Settlement, Amount Awarded to Other Party Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventories, net Total inventories Inventory, Net Annual minimum purchase quantity requirement amount Purchase Commitment, Annual Minimum Amount Committed Purchase Commitment, Annual Minimum Amount Committed Accounts payable Accounts Payable, Current Conversion rate of the notes on trading day (as percent) Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Investments Equity Securities, FV-NI, Cost Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held Investments Classified by Contractual Maturity Date [Table Text Block] Business Organization Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Basic (in shares) Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Liabilities: Liabilities, Fair Value Disclosure [Abstract] Total Share-Based Payment Arrangement, Expense Noncash investing and financing activities Noncash Investing and Financing Items [Abstract] Security Exchange Name Security Exchange Name Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Property and equipment Property, Plant and Equipment [Line Items] AmerisourceBergen Drug Corporation AmerisourceBergen Drug Corporation [Member] AmerisourceBergen Drug Corporation Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Stock option and Stock Appreciation Rights Stock Option Stock Appreciation Rights [Member] Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights. Cover page. Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction Corporate and municipal debt securities Debt Securities, Available-for-Sale, Noncurrent Share-Based Payments Share-Based Payment Arrangement [Text Block] Work in process Inventory, Work in Process, Net of Reserves Disaggregated Revenues Revenue from Contract with Customer [Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Goodwill [Roll Forward] Goodwill [Roll Forward] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Developed Technology Rights and Patent Defense Costs Developed Technology Rights And Patent Defense Costs [Member] Developed Technology Rights And Patent Defense Costs Stock options, RSU and SAR (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Acquisition of USWM, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Share-based payments Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Marketable securities Marketable Securities, Current Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in dollars per share) Earnings per share, diluted (in dollars per share) Earnings Per Share, Diluted Intangible assets, net Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Total lease liabilities Lease, Liability Lease, Liability Interest Expense Other Nonoperating Income and Expense [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Greater than 4 years Available For Sale Securities Debt Maturities, Thereafter, Fair Value Available For Sale Securities Debt Maturities, Thereafter, Fair Value Performance-Based Units Performance Based Units [Member] Performance Based Units Commitment period Long-Term Purchase Commitment, Period Customer Concentration Risk Customer Concentration Risk [Member] Cumulative effect of adoption of ASU 2020-06 Cumulative Effect, Period of Adoption, Adjustment [Member] Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Entity Address, Address Line One Entity Address, Address Line One Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Other noncurrent assets Other Assets, Noncurrent [Abstract] Adamas Acquisition Adamas [Member] Adamas Product and Service [Axis] Product and Service [Axis] Nonrecourse liability related to sale of future royalties, long term Non Recourse Debt Sale of Future Royalties Noncurrent Noncurrent portion of debt, net of the amount due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property. Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Total Interest Expense Oxtellar XR Oxtellar X R [Member] Represents information pertaining to Oxtellar XR product. Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Long-term Purchase Commitment [Line Items] Long-Term Purchase Commitment [Line Items] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Debt Conversion Description [Axis] Debt Conversion Description [Axis] Navitor Pharmaceuticals, Inc. Navitor Pharmaceuticals, Inc. [Member] Navitor Pharmaceuticals, Inc. Entity Tax Identification Number Entity Tax Identification Number GOCOVRI GOCOVRI [Member] GOCOVRI SPN-830 Future Sales Performance SPN-830 Future Sales Performance [Member] SPN-830 Future Sales Performance Advertising costs Advertising Expense Debt Conversion, Name [Domain] Debt Conversion, Name [Domain] Summary of disaggregation of revenues by nature Disaggregation of Revenue [Table Text Block] Qelbree Qelbree [Member] Qelbree Cash Cash [Member] Consolidated Entities [Domain] Consolidated Entities [Domain] VIE, qualitative or quantitative information, ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Schedule of reconciliation of income tax expense at the U.S Federal statutory income tax rate to the entity's effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Total purchase price Business Combination, Consideration Transferred Other accrued expenses Other Accrued Liabilities, Current Entity [Domain] Entity [Domain] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code Accrued professional & marketing fees Accrued Professional Fees, Current Assets Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Advertising Expense Advertising Cost [Policy Text Block] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Navitor investment R&D expense (see Note 5) Research and Development in Process Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Warrants issued (in shares) Class of Warrant or Right, Outstanding Other liabilities Total Other Liabilities, Noncurrent Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Long-term purchase commitment, amount Long-Term Purchase Commitment, Amount 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One SPN-830 Regulatory and Commercial Activities SPN-830 Regulatory And Commercial Activities [Member] SPN-830 Regulatory And Commercial Activities Schedule of computation of basic and diluted earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rights per share (in dollars per share) Business Combination, Contingent Consideration, Rights Per Share Business Combination, Contingent Consideration, Rights Per Share Summary of liability component of 2023 Notes Convertible Debt [Table Text Block] Non-cash royalty revenue Revenue From Royalty Agreement Represents revenue from the sale of certain royalty and milestone rights. Customer [Domain] Customer [Domain] Accounting Standards Update [Extensible Enumeration] Accounting Standards Update [Extensible Enumeration] EX-101.PRE 10 supn-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Oct. 31, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-35518  
Entity Registrant Name SUPERNUS PHARMACEUTICALS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 20-2590184  
Entity Address, Address Line One 9715 Key West Avenue  
Entity Address, City or Town Rockville  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 20850  
City Area Code 301  
Local Phone Number 838-2500  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Entity Common Stock, Shares Outstanding   54,058,138
Trading Symbol SUPN  
Security Exchange Name NASDAQ  
Entity Central Index Key 0001356576  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets    
Cash and cash equivalents $ 111,492 $ 203,434
Marketable securities 280,297 136,246
Accounts receivable, net 164,086 148,932
Inventories, net 83,165 85,959
Prepaid expenses and other current assets 24,846 27,019
Total current assets 663,886 601,590
Long-term marketable securities 131,937 119,166
Property and equipment, net 15,872 16,955
Intangible assets, net 722,761 784,693
Goodwill 117,383 117,516
Other assets 41,290 49,232
Total assets 1,693,129 1,689,152
Current liabilities    
Accounts payable and accrued liabilities 110,302 117,683
Accrued product returns and rebates 158,470 132,724
Contingent consideration, current portion 47,590 44,840
Convertible notes, net 401,438 0
Other current liabilities 8,187 20,132
Total current liabilities 725,987 315,379
Convertible notes, net 0 379,252
Contingent consideration, long-term 9,781 35,637
Operating lease liabilities, long-term 36,028 41,298
Deferred income tax liabilities 58,164 85,355
Other liabilities 10,371 16,380
Total liabilities 840,331 873,301
Stockholders’ equity    
Common Stock, Value, Issued 54 53
Additional paid-in capital 401,026 434,337
Accumulated other comprehensive earnings (loss), net of tax (4,046) 1,539
Retained earnings 455,764 379,922
Total stockholders’ equity 852,798 815,851
Total liabilities and stockholders’ equity $ 1,693,129 $ 1,689,152
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Stockholders’ equity    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock shares authorized (in shares) 130,000,000 130,000,000
Common stock shares issued (in shares) 54,053,513 54,053,513
Common stock shares outstanding (in shares) 53,256,094 53,256,094
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Earnings - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues        
Total revenues $ 177,353 $ 148,464 $ 499,910 $ 420,725
Costs and expenses        
Cost of goods sold [1] 25,878 18,085 64,267 58,067
Research and development 19,554 19,654 56,778 69,389
Selling, general and administrative 112,314 72,032 303,249 203,024
Amortization of intangible assets 20,644 6,009 61,932 17,964
Contingent consideration expense (gain) 486 80 1,894 (7,650)
Total costs and expenses 178,876 115,860 488,120 340,794
Operating earnings (loss) (1,523) 32,604 11,790 79,931
Other income (expense)        
Interest expense (1,724) (5,925) (5,476) (17,489)
Interest and other income, net 2,803 2,281 19,289 8,682
Total other income (expense) 1,079 (3,644) 13,813 (8,807)
Earnings (Loss) before income taxes (444) 28,960 25,603 71,124
Income tax (benefit) expense (2,193) 7,398 (9,627) 20,142
Net earnings $ 1,749 $ 21,562 $ 35,230 $ 50,982
Earnings per share        
Basic (in dollars per share) $ 0.03 $ 0.41 $ 0.66 $ 0.96
Diluted (in dollars per share) $ 0.03 $ 0.40 $ 0.62 $ 0.94
Weighted average shares outstanding        
Basic (in shares) 53,789,674 53,187,764 53,517,838 53,053,441
Diluted (in shares) 55,034,838 54,334,794 61,543,121 54,301,461
Net product sales        
Revenues        
Total revenues $ 172,724 $ 145,532 $ 485,647 $ 412,541
Royalty revenues        
Revenues        
Total revenues $ 4,629 $ 2,932 $ 14,263 $ 8,184
[1] Excludes amortization of acquired intangible assets
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Earnings - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net earnings $ 1,749 $ 21,562 $ 35,230 $ 50,982
Other comprehensive loss:        
Unrealized loss on marketable securities, net of tax (1,826) (1,224) (5,585) (4,766)
Other comprehensive loss (1,826) (1,224) (5,585) (4,766)
Comprehensive earnings (loss) $ (77) $ 20,338 $ 29,645 $ 46,216
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Changes in Stockholder's Equity - USD ($)
$ in Thousands
Total
Cumulative effect of adoption of ASU 2020-06
Balance, January 1, 2022
Common Stock
Common Stock
Balance, January 1, 2022
Additional  Paid-in Capital
Additional  Paid-in Capital
Cumulative effect of adoption of ASU 2020-06
Additional  Paid-in Capital
Balance, January 1, 2022
Accumulated Other Comprehensive Earnings (Loss)
Accumulated Other Comprehensive Earnings (Loss)
Balance, January 1, 2022
Retained Earnings
Retained Earnings
Cumulative effect of adoption of ASU 2020-06
Retained Earnings
Balance, January 1, 2022
Balance (in shares) at Dec. 31, 2020       52,868,482                  
Balance at Dec. 31, 2020 $ 744,858     $ 53   $ 409,332     $ 8,975   $ 326,498    
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,371         4,371              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       125,655                  
Issuance of common stock in connection with the Company’s equity award plans 2,247         2,247              
Net earnings 5,694                   5,694    
Unrealized loss on marketable securities, net of tax (2,726)               (2,726)        
Balance (in shares) at Mar. 31, 2021       52,994,137                  
Balance at Mar. 31, 2021 754,444     $ 53   415,950     6,249   332,192    
Balance (in shares) at Dec. 31, 2020       52,868,482                  
Balance at Dec. 31, 2020 744,858     $ 53   409,332     8,975   326,498    
Increase (Decrease) in Stockholders' Equity                          
Net earnings 50,982                        
Unrealized loss on marketable securities, net of tax (4,766)                        
Balance (in shares) at Sep. 30, 2021       53,180,643                  
Balance at Sep. 30, 2021 810,468     $ 53   428,726     4,209   377,480    
Balance (in shares) at Mar. 31, 2021       52,994,137                  
Balance at Mar. 31, 2021 754,444     $ 53   415,950     6,249   332,192    
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 5,476         5,476              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       150,622                  
Issuance of common stock in connection with the Company’s equity award plans 2,749         2,749              
Net earnings 23,726                   23,726    
Unrealized loss on marketable securities, net of tax (816)               (816)        
Balance (in shares) at Jun. 30, 2021       53,144,759                  
Balance at Jun. 30, 2021 785,579     $ 53   424,175     5,433   355,918    
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,027         4,027              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       35,884                  
Issuance of common stock in connection with the Company’s equity award plans 524         524              
Net earnings 21,562                   21,562    
Unrealized loss on marketable securities, net of tax (1,224)               (1,224)        
Balance (in shares) at Sep. 30, 2021       53,180,643                  
Balance at Sep. 30, 2021 810,468     $ 53   428,726     4,209   377,480    
Balance (in shares) at Dec. 31, 2021       53,256,094 53,256,094                
Balance at Dec. 31, 2021 815,851 $ (15,600) $ 800,251 $ 53 $ 53 434,337 $ (56,212) $ 378,125 1,539 $ 1,539 379,922 $ 40,612 $ 420,534
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,025         4,025              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       130,211                  
Issuance of common stock in connection with the Company’s equity award plans 866         866              
Net earnings 25,616                   25,616    
Unrealized loss on marketable securities, net of tax (2,312)               (2,312)        
Balance (in shares) at Mar. 31, 2022       53,386,305                  
Balance at Mar. 31, 2022 $ 828,446     $ 53   383,016     (773)   446,150    
Increase (Decrease) in Stockholders' Equity                          
Accounting Standards Update [Extensible Enumeration] Accounting Standards Update 2020-06                        
Balance (in shares) at Dec. 31, 2021       53,256,094 53,256,094                
Balance at Dec. 31, 2021 $ 815,851 $ (15,600) $ 800,251 $ 53 $ 53 434,337 $ (56,212) $ 378,125 1,539 $ 1,539 379,922 $ 40,612 $ 420,534
Increase (Decrease) in Stockholders' Equity                          
Net earnings 35,230                        
Unrealized loss on marketable securities, net of tax (5,585)                        
Balance (in shares) at Sep. 30, 2022       54,053,513                  
Balance at Sep. 30, 2022 852,798     $ 54   401,026     (4,046)   455,764    
Balance (in shares) at Mar. 31, 2022       53,386,305                  
Balance at Mar. 31, 2022 828,446     $ 53   383,016     (773)   446,150    
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,297         4,297              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       106,081                  
Issuance of common stock in connection with the Company’s equity award plans 2,273         2,273              
Net earnings 7,865                   7,865    
Unrealized loss on marketable securities, net of tax (1,447)               (1,447)        
Balance (in shares) at Jun. 30, 2022       53,492,386                  
Balance at Jun. 30, 2022 841,434     $ 53   389,586     (2,220)   454,015    
Increase (Decrease) in Stockholders' Equity                          
Share-based compensation 4,985         4,985              
Issuance of common stock in connection with the Company’s equity award plans (in shares)       561,127                  
Issuance of common stock in connection with the Company’s equity award plans 6,456     $ 1   6,455              
Net earnings 1,749                   1,749    
Unrealized loss on marketable securities, net of tax (1,826)               (1,826)        
Balance (in shares) at Sep. 30, 2022       54,053,513                  
Balance at Sep. 30, 2022 $ 852,798     $ 54   $ 401,026     $ (4,046)   $ 455,764    
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities    
Net earnings $ 35,230 $ 50,982
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation and amortization 64,694 19,888
Navitor investment R&D expense (see Note 5) 0 15,000
Other income from Navitor (see Note 5) (12,888) 0
Amortization of deferred financing costs and debt discount 1,582 13,037
Realized gains from sales of marketable securities (14) (221)
Amortization of premium/discount on marketable securities 3,215 (845)
Change in fair value of contingent consideration 1,894 (7,650)
Other noncash adjustments, net 7,983 (22)
Share-based compensation expense 13,307 13,874
Deferred income tax provision (18,564) (479)
Changes in operating assets and liabilities:    
Accounts receivable (14,958) 7,352
Inventories (6,304) (9,331)
Prepaid expenses and other assets 3,098 (13,351)
Accrued product returns and rebates 25,746 5,856
Accounts payable and other liabilities (12,659) (15,726)
Contingent consideration (2,100) 0
Net cash provided by operating activities 89,262 78,364
Cash flows from investing activities    
Purchases of marketable securities (340,665) (307,634)
Sales and maturities of marketable securities 173,189 152,546
Purchase of property and equipment and deferred legal fees paid (422) (2,005)
Acquisition of USWM, net of cash acquired 0 (950)
Net cash used in investing activities (167,898) (158,043)
Cash flows from financing activities    
Payment of contingent consideration (22,900) 0
Proceeds from issuance of common stock 9,594 5,520
Proceeds from governmental loan and grant 0 800
Net cash (used in) provided by financing activities (13,306) 6,320
Net change in cash and cash equivalents (91,942) (73,359)
Cash and cash equivalents at beginning of year 203,434 288,640
Cash and cash equivalents at end of period 111,492 215,281
Supplemental cash flow information    
Cash paid for interest on convertible notes 2,516 1,887
Cash paid for income taxes 14,558 25,111
Cash paid for operating leases 9,547 7,613
Noncash investing and financing activities    
Lease assets obtained for new operating leases 973 4,120
Deferred legal fees and fixed assets included in accounts payable and accrued expenses 144 186
Property and equipment additions from utilization of tenant improvement allowance $ 580 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Organization
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization Business Organization
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
Commercial Products
•Trokendi XR® (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older.
•Oxtellar XR® (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.
•Qelbree® (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company launched Qelbree for adult patients in May 2022.
•GOCOVRI® (amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes.
•APOKYN® (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD.
•XADAGO® (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.
•Osmolex ER® (amantadine) extended-release is a once-daily product for the treatment of PD and drug-induced extrapyramidal reactions in adult patients.
•MYOBLOC® (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.
Product Candidates
The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following:
•SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. In October 2022, the FDA issued a Complete Response Letter (CRL) regarding the NDA for SPN-830. Refer to Note 17, Subsequent Events.
•SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).
•SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development.
Adamas Acquisition and Reorganization
On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas, pursuant to the Adamas Agreement dated October 10, 2021, and the Purchaser was merged with and into Adamas (the Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and Osmolex ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.
In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, Income Tax (Benefit) Expense.)
COVID-19 Impact
The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of September 30, 2022.
Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Consolidation
The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.
The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to
liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the fair values of financial instruments and the recoverability of intangible assets, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as television, print media, digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $52.0 million and $112.8 million in advertising expense for the three and nine months ended September 30, 2022, respectively, and approximately $22.6 million and $59.7 million for the three and nine months ended September 30, 2021, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
Accounting Standards Update (ASU) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.
The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method.
ASU 2021-10, Government Assistance (Topic 832) - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific U.S. GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisition Acquisition
Adamas Acquisition
In connection with the Adamas Acquisition (see Note 1), the Company paid the Adamas shareholders $400.8 million and transferred two non-tradable contingent value rights (CVRs). Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer & Trust Company, LLC, as rights agent (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once.
In connection with the two CVRs, the Company recorded contingent consideration liabilities of $10.3 million as of the date of the acquisition, to reflect the estimated fair value of the contingent consideration. The estimated fair values of the contingent consideration liabilities were determined using Monte Carlo simulations. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs and thus represent Level 3 fair value measurements. The key assumptions considered include the estimated amount and timing of projected revenues, volatility, estimated discount rates and the risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liabilities and will record increases or decreases in the fair value of the liabilities in its consolidated statements of earnings. Changes in fair value will result from actual milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but they reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.
The acquisition was accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, Business Combinations. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill, have been included in the Company's consolidated financial statements since the acquisition Closing Date.
The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed. The activities the Company is currently undertaking include review and evaluation of the tax positions, and other tax-related matters. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date are subject to change.
The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):
As Initially Reported
Measurement Period Adjustments (1)
As Adjusted
(unaudited)(unaudited)
Cash and cash equivalents$90,064 $— $90,064 
Accounts receivable11,156 — 11,156 
Inventories20,200 — 20,200 
Prepaid expenses and other current assets5,077 — 5,077 
Property and equipment1,254 — 1,254 
Intangibles450,100 — 450,100 
Other assets(2)
6,442 (1,620)4,822 
Total fair value of assets acquired584,293 (1,620)582,673 
Accounts payable(4,592)— (4,592)
Accrued expenses and other current liabilities(8,014)— (8,014)
Current debt(138,315)— (138,315)
Operating lease liabilities, long-term(5,224)— (5,224)
Deferred income tax liabilities(2)(3)
(56,588)1,753 (54,835)
Total fair value of liabilities assumed(212,733)1,753 (210,980)
Total identifiable net assets371,560 133 371,693 
Goodwill39,553 (133)39,420 
Total purchase price$411,113 $— $411,113 
Cash consideration paid$400,806 $— $400,806 
Fair value of contingent consideration10,307 — 10,307 
Total purchase price$411,113 $— $411,113 
______________________________
(1) Measurement period adjustments reflect changes for the nine months ended September 30, 2022 based on information related to the facts and circumstances that existed as of the Closing Date.
(2) Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease recorded in the first quarter of 2022. Refer to Note 13, Leases.
(3) Represents tax impact for the changes in fair value estimate of the right of use asset and changes made to finalize the accounting of certain state tax attributes which existed at the opening balance sheet date.
Acquired Inventory
The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or dispose of the inventory, as well as a profit on the sale.
Acquired Intangible Assets
The acquired intangible assets include the acquired developed technology and product rights to GOCOVRI and Osmolex ER, as well as the right to receive royalties from Allergan plc for sales of Namzaric. The Company determined the estimated fair values for the acquired intangible assets as of the Closing Date using the income approach. This is a valuation technique that provides an estimate of fair value of the assets, based on the market participant's expectations of the cash flows that the assets are forecasted to generate. The cash flows were discounted at a rate commensurate with the level of risk associated with its projected cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value.
The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and thus represent Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation includes: the estimated future cash flows from product sales, the timing and projection of costs and expenses, discount rates and tax rates.
Acquired intangible assets consist of developed technology and product rights and are amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation and the average remaining useful lives for identifiable intangible assets (dollars in thousands):
Estimated Fair ValueEstimated Useful Life as of Closing Date (in years)
Acquired developed technology and product rights$450,100 
3.1 - 8.1
Goodwill
Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is primarily attributable to the anticipated cost synergies, additional growth platforms, and an expanded revenue base with the addition of the assets from the Adamas Acquisition. The goodwill is not expected to be deductible for tax purposes.
Acquired Deferred Income Tax Liabilities, net
The deferred income tax liabilities, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. The acquired federal and state net operating loss carryforwards are reduced by a valuation allowance for amounts that are not expected to be realizable in the future. The reported measurement period adjustment of $1.8 million for the nine months ended September 30, 2022 consisted of a reduction to deferred tax liabilities of $3.7 million recorded in the first quarter of 2022 and an increase to deferred tax liabilities of $1.9 million recorded in the third quarter of 2022.
Revenue and Net Earnings of Adamas
The operations of Adamas and its subsidiaries have been included in the Company's consolidated statements of earnings for the periods subsequent to the Closing Date.
Pro Forma Information
The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
20212021
Pro forma total revenues$174,360 $487,904 
Pro forma net loss(10,405)(30,905)
The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition on January 1, 2020, the unaudited pro forma combined financial information reflects the recognition of additional amortization expense on intangible assets and estimated additional cost of products sold related to the inventory step-up adjustment; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Adamas Acquisition, and the estimated tax impact of the pro forma adjustments.
The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Disaggregated Revenues
 9 Months Ended
Sep. 30, 2022
Disaggregation of Revenue [Abstract]  
Disaggregated Revenues Disaggregated Revenues
The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):
Three Months Ended
September 30,		 Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Net product sales
Trokendi XR$69,599 $80,935 $204,033 $231,531 
Oxtellar XR30,528 29,728 88,007 82,120 
GOCOVRI27,878 — 75,179 — 
Qelbree18,326 2,370 37,708 2,685 
APOKYN$18,261 $24,627 $57,156 $73,338 
Other(1)
8,132 7,872 23,564 22,867 
Total net product sales$172,724 $145,532 $485,647 $412,541 
Royalty revenues4,629 2,932 14,263 8,184 
Total revenues$177,353 $148,464 $499,910 $420,725 
______________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
Trokendi XR accounted for more than 40% of the Company’s total net product sales for both the three and nine months ended September 30, 2022, and 56% of the Company's total net product sales for both the three and nine months ended September 30, 2021, respectively.
Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales for both the nine months ended September 30, 2022 and 2021, and collectively accounted for more than 80% and 85% of our total net product sales for the nine months ended September 30, 2022 and 2021, respectively.
Royalty revenues include noncash royalty revenues. The Company recognized noncash royalty revenue of $2.5 million and $7.2 million, for the three and nine months ended September 30, 2022, respectively. The Company recognized noncash royalty revenue of $2.4 million and $6.8 million, for the three and nine months ended September 30, 2021, respectively. Refer to Note 16, Commitments and Contingencies.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Marketable Securities
Unrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):
September 30,
2022		December 31,
2021
(unaudited)
Corporate and U.S. government agency and municipal debt securities
Amortized cost$417,576 $253,301 
Gross unrealized gains— 2,349 
Gross unrealized losses(5,342)(238)
Total fair value$412,234 $255,412 
The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
September 30,
2022
(unaudited)
Less than 1 year$280,297 
1 year to 2 years104,346 
2 years to 3 years27,591 
3 years to 4 years— 
Greater than 4 years— 
Total$412,234 
As of September 30, 2022, there was no impairment due to credit loss on any available-for-sale marketable securities.
Investment in Navitor
Development Agreement
In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required.
Equity investment
In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc.
In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals LLC (Navitor LLC), and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Units in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.
The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance.
Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company's ability to exert significant influence over but not control the financial and operating decisions of Navitor LLC. As a result of the change from a cost method investment to an equity method investment, the Company was required to measure its investment initially in accordance with the guidance in ASC 805. The majority of the assets and liabilities recorded in Navitor LLC's financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company's investment in Navitor LLC, which created a significant basis difference for the Company's investment in the underlying net assets. The Company determined that substantially all of the fair value of the investment was attributable to a single in-process research and development (IPR&D) asset. As a result, Navitor LLC was not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in Other assets in the condensed consolidated balance sheets, was expensed and recorded in Research and development expense in the condensed consolidated statements of earnings.
The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. In December 2021, Navitor LLC sold one of its subsidiaries and distributed cash to its members in accordance with each member's share of the proceeds from the sale. The Company received $12.9 million in December 2021 from Navitor LLC in connection with this sale. As the Company's policy is to record its share of the results in its equity method investment on a quarter lag as previously indicated, the Company recorded the cash amount received in Other current liabilities in the consolidated balance sheets as of December 31, 2021. In the first quarter of 2022, the Company determined its estimated share of Navitor LLC's year-end 2021 earnings and recorded a gain of $12.9 million in Interest and other income, net in the condensed consolidated statement of earnings.
The maximum exposure to losses related to Navitor LLC is approximately $50 million for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.
Subsequent to the Development Agreement entered into in 2020, no additional equity investment has been made or financing has been provided to Navitor LLC.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments and Contingent Consideration Fair Value of Financial Instruments
The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.
The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. The fair value hierarchy consists of the following three levels:
•Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets.
•Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves).
•Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data.
The fair value of the restricted marketable securities which are classified as Level 2 financial assets are recorded in Other assets on the condensed consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.
Financial Assets and Liabilities Recorded at Fair Value on a Recurring Basis
The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements at September 30, 2022 (unaudited)
Total Fair Value at September 30,
2022		Level 1Level 2Level 3
Assets:(unaudited)
Cash and cash equivalents
Cash$111,087 $111,087 $— $— 
Money market funds405 405 — — 
Marketable securities
Corporate and municipal debt securities280,297 — 280,297 — 
Long term marketable securities
Corporate and municipal debt securities131,937 — 131,937 — 
Other noncurrent assets
Marketable securities - restricted (SERP)464 9 455 — 
Total assets at fair value$524,190 $111,501 $412,689 $— 
Liabilities:
Contingent consideration $57,371 $— $— $57,371 
Total liabilities at fair value$57,371 $— $— $57,371 
Fair Value Measurements at December 31, 2021
Total Fair Value at December 31,
2021		Level 1Level 2Level 3
Assets:
Cash and cash equivalents
Cash$148,863 $148,863 $— $— 
Money market funds54,571 54,571 — — 
Marketable securities
Corporate and municipal debt securities136,246 251 135,995 — 
Long term marketable securities
Corporate and municipal debt securities119,166 — 119,166 — 
Other noncurrent assets
Marketable securities - restricted (SERP)630 7 623 — 
Total assets at fair value$459,476 $203,692 $255,784 $— 
Liabilities:
Contingent consideration$80,477 $— $— $80,477 
Total liabilities at fair value$80,477 $— $— $80,477 
Other Financial Instruments
The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities.
Financial Liabilities Recorded at Carrying Value
The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands):
September 30, 2022December 31, 2021
(unaudited)
Carrying ValueFair Value (Level 2)Carrying ValueFair Value (Level 2)
2023 Notes$401,438 $392,438 $379,252 $400,236 
The fair value has been estimated based on actual trading information, and quoted prices, both provided by bond traders. As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Contingent Consideration Disclosure Contingent Consideration
The Company's contingent consideration liabilities are related to the USWM Acquisition (as defined below) and the Adamas Acquisition. The contingent consideration liabilities are measured at fair value on a recurring basis using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement.
USWM Contingent Consideration
On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments of up to $230 million comprised of the following:
•Regulatory and developmental milestones - gross contingent consideration of up to $130 million contingent upon achievement of regulatory and developmental milestones.
This includes a $25 million milestone due upon the FDA acceptance of the SPN-830 NDA for review, which was paid in the first quarter of 2022. This milestone payment is reported under both financing and operating activities in the condensed consolidated statements of cash flows. Of the $25 million payment, $22.9 million represents the acquisition date fair value of the contingent consideration liability and was reported under cash flows from financing activities. The remaining $2.1 million represents the excess of the acquisition date fair value and was reported under cash flows from operating activities.
The remaining $105 million is comprised of amounts due upon achievement of certain FDA's regulatory approval and commercial launch of SPN-830. This includes a $50 million milestone which has a time-based mechanism for full or partial payment. As of September 30, 2022, the achievement of this milestone is remote. The remaining $55 million, which does not have a time-based mechanism for payment, relates to the FDA's approval of the SPN-830 NDA and the subsequent commercial product launch. Refer to Note 1, Business Organization and Note 17, Subsequent Events.
•Sales-based milestones consist of gross contingent consideration payments of up to $100 million related to future sales performance of the acquired USWM products. Of the $100 million sales-based contingent consideration, a $35 million milestone due upon the achievement of certain U.S. net product sales of APOKYN in 2021 was not achieved. The remaining $65 million relates to the achievement of certain net product sales of the acquired USWM products in 2022 and 2023. As of September 30, 2022, the Company assessed that the remaining sales-based milestones will not be achieved based on net sales projections.
The change in fair value is reported on the condensed consolidated statement of earnings in Contingent consideration expense (gain). The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, discount rate, the estimated revenue volatility and the estimated amount and timing of projected revenues from the acquired USWM products.
The Company recorded a $0.4 million expense and a $2.4 million expense due to the change in fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2022, respectively. The change in the fair value of contingent consideration for USWM milestones was primarily driven by the increase in estimated fair value of regulatory and developmental milestones due to passage of time and the accretion to the payout amount related to the milestone achieved in the first quarter of 2022.
The Company recorded a $0.1 million expense and a $7.7 million gain due to the change in fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2021, respectively. In the second quarter of 2021, the Company recorded a change in fair value of $7.7 million, which was primarily due to the write-down of the sales-based contingent consideration. The Company assessed that the sales-based milestones will not be achieved based on the revised net sales projections.
Adamas Contingent Consideration
As discussed in Note 3, Acquisition, the Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI.
During the measurement period, changes in the fair value of contingent consideration related to the Adamas Acquisition are recorded against goodwill if such changes are related to facts and circumstances that existed at the acquisition date. In each reporting period after the acquisition, the Company remeasures the fair value of contingent consideration liabilities and records in its consolidated statements of earnings the increases or decreases in the fair value of the liabilities. The Company recorded a $0.1 million expense and a $0.5 million gain due to the change in fair value of the contingent consideration liabilities for the three and nine months ended September 30, 2022, respectively. The change in fair value was reported on the condensed consolidated statement of earnings in Contingent consideration expense (gain).
The change in estimated fair value of contingent consideration for the sales-based Adamas milestones was primarily due to changes in market data and the passage of time. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated amount and timing of projected revenues, volatility, estimated discount rates and risk-free interest rate. Refer to Note 3, Acquisition, for further discussion of significant inputs and assumptions used in the valuation of the contingent consideration for the Adamas Acquisition.
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2021$70,170 $10,307 $80,477 
Milestone payments(25,000)— (25,000)
Change in fair value recognized in earnings2,420 (526)1,894 
Balance at September 30, 2022 (unaudited)$47,590 $9,781 $57,371 
Regulatory and developmental contingent consideration liabilities$47,590 $— $47,590 
Sales-based contingent consideration liabilities— 9,781 9,781 
Balance at September 30, 2022 (unaudited)$47,590 $9,781 $57,371 
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
September 30,
2022		December 31,
2021
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$47,590 $44,840 
Contingent consideration, long-term9,781 35,637 
Total$57,371 $80,477 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets, Net
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net
Goodwill
The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):
Balance as of December 31, 2021
$117,516 
Measurement period adjustments related to the acquisition of Adamas (see Note 3)(133)
Balance as of September 30, 2022 (unaudited)
$117,383 
Intangible Assets, Net
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets and goodwill (dollars in thousands):
September 30, 2022December 31, 2021
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights8.02681,100 (93,642)587,458 681,100 (35,550)645,550 
Capitalized patent defense costs4.2443,820 (32,517)11,303 43,820 (28,677)15,143 
Total intangible assets7.95$848,920 $(126,159)$722,761 $848,920 $(64,227)$784,693 
Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regards to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances.
Amortization expense for intangible assets was approximately $20.6 million and $61.9 million for the three and nine months ended September 30, 2022, respectively, and approximately $6.0 million and $18.0 million for the three and nine months ended September 30, 2021, respectively. The increase in expense is primarily due to amortization of the acquired developed technology and product rights from the Adamas Acquisition.
Anticipated annual amortization expense for intangible assets is estimated at $79.8 million each in both 2023 and 2024, $75.1 million in 2025, $74.9 million in 2026, and $73.2 million in 2027.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Senior Notes Due 2023
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Convertible Senior Notes Due 2023 Convertible Senior Notes Due 2023
The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million. We have reclassified the debt from long-term to current liabilities on our Condensed Consolidated Balance Sheet, as the debt matures in less than twelve months as of September 30, 2022.
The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.
Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar
quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date.
At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.
If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.
Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.
Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.91 per share of the Company’s common stock, and is subject to adjustment.
The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be.
The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.
The liability component of the 2023 Notes consists of the following (dollars in thousands):
September 30,
2022		December 31,
2021
(unaudited) 
2023 Notes$402,500 $402,500 
Unamortized debt discount and deferred financing costs(1,062)(23,248)
Total carrying value$401,438 $379,252 
As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion of the accounting standard adoption. No 2023 Notes were converted as of September 30, 2022 or December 31, 2021.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Payments Share-Based Payments
Share-based compensation expense is as follows (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
(unaudited)(unaudited)
Research and development$825 $615 $2,284 $1,909 
Selling, general and administrative4,160 3,412 11,023 11,965 
Total$4,985 $4,027 $13,307 $13,874 
Stock Option and Stock Appreciation Rights
The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options & SARs		Weighted
Average
Exercise Price
(per share)		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20215,774,076 $24.15 5.95
Granted 1,046,785 $31.95 
Exercised (673,120)$12.79 
Forfeited (145,473)$30.06 
Outstanding, September 30, 2022 (unaudited)6,002,268 $26.64 6.29
As of December 31, 2021:
Vested and expected to vest5,774,076 $24.15 5.95
Exercisable3,651,824 $21.29 4.53
As of September 30, 2022 (unaudited):
Vested and expected to vest6,002,268 $26.64 6.29
Exercisable 3,682,170 $24.61 4.83
Restricted Stock Units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 202121,110 $29.61 
Granted134,460 $32.17 
Vested(21,110)$29.61 
Nonvested, September 30, 2022 (unaudited)134,460 $32.17 
There were no forfeited RSU awards during the nine months ended September 30, 2022.
Performance Share Units

The following table summarizes performance share unit (PSU) activities:

Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 202153,500 $29.82 35,625 $26.34 89,125 $28.43 
Granted155,000$28.93 ——155,000$28.93 
Vested(22,250)$29.69 ——(22,250)$29.69 
Forfeited(1,500)$30.45 ——(1,500)$30.45 
Nonvested, September 30, 2022 (unaudited)184,750$29.08 35,625$26.34 220,375$28.64 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, whereas the Company previously calculated diluted earnings per share under the treasury stock method. Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock option grants, SARs, RSUs, employee stock purchase plan (ESPP) awards, and the 2023 Notes, as determined per the if-converted method for the three and nine months ended September 30, 2022 in connection with the adoption of ASU 2020-06 and the treasury stock method for the three and nine months ended September 30, 2021.
Effect of Convertible Notes and Related Convertible Note Hedges and Warrants
In connection with the issuance of the 2023 Notes, the Company entered into Convertible Note Hedge and Warrant Transactions as described further in Note 9, Convertible Senior Notes Due 2023. The expected collective impact of the Convertible Note Hedge and Warrant Transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $59.33 per share and the strike price of the warrants of $80.91 per share.
Diluted EPS related to the 2023 Notes in the current year is calculated using the if-converted method. The number of dilutive shares is based on the initial conversion rate associated with the 2023 Notes. The Convertible Note Hedge and Warrant Transactions are excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $80.91 per share. Prior to actual conversion, the Convertible Note Hedge Transactions are not considered in calculating diluted earnings per share, as their impact would be anti-dilutive.
In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards and shares associated with the conversion of the 2023 Notes in the calculation of diluted EPS, because their inclusion would be anti-dilutive:
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
2023 Notes6,783,936 — — — 
Stock options, RSUs, PSUs792,904 1,654,816 470,822 1,397,424 
As mentioned in Note 2, as a result of the adoption of ASU 2020-06 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are not included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended September 30, 2022 because their inclusion would be anti-dilutive. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.The following table sets forth the computation of basic and diluted net earnings per share for the three and nine months ended September 30, 2022 under the if-converted method and for the three and nine months ended September 30, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Numerator:
Net earnings $1,749 $21,562 $35,230 $50,982 
After-tax interest expense for 2023 Notes— — 2,664 — 
Numerator for dilutive earnings per share$1,749 $21,562 $37,894 $50,982 
Denominator:
Weighted average shares outstanding, basic53,789,674 53,187,764 53,517,838 53,053,441 
Effect of dilutive securities:
Stock options, RSUs and SARs1,245,164 1,147,030 1,241,347 1,248,020 
Convertible notes— — 6,783,936 — 
Weighted average shares outstanding, diluted55,034,838 54,334,794 61,543,121 54,301,461 
Earnings per share, basic$0.03 $0.41 $0.66 $0.96 
Earnings per share, diluted$0.03 $0.40 $0.62 $0.94 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Tax (Benefit) Expense
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Tax (Benefit) Expense Income Tax (Benefit) Expense
The following table provides information regarding the Company’s income tax (benefit) expense for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Income tax (benefit) expense$(2,193)$7,398 $(9,627)$20,142 
Effective tax rate493.9 %25.5 %(37.6)%28.3 %

The decrease in income tax expense for the three months ended September 30, 2022 compared to the same period in prior year was primarily due to lower earnings before income taxes. The change in effective tax rate for the three months ended September 30, 2022 compared to the same period in prior year was primarily due to larger excess tax benefits of stock-based awards in 2022.

The change in income tax (benefit) expense and effective tax rate for the nine months ended September 30, 2022 compared to the same period in the prior year was primarily due to tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases Leases
Office Space and Fleet Vehicle Leases
The Company has operating leases for its headquarters lease, certain other office space, and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company also elected to combine the lease and non-lease components for the fleet vehicles and headquarters leases.
The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless earlier terminated in accordance with the terms of the lease. The lease includes options to extend the lease for up to 10 years.
As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term will continue until April 30, 2025. The lease contains an option to extend the term for one additional five-year period.
During a measurement period, changes in fair value due to measurement period adjustments are recorded against goodwill. The Company recorded in the first quarter of 2022 a measurement period adjustment associated with the valuation of the acquired Adamas lease which decreased the fair value estimate of the operating lease right of use asset by $1.6 million. Refer to Note 3, Acquisition.
Contract Manufacturing Lease
The Company has a contract manufacturing agreement with Merz Pharma GmbH & Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience.
Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounts for as an embedded lease.
The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classifies and accounts for the embedded lease as an operating lease.
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationSeptember 30, 2022December 31, 2021
(unaudited)
Assets
Operating lease assetsOther assets$29,663 $35,365 
Total lease assets$29,663 $35,365 
Liabilities
Lease liabilities, current
Operating lease liabilities, current portionAccounts payable and accrued liabilities$6,757 $6,477 
Lease liabilities, long-term
Operating lease liabilities, long-termOperating lease liabilities, long-term36,028 41,298 
Total lease liabilities$42,785 $47,775 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Composition of Other Balance Sheet Items Composition of Other Balance Sheet ItemsThe following details the composition of other balance sheet items (dollars in thousands for amounts in tables):
Accounts Receivables, Net
As of September 30, 2022 and December 31, 2021, the Company has recorded allowances reducing accounts receivable by approximately $12.8 million and $13.5 million, respectively. These allowances represent prompt pay discounts and contractual service fees, which were originally recorded as a reduction to revenues, representing estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.
Inventories, Net
September 30,
2022		December 31,
2021
(unaudited)
Raw materials$11,012 $7,325 
Work in process25,461 45,711 
Finished goods46,692 32,923 
Total$83,165 $85,959 
Inventories as of September 30, 2022 include acquired inventory from the Adamas Acquisition. Refer to Note 3, Acquisition, for further discussion of the acquisition.
Property and Equipment, Net
September 30,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,207 $12,287 
Leasehold improvements14,023 14,369 
Software1,007 4,776 
Computer equipment1,282 1,944 
Construction-in-progress291 33 
28,810 33,409 
Less accumulated depreciation and amortization(12,938)(16,454)
Property and equipment, net$15,872 $16,955 
Depreciation and amortization expense on property and equipment was approximately $0.8 million and $2.2 million for the three and nine months ended September 30, 2022, respectively, and approximately $0.6 million and $1.9 million for the three and nine months ended September 30, 2021, respectively. The Company retired certain fully depreciated property and equipment in the nine months ended September 30, 2022.
Accounts Payable and Accrued Liabilities
September 30,
2022		December 31,
2021
(unaudited)
Accounts payable$16,015 $9,331 
Accrued professional & marketing fees31,269 26,728 
Accrued compensation16,748 28,068 
Accrued product costs11,129 18,460 
Accrued royalties (1)
11,671 13,821 
Accrued clinical trial costs (2)
6,823 9,125 
Operating lease liabilities, current portion (3)
6,757 6,477 
Other accrued expenses9,890 5,673 
Total$110,302 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Accrued Product Returns and Rebates
September 30,
2022		December 31,
2021
(unaudited)
Accrued product rebates$119,162 $97,597 
Accrued product returns39,308 35,127 
Total$158,470 $132,724 
Other Liabilities
September 30,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$— $5,977 
Other liabilities10,371 10,403 
Total$10,371 $16,380 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Interest Expense
 9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Interest Expense Interest Expense
The following details the composition of interest expense (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Interest expense$(1,158)$(5,033)$(3,488)$(14,593)
Interest expense on nonrecourse liability related to sale of future royalties(566)(892)(1,988)(2,896)
Total$(1,724)$(5,925)$(5,476)$(17,489)
For the three and nine months ended September 30, 2022, interest expense includes noncash interest expense related to amortization of deferred financing costs of $0.5 million and $1.6 million. For the three and nine months ended September 30, 2021, interest expense includes noncash interest expense related to amortization of deferred financing costs and amortization of the debt discount on the 2023 Notes of $4.4 million and $13.0 million. As discussed in Note 2, Summary of Significant Accounting Policies, the Company adopted ASU 2020-06 on January 1, 2022. As a result, interest expense for the three and nine months ended September 30, 2022 significantly decreased compared to the three and nine months ended September 30, 2021 due to the Company no longer recording interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Product Licenses
The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.
Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as Cost of goods sold in the condensed consolidated statements of earnings.
Royalty Agreement
In the third quarter of 2014, the Company received $30 million pursuant to a Royalty Interest Acquisition Agreement related to the purchase by HC Royalty of certain of the Company's rights under the Company's agreement with United Therapeutics related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets. Full ownership of the royalty rights will revert to the Company if and when a certain cumulative payment threshold is reached (see Note 4, Note 14, and Note 15).
USWM Enterprises Commitments Assumed
As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below.
The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. Refer to Note 13, Leases for further discussion related to the Merz Agreement in connection with the MYOBLOC annual minimum purchase requirement.
In addition, USWM Enterprises had an existing license and distribution agreement for XADAGO. This included an annual minimum promotional spend to support the marketing of XADAGO for the first five years of the agreement which will end in 2022. As of September 30, 2022, there is no remaining contractual commitment.
In March 2019, MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector
General of the U.S. Department of Health and Human Services. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to maintain a broad array of processes, policies and procedures necessary to comply with the CIA through March 2024.
Data Breach-related Contingency
On November 24, 2021, the Company announced that it was the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on its internal investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from the Company's systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to the Company's systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. In the fourth quarter of 2021, the Company had successfully recovered the impacted files and took additional steps designed to further protect its networks and files.
Furthermore, while the Company has not been the subject of any legal proceedings involving the attack, the likelihood that the Company could be the subject of claims from persons alleging they suffered damages from the incident or actions by governmental authorities is possible, but the amount of such fines, penalties or costs, if any, cannot be estimated at this time. The Company continues to monitor the situation.
Claims and Litigation
From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.
NAMENDA XR/Namzaric Qui Tam Litigation
On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a qui tam complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit. The petition remains pending. No decision has been reached as of the date of this filing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Subsequent Events
 9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
SPN-830 Regulatory Development
In December 2021, we resubmitted the NDA for SPN-830 to the FDA. In February 2022, we received a notice from the FDA that the resubmission of the NDA for SPN-830 is considered as a Standard Review, thereby was assigned a PDUFA target action date in early October 2022. In October 2022, the FDA issued a CRL regarding the NDA for SPN-830. The CRL requires additional information and analysis related to the infusion device and drug product across several areas of the NDA including, but not limited to, labeling, product quality and manufacturing, device performance and risk analysis. In addition, the FDA mentions that approval of the NDA requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. The CRL does not request additional efficacy and safety clinical studies. The FDA has made an initial determination that the amendment to the Company’s application in response to the CRL will be subject to a Class 2, or six-month, review timeline.
The Company is in the process of analyzing the CRL and determining next steps for the resubmission of the NDA. While it is too early to ascertain the full impact to our financial statements, we anticipate that we may identify indicators of impairment for the IPR&D asset that represents an estimate of the fair value of SPN-830, the product candidate, that could result from the non-approval of the NDA. The potential adjustment to the IPR&D asset that may be necessary as a result of any required interim impairment analysis may be material. Additionally, the Company also expects to assess adjustments to the fair value of the contingent consideration arrangements which includes milestones payments due upon achievement of certain FDA's regulatory approval and commercial launch of SPN-830. While we are unable to estimate the anticipated financial impact at this time, we expect potential adjustments, which may be material, will be recognized and reported within the fourth quarter of 2022. These adjustments could impact the Company’s future results of operations and financial condition.
APOKYN Litigation
     On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware (Case No. 22-cv-1302) alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN. The Company is currently reviewing the details of the complaint and will respond as appropriate.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.
In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.
The Company, which is primarily located in the U.S., operates in one operating segment.
Consolidation
Consolidation
The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.
The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to
liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate.
The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.
Use of Estimates
Use of Estimates
The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.
The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the fair values of financial instruments and the recoverability of intangible assets, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.
Advertising Expense
Advertising Expense
Advertising expense includes the cost of promotional materials and activities, such as television, print media, digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.
The Company incurred approximately $52.0 million and $112.8 million in advertising expense for the three and nine months ended September 30, 2022, respectively, and approximately $22.6 million and $59.7 million for the three and nine months ended September 30, 2021, respectively. These expenses are recorded as a component of Selling, general and administrative expenses in the condensed consolidated statements of earnings.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Accounting Pronouncements Adopted
Accounting Standards Update (ASU) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.
The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method.
ASU 2021-10, Government Assistance (Topic 832) - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific U.S. GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, Income Taxes. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition (Tables)
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of recognized identified assets acquired and liabilities assumed
The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):
As Initially Reported
Measurement Period Adjustments (1)
As Adjusted
(unaudited)(unaudited)
Cash and cash equivalents$90,064 $— $90,064 
Accounts receivable11,156 — 11,156 
Inventories20,200 — 20,200 
Prepaid expenses and other current assets5,077 — 5,077 
Property and equipment1,254 — 1,254 
Intangibles450,100 — 450,100 
Other assets(2)
6,442 (1,620)4,822 
Total fair value of assets acquired584,293 (1,620)582,673 
Accounts payable(4,592)— (4,592)
Accrued expenses and other current liabilities(8,014)— (8,014)
Current debt(138,315)— (138,315)
Operating lease liabilities, long-term(5,224)— (5,224)
Deferred income tax liabilities(2)(3)
(56,588)1,753 (54,835)
Total fair value of liabilities assumed(212,733)1,753 (210,980)
Total identifiable net assets371,560 133 371,693 
Goodwill39,553 (133)39,420 
Total purchase price$411,113 $— $411,113 
Cash consideration paid$400,806 $— $400,806 
Fair value of contingent consideration10,307 — 10,307 
Total purchase price$411,113 $— $411,113 
______________________________
(1) Measurement period adjustments reflect changes for the nine months ended September 30, 2022 based on information related to the facts and circumstances that existed as of the Closing Date.
(2) Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease recorded in the first quarter of 2022. Refer to Note 13, Leases.
(3) Represents tax impact for the changes in fair value estimate of the right of use asset and changes made to finalize the accounting of certain state tax attributes which existed at the opening balance sheet date.
Finite-lived and indefinite-lived intangible assets acquired as part of business combination The following table summarizes the preliminary purchase price allocation and the average remaining useful lives for identifiable intangible assets (dollars in thousands):
Estimated Fair ValueEstimated Useful Life as of Closing Date (in years)
Acquired developed technology and product rights$450,100 
3.1 - 8.1
Business acquisition, pro forma information
The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
20212021
Pro forma total revenues$174,360 $487,904 
Pro forma net loss(10,405)(30,905)
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Disaggregated Revenues (Tables)
 9 Months Ended
Sep. 30, 2022
Disaggregation of Revenue [Abstract]  
Summary of disaggregation of revenues by nature
The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):
Three Months Ended
September 30,		 Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Net product sales
Trokendi XR$69,599 $80,935 $204,033 $231,531 
Oxtellar XR30,528 29,728 88,007 82,120 
GOCOVRI27,878 — 75,179 — 
Qelbree18,326 2,370 37,708 2,685 
APOKYN$18,261 $24,627 $57,156 $73,338 
Other(1)
8,132 7,872 23,564 22,867 
Total net product sales$172,724 $145,532 $485,647 $412,541 
Royalty revenues4,629 2,932 14,263 8,184 
Total revenues$177,353 $148,464 $499,910 $420,725 
______________________________
(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of unrestricted available-for-sale marketable securities Unrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):
September 30,
2022		December 31,
2021
(unaudited)
Corporate and U.S. government agency and municipal debt securities
Amortized cost$417,576 $253,301 
Gross unrealized gains— 2,349 
Gross unrealized losses(5,342)(238)
Total fair value$412,234 $255,412 
Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):
September 30,
2022
(unaudited)
Less than 1 year$280,297 
1 year to 2 years104,346 
2 years to 3 years27,591 
3 years to 4 years— 
Greater than 4 years— 
Total$412,234 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of fair value of the financial assets and liabilities
The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):
Fair Value Measurements at September 30, 2022 (unaudited)
Total Fair Value at September 30,
2022		Level 1Level 2Level 3
Assets:(unaudited)
Cash and cash equivalents
Cash$111,087 $111,087 $— $— 
Money market funds405 405 — — 
Marketable securities
Corporate and municipal debt securities280,297 — 280,297 — 
Long term marketable securities
Corporate and municipal debt securities131,937 — 131,937 — 
Other noncurrent assets
Marketable securities - restricted (SERP)464 9 455 — 
Total assets at fair value$524,190 $111,501 $412,689 $— 
Liabilities:
Contingent consideration $57,371 $— $— $57,371 
Total liabilities at fair value$57,371 $— $— $57,371 
Fair Value Measurements at December 31, 2021
Total Fair Value at December 31,
2021		Level 1Level 2Level 3
Assets:
Cash and cash equivalents
Cash$148,863 $148,863 $— $— 
Money market funds54,571 54,571 — — 
Marketable securities
Corporate and municipal debt securities136,246 251 135,995 — 
Long term marketable securities
Corporate and municipal debt securities119,166 — 119,166 — 
Other noncurrent assets
Marketable securities - restricted (SERP)630 7 623 — 
Total assets at fair value$459,476 $203,692 $255,784 $— 
Liabilities:
Contingent consideration$80,477 $— $— $80,477 
Total liabilities at fair value$80,477 $— $— $80,477 
Schedule of financial liabilities that are not carried at fair value The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands):
September 30, 2022December 31, 2021
(unaudited)
Carrying ValueFair Value (Level 2)Carrying ValueFair Value (Level 2)
2023 Notes$401,438 $392,438 $379,252 $400,236 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration (Tables)
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Reconciliation of the beginning and ending balances related to the contingent consideration
The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
USWM AcquisitionAdamas AcquisitionTotal
Balance at December 31, 2021$70,170 $10,307 $80,477 
Milestone payments(25,000)— (25,000)
Change in fair value recognized in earnings2,420 (526)1,894 
Balance at September 30, 2022 (unaudited)$47,590 $9,781 $57,371 
Regulatory and developmental contingent consideration liabilities$47,590 $— $47,590 
Sales-based contingent consideration liabilities— 9,781 9,781 
Balance at September 30, 2022 (unaudited)$47,590 $9,781 $57,371 
The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):
September 30,
2022		December 31,
2021
Reported under the following captions in the condensed consolidated balance sheets:(unaudited)
Contingent consideration, current portion$47,590 $44,840 
Contingent consideration, long-term9,781 35,637 
Total$57,371 $80,477 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets, Net (Tables)
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill
The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):
Balance as of December 31, 2021
$117,516 
Measurement period adjustments related to the acquisition of Adamas (see Note 3)(133)
Balance as of September 30, 2022 (unaudited)
$117,383 
Schedule of intangible assets and goodwill
The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets and goodwill (dollars in thousands):
September 30, 2022December 31, 2021
(unaudited)
Remaining Weighted
Average Life (Years)		Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, Net
Acquired in-process research and development$124,000 $— $124,000 $124,000 $— $124,000 
Intangible assets subject to amortization:
Acquired developed technology and product rights8.02681,100 (93,642)587,458 681,100 (35,550)645,550 
Capitalized patent defense costs4.2443,820 (32,517)11,303 43,820 (28,677)15,143 
Total intangible assets7.95$848,920 $(126,159)$722,761 $848,920 $(64,227)$784,693 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Senior Notes Due 2023 (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Summary of liability component of 2023 Notes The liability component of the 2023 Notes consists of the following (dollars in thousands):
September 30,
2022		December 31,
2021
(unaudited) 
2023 Notes$402,500 $402,500 
Unamortized debt discount and deferred financing costs(1,062)(23,248)
Total carrying value$401,438 $379,252 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based compensation expense Share-based compensation expense is as follows (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
(unaudited)(unaudited)
Research and development$825 $615 $2,284 $1,909 
Selling, general and administrative4,160 3,412 11,023 11,965 
Total$4,985 $4,027 $13,307 $13,874 
Summary of stock options and SAR activities The following table summarizes stock option and stock appreciation rights (SAR) activities:
Number of
Options & SARs		Weighted
Average
Exercise Price
(per share)		Weighted
Average
Remaining
Contractual
Term (in years)
Outstanding, December 31, 20215,774,076 $24.15 5.95
Granted 1,046,785 $31.95 
Exercised (673,120)$12.79 
Forfeited (145,473)$30.06 
Outstanding, September 30, 2022 (unaudited)6,002,268 $26.64 6.29
As of December 31, 2021:
Vested and expected to vest5,774,076 $24.15 5.95
Exercisable3,651,824 $21.29 4.53
As of September 30, 2022 (unaudited):
Vested and expected to vest6,002,268 $26.64 6.29
Exercisable 3,682,170 $24.61 4.83
Summary of restricted stock units
The following table summarizes restricted stock unit (RSU) activities:
Number of
RSUs		Weighted Average
Grant Date Fair Value per Share
Nonvested, December 31, 202121,110 $29.61 
Granted134,460 $32.17 
Vested(21,110)$29.61 
Nonvested, September 30, 2022 (unaudited)134,460 $32.17 
There were no forfeited RSU awards during the nine months ended September 30, 2022.
Summary of performance stock unit
The following table summarizes performance share unit (PSU) activities:

Performance-Based UnitsMarket-Based UnitsTotal PSUs
Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share		Number of PSUsWeighted
Average
Grant Date Fair Value per Share
Nonvested, December 31, 202153,500 $29.82 35,625 $26.34 89,125 $28.43 
Granted155,000$28.93 ——155,000$28.93 
Vested(22,250)$29.69 ——(22,250)$29.69 
Forfeited(1,500)$30.45 ——(1,500)$30.45 
Nonvested, September 30, 2022 (unaudited)184,750$29.08 35,625$26.34 220,375$28.64 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of common stock equivalents excluded in the calculation of diluted earnings per share In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards and shares associated with the conversion of the 2023 Notes in the calculation of diluted EPS, because their inclusion would be anti-dilutive:
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
2023 Notes6,783,936 — — — 
Stock options, RSUs, PSUs792,904 1,654,816 470,822 1,397,424 
As mentioned in Note 2, as a result of the adoption of ASU 2020-06 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are not included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended September 30, 2022 because their inclusion would be anti-dilutive. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.
Schedule of computation of basic and diluted earnings per share The following table sets forth the computation of basic and diluted net earnings per share for the three and nine months ended September 30, 2022 under the if-converted method and for the three and nine months ended September 30, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Numerator:
Net earnings $1,749 $21,562 $35,230 $50,982 
After-tax interest expense for 2023 Notes— — 2,664 — 
Numerator for dilutive earnings per share$1,749 $21,562 $37,894 $50,982 
Denominator:
Weighted average shares outstanding, basic53,789,674 53,187,764 53,517,838 53,053,441 
Effect of dilutive securities:
Stock options, RSUs and SARs1,245,164 1,147,030 1,241,347 1,248,020 
Convertible notes— — 6,783,936 — 
Weighted average shares outstanding, diluted55,034,838 54,334,794 61,543,121 54,301,461 
Earnings per share, basic$0.03 $0.41 $0.66 $0.96 
Earnings per share, diluted$0.03 $0.40 $0.62 $0.94 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Tax (Benefit) Expense (Tables)
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Schedule of reconciliation of income tax expense at the U.S Federal statutory income tax rate to the entity's effective income tax rate The following table provides information regarding the Company’s income tax (benefit) expense for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Income tax (benefit) expense$(2,193)$7,398 $(9,627)$20,142 
Effective tax rate493.9 %25.5 %(37.6)%28.3 %
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of balance sheet information related to leases
Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):

Balance Sheet ClassificationSeptember 30, 2022December 31, 2021
(unaudited)
Assets
Operating lease assetsOther assets$29,663 $35,365 
Total lease assets$29,663 $35,365 
Liabilities
Lease liabilities, current
Operating lease liabilities, current portionAccounts payable and accrued liabilities$6,757 $6,477 
Lease liabilities, long-term
Operating lease liabilities, long-termOperating lease liabilities, long-term36,028 41,298 
Total lease liabilities$42,785 $47,775 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories
Inventories, Net
September 30,
2022		December 31,
2021
(unaudited)
Raw materials$11,012 $7,325 
Work in process25,461 45,711 
Finished goods46,692 32,923 
Total$83,165 $85,959 
Schedule of property and equipment
Property and Equipment, Net
September 30,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,207 $12,287 
Leasehold improvements14,023 14,369 
Software1,007 4,776 
Computer equipment1,282 1,944 
Construction-in-progress291 33 
28,810 33,409 
Less accumulated depreciation and amortization(12,938)(16,454)
Property and equipment, net$15,872 $16,955 
Schedule of accounts payable and accrued liabilities
Accounts Payable and Accrued Liabilities
September 30,
2022		December 31,
2021
(unaudited)
Accounts payable$16,015 $9,331 
Accrued professional & marketing fees31,269 26,728 
Accrued compensation16,748 28,068 
Accrued product costs11,129 18,460 
Accrued royalties (1)
11,671 13,821 
Accrued clinical trial costs (2)
6,823 9,125 
Operating lease liabilities, current portion (3)
6,757 6,477 
Other accrued expenses9,890 5,673 
Total$110,302 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Schedule of accrued product returns and rebates
Accrued Product Returns and Rebates
September 30,
2022		December 31,
2021
(unaudited)
Accrued product rebates$119,162 $97,597 
Accrued product returns39,308 35,127 
Total$158,470 $132,724 
Other liabilities
Other Liabilities
September 30,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$— $5,977 
Other liabilities10,371 10,403 
Total$10,371 $16,380 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Interest Expense (Tables)
 9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Schedule of interest expense
The following details the composition of interest expense (dollars in thousands):
Three Months Ended
September 30,		Nine Months Ended September 30,
2022202120222021
(unaudited)(unaudited)
Interest expense$(1,158)$(5,033)$(3,488)$(14,593)
Interest expense on nonrecourse liability related to sale of future royalties(566)(892)(1,988)(2,896)
Total$(1,724)$(5,925)$(5,476)$(17,489)
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Business Organization (Details)
Nov. 24, 2021
marketedProduct
Adamas Pharmaceuticals  
Business Acquisition [Line Items]  
Number of established marketed products 2
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Basis of Presentation (Details)
 9 Months Ended
Sep. 30, 2022
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Advertising Expense (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accounting Policies [Abstract]        
Advertising costs $ 52.0 $ 22.6 $ 112.8 $ 59.7
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jan. 01, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Jun. 30, 2021
Mar. 31, 2021
Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent   $ (852,798) $ (810,468) $ (852,798) $ (810,468) $ (841,434) $ (828,446) $ (815,851) $ (785,579) $ (754,444) $ (744,858)
Convertible notes (in shares)   0 0 6,783,936 0            
Convertible Debt                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Long-term debt   $ 401,438   $ 401,438       379,252      
Retained Earnings                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent   (455,764) $ (377,480) (455,764) $ (377,480) (454,015) (446,150) (379,922) (355,918) (332,192) (326,498)
Additional  Paid-in Capital                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent   $ (401,026) $ (428,726) $ (401,026) $ (428,726) $ (389,586) $ (383,016) (434,337) $ (424,175) $ (415,950) $ (409,332)
Cumulative effect of adoption of ASU 2020-06                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent               15,600      
Cumulative effect of adoption of ASU 2020-06 | Retained Earnings                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent               (40,612)      
Cumulative effect of adoption of ASU 2020-06 | Additional  Paid-in Capital                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent               $ 56,212      
Accounting Standards Update 2020-06                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Long-term debt $ 20,600                    
Deferred tax liabilities, net $ 5,000                    
Accounting Standards Update 2020-06 | Convertible Debt                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Convertible notes (in shares) 6,800,000     6,800,000              
Accounting Standards Update 2020-06 | Cumulative effect of adoption of ASU 2020-06 | Retained Earnings                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent $ (40,600)                    
Accounting Standards Update 2020-06 | Cumulative effect of adoption of ASU 2020-06 | Additional  Paid-in Capital                      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                      
Stockholders' equity attributable to parent $ 56,200                    
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition - Narrative (Details)
 3 Months Ended 7 Months Ended 9 Months Ended
Nov. 24, 2021
USD ($)
right
$ / shares
Sep. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]            
Contingent consideration   $ 57,371,000     $ 57,371,000 $ 80,477,000
Deferred income tax liabilities adjustments         $ 1,800,000  
Income tax expense (benefit), adjustment of deferred tax (asset) liability   $ (1,900,000) $ 3,700,000      
Adamas Pharmaceuticals            
Business Acquisition [Line Items]            
Cash consideration paid $ 400,806,000          
Contingents value rights | right 2          
Rights per share (in dollars per share) | $ / shares $ 0.50          
Additional cash payments upon milestone achievements minimum $ 150,000,000          
Additional cash payments upon milestone achievements maximum 225,000,000          
Contingent consideration 10,300,000          
Additional cash payments upon milestone achievements minimum 0          
Additional cash payments upon milestone achievements maximum $ 50,900,000          
Deferred income tax liabilities adjustments       $ 1,753,000    
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 3 Months Ended 7 Months Ended 9 Months Ended
Nov. 24, 2021
Jun. 09, 2020
Mar. 31, 2022
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2021
Business Acquisition [Line Items]            
Goodwill         $ 117,383 $ 117,516
Fair value of contingent consideration   $ 230,000        
Measurement Period Adjustments            
Deferred income tax liabilities adjustments         1,800  
Goodwill, adjustments         $ (133)  
Adamas Pharmaceuticals            
Business Acquisition [Line Items]            
Cash and cash equivalents $ 90,064          
Accounts receivable 11,156          
Inventories 20,200          
Prepaid expenses and other current assets 5,077          
Property and equipment 1,254          
Intangibles 450,100          
Other assets 4,822          
Total fair value of assets acquired 582,673          
Accounts payable (4,592)          
Accrued expenses and other current liabilities (8,014)          
Current debt (138,315)          
Operating lease liabilities, long-term (5,224)          
Deferred income tax liabilities (54,835)          
Total fair value of liabilities assumed (210,980)          
Total identifiable net assets 371,693          
Goodwill 39,420          
Total purchase price 411,113          
Cash consideration paid 400,806          
Fair value of contingent consideration 10,307          
Total purchase price 411,113          
Measurement Period Adjustments            
Change in fair value of operating lease acquired     $ 1,600 $ (1,620)    
Deferred income tax liabilities adjustments       1,753    
Total identifiable net assets, adjustments       133    
Goodwill, adjustments       $ (133)    
Adamas Pharmaceuticals | As Initially Reported            
Business Acquisition [Line Items]            
Cash and cash equivalents 90,064          
Accounts receivable 11,156          
Inventories 20,200          
Prepaid expenses and other current assets 5,077          
Property and equipment 1,254          
Intangibles 450,100          
Other assets 6,442          
Total fair value of assets acquired 584,293          
Accounts payable (4,592)          
Accrued expenses and other current liabilities (8,014)          
Current debt (138,315)          
Operating lease liabilities, long-term (5,224)          
Deferred income tax liabilities (56,588)          
Total fair value of liabilities assumed (212,733)          
Total identifiable net assets 371,560          
Goodwill 39,553          
Total purchase price 411,113          
Cash consideration paid 400,806          
Fair value of contingent consideration 10,307          
Total purchase price $ 411,113          
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) - Adamas Pharmaceuticals - USD ($)
$ in Thousands
Jan. 01, 2020
Nov. 24, 2021
Business Acquisition [Line Items]    
Intangibles   $ 450,100
Acquired developed technology and product rights    
Business Acquisition [Line Items]    
Intangibles   $ 450,100
Acquired developed technology and product rights | Minimum    
Business Acquisition [Line Items]    
Finite-lived intangible asset, useful life 3 years 1 month 6 days  
Acquired developed technology and product rights | Maximum    
Business Acquisition [Line Items]    
Finite-lived intangible asset, useful life 8 years 1 month 6 days  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisition - Pro Forma Information (Details) - Adamas Pharmaceuticals - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Business Acquisition [Line Items]    
Pro forma total revenues $ 174,360 $ 487,904
Pro forma net loss $ (10,405) $ (30,905)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Disaggregated Revenues - Summary of Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Total revenues $ 177,353 $ 148,464 $ 499,910 $ 420,725
Net product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 172,724 145,532 485,647 412,541
Trokendi XR        
Disaggregation of Revenue [Line Items]        
Total revenues 69,599 80,935 204,033 231,531
Oxtellar XR        
Disaggregation of Revenue [Line Items]        
Total revenues 30,528 29,728 88,007 82,120
GOCOVRI        
Disaggregation of Revenue [Line Items]        
Total revenues 27,878 0 75,179 0
Qelbree        
Disaggregation of Revenue [Line Items]        
Total revenues 18,326 2,370 37,708 2,685
APOKYN        
Disaggregation of Revenue [Line Items]        
Total revenues 18,261 24,627 57,156 73,338
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 8,132 7,872 23,564 22,867
Royalty revenues        
Disaggregation of Revenue [Line Items]        
Total revenues $ 4,629 $ 2,932 $ 14,263 $ 8,184
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Disaggregated Revenues - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Non-cash royalty revenue $ 2.5 $ 2.4 $ 7.2 $ 6.8
Revenue from Contract with Customer Benchmark | Product Concentration Risk | Trokendi XR        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage (more than) 40.00% 56.00%    
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Three Major Customers        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage (more than)     80.00% 85.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | AmerisourceBergen Drug Corporation        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage (more than)     25.00% 25.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Cardinal Health        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage (more than)     25.00% 25.00%
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | McKesson        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage (more than)     25.00% 25.00%
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Unrestricted Marketable Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Amortized cost $ 417,576 $ 253,301
Gross unrealized gains 0 2,349
Gross unrealized losses (5,342) (238)
Total fair value $ 412,234 $ 255,412
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Contractual Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Less than 1 year $ 280,297  
1 year to 2 years 104,346  
2 years to 3 years 27,591  
3 years to 4 years 0  
Greater than 4 years 0  
Total $ 412,234 $ 255,412
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Narrative (Details) - USD ($)
 1 Months Ended 9 Months Ended
Dec. 31, 2021
Apr. 30, 2020
Sep. 30, 2022
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]        
Debt securities, available-for-sale, excluding accrued interest, allowance for credit loss, not previously recorded     $ 0  
Variable Interest Entity [Line Items]        
Cash distributions received $ 12,900,000      
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary        
Variable Interest Entity [Line Items]        
Agreement termination notice period   30 days    
Threshold for development costs payments   $ 50,000,000    
Investments   $ 15,000,000   $ 15,000,000
VIE, qualitative or quantitative information, ownership percentage   13.00%    
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Jan. 01, 2022
Dec. 31, 2021
Accounting Standards Update 2020-06      
Fair value of financial instruments      
Long-term debt   $ 20,600  
Recurring      
Fair value of financial instruments      
Total assets at fair value $ 524,190   $ 459,476
Recurring | Level 3      
Fair value of financial instruments      
Total assets at fair value $ 0   $ 0
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Carrying Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Liabilities:    
Contingent consideration $ 57,371 $ 80,477
Recurring    
Other noncurrent assets    
Marketable securities - restricted (SERP) 464 630
Total assets at fair value 524,190 459,476
Liabilities:    
Contingent consideration 57,371 80,477
Total liabilities at fair value 57,371 80,477
Recurring | Corporate and Municipal Debt Securities    
Marketable securities    
Corporate and municipal debt securities 280,297 136,246
Long term marketable securities    
Corporate and municipal debt securities 131,937 119,166
Recurring | Cash    
Cash and cash equivalents    
Cash and Money market funds 111,087 148,863
Recurring | Money market funds    
Cash and cash equivalents    
Cash and Money market funds 405 54,571
Recurring | Level 1    
Other noncurrent assets    
Marketable securities - restricted (SERP) 9 7
Total assets at fair value 111,501 203,692
Liabilities:    
Contingent consideration 0 0
Total liabilities at fair value 0 0
Recurring | Level 1 | Corporate and Municipal Debt Securities    
Marketable securities    
Corporate and municipal debt securities 0 251
Long term marketable securities    
Corporate and municipal debt securities 0 0
Recurring | Level 1 | Cash    
Cash and cash equivalents    
Cash and Money market funds 111,087 148,863
Recurring | Level 1 | Money market funds    
Cash and cash equivalents    
Cash and Money market funds 405 54,571
Recurring | Level 2    
Other noncurrent assets    
Marketable securities - restricted (SERP) 455 623
Total assets at fair value 412,689 255,784
Liabilities:    
Contingent consideration 0 0
Total liabilities at fair value 0 0
Recurring | Level 2 | Corporate and Municipal Debt Securities    
Marketable securities    
Corporate and municipal debt securities 280,297 135,995
Long term marketable securities    
Corporate and municipal debt securities 131,937 119,166
Recurring | Level 2 | Cash    
Cash and cash equivalents    
Cash and Money market funds 0 0
Recurring | Level 2 | Money market funds    
Cash and cash equivalents    
Cash and Money market funds 0 0
Recurring | Level 3    
Other noncurrent assets    
Marketable securities - restricted (SERP) 0 0
Total assets at fair value 0 0
Liabilities:    
Contingent consideration 57,371 80,477
Total liabilities at fair value 57,371 80,477
Recurring | Level 3 | Corporate and Municipal Debt Securities    
Marketable securities    
Corporate and municipal debt securities 0 0
Long term marketable securities    
Corporate and municipal debt securities 0 0
Recurring | Level 3 | Cash    
Cash and cash equivalents    
Cash and Money market funds 0 0
Recurring | Level 3 | Money market funds    
Cash and cash equivalents    
Cash and Money market funds $ 0 $ 0
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments- Financial Instruments (Details) - Level 2 - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair value of financial instruments    
Carrying Value $ 401,438 $ 379,252
Fair Value (Level 2) $ 392,438 $ 400,236
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Nov. 24, 2021
USD ($)
right
Jun. 09, 2020
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Business Acquisition [Line Items]              
Fair value of contingent consideration   $ 230,000          
Payment of contingent consideration           $ 22,900 $ 0
Fair value of excess of the acquisition           2,100  
Change in fair value of contingent consideration     $ 486 $ 80   1,894 (7,650)
USWM Enterprises              
Business Acquisition [Line Items]              
Change in fair value of contingent consideration     400 $ (100) $ (7,700) (2,400) $ (7,700)
Adamas Pharmaceuticals              
Business Acquisition [Line Items]              
Fair value of contingent consideration $ 10,307            
Change in fair value of contingent consideration     $ (100)     500  
Contingents value rights | right 2            
SPN-830 Regulatory and Commercial Activities              
Business Acquisition [Line Items]              
Fair value of contingent consideration   130,000          
SPN-830 NDA Approval Milestone              
Business Acquisition [Line Items]              
Fair value of contingent consideration   105,000          
SPN-830 Future Sales Performance              
Business Acquisition [Line Items]              
Fair value of contingent consideration   100,000          
SPN-830 First Commercial And Sale              
Business Acquisition [Line Items]              
Fair value of contingent consideration   100,000          
APOKYN              
Business Acquisition [Line Items]              
Fair value of contingent consideration   35,000          
APOKYN and SPN-830              
Business Acquisition [Line Items]              
Fair value of contingent consideration   65,000          
SPN-830 FDA Acceptance Milestone              
Business Acquisition [Line Items]              
Fair value of contingent consideration   25,000          
SPN-830 NDA Approval Milestone, Time-Based              
Business Acquisition [Line Items]              
Fair value of contingent consideration   $ 50,000          
SPN-830 NDA Approval Milestone, Approval-Based              
Business Acquisition [Line Items]              
Fair value of contingent consideration           $ 55,000  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at December 31, 2021 $ 80,477  
Milestone payments (25,000)  
Change in fair value recognized in earnings 1,894  
Balance at September 30, 2022 (unaudited) 57,371  
Contingent consideration, current portion 47,590 $ 44,840
Contingent consideration, long-term 9,781 35,637
Contingent consideration 57,371 $ 80,477
Regulatory and developmental contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 47,590  
Sales-based contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 9,781  
USWM Enterprises    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at December 31, 2021 70,170  
Milestone payments (25,000)  
Change in fair value recognized in earnings 2,420  
Balance at September 30, 2022 (unaudited) 47,590  
Contingent consideration 47,590  
USWM Enterprises | Regulatory and developmental contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 47,590  
USWM Enterprises | Sales-based contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 0  
Adamas Acquisition    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at December 31, 2021 10,307  
Milestone payments 0  
Change in fair value recognized in earnings (526)  
Balance at September 30, 2022 (unaudited) 9,781  
Contingent consideration 9,781  
Adamas Acquisition | Regulatory and developmental contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration 0  
Adamas Acquisition | Sales-based contingent consideration liabilities    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Contingent consideration $ 9,781  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
USD ($)
Goodwill [Roll Forward]  
Balance as of December 31, 2021 $ 117,516
Goodwill, adjustments (133)
Balance as of September 30, 2022 (unaudited) $ 117,383
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 7 years 11 months 12 days  
Accumulated Amortization $ (126,159) $ (64,227)
Total intangible assets, carrying amount, gross 848,920 848,920
Intangible assets, net 722,761 784,693
Acquired in-process research and development    
Indefinite-Lived Intangible Assets [Line Items]    
Acquired in-process research and development $ 124,000 124,000
Acquired developed technology and product rights    
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 8 years 7 days  
Carrying Amount, Gross $ 681,100 681,100
Accumulated Amortization (93,642) (35,550)
Carrying Amount, Net $ 587,458 645,550
Capitalized patent defense costs    
Finite-Lived Intangible Assets [Line Items]    
Remaining Weighted Average Life (Years) 4 years 2 months 26 days  
Carrying Amount, Gross $ 43,820 43,820
Accumulated Amortization (32,517) (28,677)
Carrying Amount, Net $ 11,303 $ 15,143
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Goodwill and Intangible Assets, Net - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]        
Amortization of intangible assets $ 20,644 $ 6,009 $ 61,932 $ 17,964
2023 79,800   79,800  
2024 79,800   79,800  
2025 75,100   75,100  
2026 74,900   74,900  
2027 73,200   73,200  
Developed Technology Rights and Patent Defense Costs        
Finite-Lived Intangible Assets [Line Items]        
Amortization of intangible assets $ 20,600 $ 6,000 $ 61,900 $ 18,000
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Senior Notes Due 2023 - Narrative (Details)
 1 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
Mar. 31, 2018
day
$ / shares
Rate
shares
Sep. 30, 2022
USD ($)
$ / shares
Jan. 01, 2022
USD ($)
Debt Instrument [Line Items]          
Strike price of the warrant transactions (in dollars per share) | $ / shares $ 80.91   $ 80.91 $ 80.91  
Accounting Standards Update 2020-06          
Debt Instrument [Line Items]          
Long-term debt | $         $ 20,600,000
Convertible Debt          
Debt Instrument [Line Items]          
Interest rate     0.625%    
Principal amount of debt | $ $ 402,500,000 $ 402,500,000   $ 402,500,000  
Conversion rate for the notes (in shares per $1,000 principal amount)       0.0168545  
Conversion price, per share of common stock (in dollars per share) | $ / shares $ 59.33   $ 59.33 $ 59.33  
Convertible note hedge options issued (in shares) | shares     402,500    
Common stock issued upon conversion of notes (in shares) | shares     6,800,000    
Warrants issued (in shares) | shares     6,783,939    
Number of shares per warrant entitled to holder (in shares) | shares     1    
Long-term debt | $ $ 401,438,000 379,252,000   $ 401,438,000  
Conversion of debt to equity | $ $ 0 $ 0      
Convertible Debt | Conversion Circumstance One          
Debt Instrument [Line Items]          
Threshold trading days (whether or not consecutive) | day     20    
Consecutive trading day period (in days) | day     30    
Conversion rate of the notes on trading day (as percent)     130.00%    
Conversion option stock price trigger (in dollars per share) | $ / shares     $ 77.13    
Convertible Debt | Conversion Circumstance Two          
Debt Instrument [Line Items]          
Threshold trading days (whether or not consecutive) | day     5    
Consecutive trading day period (in days) | day     10    
Conversion rate of the notes on trading day (as percent) | Rate     98.00%    
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) - Convertible Debt - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
2023 Notes $ 402,500,000 $ 402,500,000
Unamortized debt discount and deferred financing costs (1,062,000) (23,248,000)
Total carrying value $ 401,438,000 $ 379,252,000
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based payments        
Total $ 4,985 $ 4,027 $ 13,307 $ 13,874
Research and development        
Share-based payments        
Total 825 615 2,284 1,909
Selling, general and administrative        
Share-based payments        
Total $ 4,160 $ 3,412 $ 11,023 $ 11,965
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments - SAR Activity (Details) - Stock option and Stock Appreciation Rights - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Number of Options & SARs    
Outstanding at the beginning of the period (in shares) 5,774,076  
Granted (in shares) 1,046,785  
Exercised (in shares) (673,120)  
Forfeited (in shares) (145,473)  
Outstanding at the end of the period (in shares) 6,002,268 5,774,076
Vested and expected to vest (in shares) 6,002,268 5,774,076
Exercisable (in shares) 3,682,170 3,651,824
Weighted Average Exercise Price (per share)    
Outstanding at the beginning of the period (in dollars per share) $ 24.15  
Granted (in dollars per share) 31.95  
Exercised (in dollars per share) 12.79  
Forfeited (in dollars per share) 30.06  
Outstanding at the end of the period (in dollars per share) 26.64 $ 24.15
Vested and expected to vest (in dollars per share) 26.64 24.15
Exercisable (in dollars per share) $ 24.61 $ 21.29
Weighted Average Remaining Contractual Term (in years)    
Outstanding at the end of the period 6 years 3 months 14 days 5 years 11 months 12 days
Vested and expected to vest 6 years 3 months 14 days 5 years 11 months 12 days
Exercisable 4 years 9 months 29 days 4 years 6 months 10 days
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments - Restricted Stock Units (Details) - RSUs
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Number of RSUs  
Nonvested, beginning balance (in shares) 21,110
Granted (in shares) 134,460
Vested (in shares) (21,110)
Nonvested, ending balance (in shares) 134,460
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 29.61
Granted (in dollars per share) | $ / shares 32.17
Vested (in dollars per share) | $ / shares 29.61
Nonvested, ending balance (in dollars per share) | $ / shares $ 32.17
Forfeited (in shares) 0
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Payments - Performance Stock Units (Details)
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Total PSUs  
Number of PSUs  
Nonvested, beginning balance (in shares) | shares 89,125
Granted (in shares) | shares 155,000
Vested (in shares) | shares (22,250)
Forfeited (in shares) | shares (1,500)
Nonvested, ending balance (in shares) | shares 220,375
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 28.43
Granted (in dollars per share) | $ / shares 28.93
Vested (in dollars per share) | $ / shares 29.69
Forfeited (in dollars per share) | $ / shares 30.45
Nonvested, ending balance (in dollars per share) | $ / shares $ 28.64
Performance-Based Units  
Number of PSUs  
Nonvested, beginning balance (in shares) | shares 53,500
Granted (in shares) | shares 155,000
Vested (in shares) | shares (22,250)
Forfeited (in shares) | shares (1,500)
Nonvested, ending balance (in shares) | shares 184,750
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 29.82
Granted (in dollars per share) | $ / shares 28.93
Vested (in dollars per share) | $ / shares 29.69
Forfeited (in dollars per share) | $ / shares 30.45
Nonvested, ending balance (in dollars per share) | $ / shares $ 29.08
Market-Based Units  
Number of PSUs  
Nonvested, beginning balance (in shares) | shares 35,625
Granted (in shares) | shares 0
Vested (in shares) | shares 0
Forfeited (in shares) | shares 0
Nonvested, ending balance (in shares) | shares 35,625
Weighted Average Grant Date Fair Value per Share  
Nonvested, beginning balance (in dollars per share) | $ / shares $ 26.34
Granted (in dollars per share) | $ / shares 0
Vested (in dollars per share) | $ / shares 0
Forfeited (in dollars per share) | $ / shares 0
Nonvested, ending balance (in dollars per share) | $ / shares $ 26.34
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Jan. 01, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Mar. 31, 2018
Income per share                    
Strike price of the warrant transactions (in dollars per share)   $ 80.91           $ 80.91   $ 80.91
Numerator:                    
Net earnings   $ 1,749 $ 7,865 $ 25,616 $ 21,562 $ 23,726 $ 5,694 $ 35,230 $ 50,982  
After-tax interest expense for 2023 Notes   0     0     2,664 0  
Numerator for dilutive earnings per share   $ 1,749     $ 21,562     $ 37,894 $ 50,982  
Denominator:                    
Weighted average shares outstanding, basic (in shares)   53,789,674     53,187,764     53,517,838 53,053,441  
Effect of dilutive securities:                    
Stock options, RSU and SAR (in shares)   1,245,164     1,147,030     1,241,347 1,248,020  
Convertible notes (in shares)   0     0     6,783,936 0  
Weighted average shares outstanding, diluted (in shares)   55,034,838     54,334,794     61,543,121 54,301,461  
Earnings per share, basic (in dollars per share)   $ 0.03     $ 0.41     $ 0.66 $ 0.96  
Earnings per share, diluted (in dollars per share)   0.03     $ 0.40     0.62 $ 0.94  
Convertible Debt                    
Income per share                    
Conversion price, per share of common stock (in dollars per share)   $ 59.33           $ 59.33   $ 59.33
Convertible Debt | Accounting Standards Update 2020-06                    
Effect of dilutive securities:                    
Convertible notes (in shares) 6,800,000             6,800,000    
2023 Notes                    
Income per share                    
Common stock equivalents excluded in the calculation of diluted income per share (in shares)   6,783,936     0     0 0  
Stock options, RSUs, PSUs                    
Income per share                    
Common stock equivalents excluded in the calculation of diluted income per share (in shares)   792,904     1,654,816     470,822 1,397,424  
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Tax (Benefit) Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ (2,193) $ 7,398 $ (9,627) $ 20,142
Effective tax rate 493.90% 25.50% (37.60%) 28.30%
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Narrative (Details)
$ in Thousands
 3 Months Ended 7 Months Ended
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
Nov. 24, 2021
renewalOption
Feb. 01, 2019
Leases [Abstract]        
Optional lease renewal term (in years)     5 years 10 years
Lessee, Operating Lease, Number Of Renewal Options | renewalOption     1  
Adamas Pharmaceuticals        
Leases        
Change in fair value of operating lease acquired | $ $ 1,600 $ (1,620)    
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Leases Balance Sheet Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Assets    
Operating lease assets $ 29,663 $ 35,365
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Other assets Other assets
Lease liabilities, current    
Operating lease liabilities, current portion $ 6,757 $ 6,477
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Lease liabilities, long-term    
Operating lease liabilities, long-term $ 36,028 $ 41,298
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Operating lease liabilities, long-term Operating lease liabilities, long-term
Total lease liabilities $ 42,785 $ 47,775
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items - Accounts Receivables (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Allowance for expected sales discounts and allowances $ 12.8 $ 13.5
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items - Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Raw materials $ 11,012 $ 7,325
Work in process 25,461 45,711
Finished goods 46,692 32,923
Total inventories $ 83,165 $ 85,959
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items - Property and Equipment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property and equipment          
Property and equipment, gross $ 28,810   $ 28,810   $ 33,409
Less accumulated depreciation and amortization (12,938)   (12,938)   (16,454)
Property and equipment, net 15,872   15,872   16,955
Depreciation and amortization expense 800 $ 600 2,200 $ 1,900  
Lab equipment and furniture          
Property and equipment          
Property and equipment, gross 12,207   12,207   12,287
Leasehold improvements          
Property and equipment          
Property and equipment, gross 14,023   14,023   14,369
Software          
Property and equipment          
Property and equipment, gross 1,007   1,007   4,776
Computer equipment          
Property and equipment          
Property and equipment, gross 1,282   1,282   1,944
Construction-in-progress          
Property and equipment          
Property and equipment, gross $ 291   $ 291   $ 33
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items - Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accounts payable $ 16,015 $ 9,331
Accrued professional & marketing fees 31,269 26,728
Accrued compensation 16,748 28,068
Accrued product costs 11,129 18,460
Accrued royalties 11,671 13,821
Accrued clinical trial costs 6,823 9,125
Operating lease liabilities, current portion 6,757 6,477
Other accrued expenses 9,890 5,673
Total $ 110,302 $ 117,683
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accrued product rebates $ 119,162 $ 97,597
Accrued product returns 39,308 35,127
Total $ 158,470 $ 132,724
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items - Other Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Nonrecourse liability related to sale of future royalties, long-term $ 0 $ 5,977
Other liabilities 10,371 10,403
Total $ 10,371 $ 16,380
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
Interest Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Other Income and Expenses [Abstract]        
Interest expense $ (1,158) $ (5,033) $ (3,488) $ (14,593)
Interest expense on nonrecourse liability related to sale of future royalties (566) (892) (1,988) (2,896)
Total (1,724) (5,925) (5,476) (17,489)
Amortization of deferred financing costs and debt discount $ 500 $ 4,400 $ 1,582 $ 13,037
XML 87 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Details)
€ in Millions
 1 Months Ended 9 Months Ended
Apr. 01, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
EUR (€)
Sep. 30, 2014
USD ($)
Long-term Purchase Commitment [Line Items]          
Nonrecourse liability related to sale of future royalties, long term         $ 30,000,000
Long-term purchase commitment, amount     $ 0    
MDD Subsidiaries          
Long-term Purchase Commitment [Line Items]          
Payment to resolve U.S. Department of Justice allegations   $ 17,500,000      
NAMENDA XR/Namzaric Qui Tam Litigation          
Long-term Purchase Commitment [Line Items]          
Loss contingency, damages sought, value $ 2,500,000,000        
USWM Enterprises          
Long-term Purchase Commitment [Line Items]          
Annual minimum purchase quantity requirement amount | €       € 3.9  
Commitment period     5 years    
XML 88 supn-20220930_htm.xml IDEA: XBRL DOCUMENT 0001356576 2022-01-01 2022-09-30 0001356576 2022-10-31 0001356576 2022-09-30 0001356576 2021-12-31 0001356576 us-gaap:ProductMember 2022-07-01 2022-09-30 0001356576 us-gaap:ProductMember 2021-07-01 2021-09-30 0001356576 us-gaap:ProductMember 2022-01-01 2022-09-30 0001356576 us-gaap:ProductMember 2021-01-01 2021-09-30 0001356576 us-gaap:RoyaltyMember 2022-07-01 2022-09-30 0001356576 us-gaap:RoyaltyMember 2021-07-01 2021-09-30 0001356576 us-gaap:RoyaltyMember 2022-01-01 2022-09-30 0001356576 us-gaap:RoyaltyMember 2021-01-01 2021-09-30 0001356576 2022-07-01 2022-09-30 0001356576 2021-07-01 2021-09-30 0001356576 2021-01-01 2021-09-30 0001356576 us-gaap:CommonStockMember 2021-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001356576 us-gaap:RetainedEarningsMember 2021-12-31 0001356576 2022-01-01 2022-03-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:CommonStockMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember us-gaap:RetainedEarningsMember 2021-12-31 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember 2021-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001356576 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001356576 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001356576 us-gaap:CommonStockMember 2022-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001356576 us-gaap:RetainedEarningsMember 2022-03-31 0001356576 2022-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001356576 2022-04-01 2022-06-30 0001356576 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001356576 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001356576 us-gaap:CommonStockMember 2022-06-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001356576 us-gaap:RetainedEarningsMember 2022-06-30 0001356576 2022-06-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001356576 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001356576 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001356576 us-gaap:CommonStockMember 2022-09-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001356576 us-gaap:RetainedEarningsMember 2022-09-30 0001356576 us-gaap:CommonStockMember 2020-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001356576 us-gaap:RetainedEarningsMember 2020-12-31 0001356576 2020-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001356576 2021-01-01 2021-03-31 0001356576 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001356576 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001356576 us-gaap:CommonStockMember 2021-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001356576 us-gaap:RetainedEarningsMember 2021-03-31 0001356576 2021-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001356576 2021-04-01 2021-06-30 0001356576 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001356576 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001356576 us-gaap:CommonStockMember 2021-06-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001356576 us-gaap:RetainedEarningsMember 2021-06-30 0001356576 2021-06-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001356576 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001356576 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001356576 us-gaap:CommonStockMember 2021-09-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001356576 us-gaap:RetainedEarningsMember 2021-09-30 0001356576 2021-09-30 0001356576 supn:AdamasPharmaceuticalsMember 2021-11-24 2021-11-24 0001356576 us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member us-gaap:RetainedEarningsMember 2022-01-01 0001356576 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member us-gaap:AdditionalPaidInCapitalMember 2022-01-01 0001356576 us-gaap:AccountingStandardsUpdate202006Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-01-01 0001356576 supn:AdamasPharmaceuticalsMember 2021-11-24 0001356576 srt:ScenarioPreviouslyReportedMember supn:AdamasPharmaceuticalsMember 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember 2021-11-24 2022-06-30 0001356576 srt:ScenarioPreviouslyReportedMember supn:AdamasPharmaceuticalsMember 2021-11-24 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember us-gaap:DevelopedTechnologyRightsMember 2021-11-24 0001356576 srt:MinimumMember supn:AdamasPharmaceuticalsMember us-gaap:DevelopedTechnologyRightsMember 2020-01-01 2020-01-01 0001356576 srt:MaximumMember supn:AdamasPharmaceuticalsMember us-gaap:DevelopedTechnologyRightsMember 2020-01-01 2020-01-01 0001356576 supn:AdamasPharmaceuticalsMember 2021-07-01 2021-09-30 0001356576 supn:AdamasPharmaceuticalsMember 2021-01-01 2021-09-30 0001356576 supn:TrokendiXrMember 2022-07-01 2022-09-30 0001356576 supn:TrokendiXrMember 2021-07-01 2021-09-30 0001356576 supn:TrokendiXrMember 2022-01-01 2022-09-30 0001356576 supn:TrokendiXrMember 2021-01-01 2021-09-30 0001356576 supn:OxtellarXRMember 2022-07-01 2022-09-30 0001356576 supn:OxtellarXRMember 2021-07-01 2021-09-30 0001356576 supn:OxtellarXRMember 2022-01-01 2022-09-30 0001356576 supn:OxtellarXRMember 2021-01-01 2021-09-30 0001356576 supn:GOCOVRIMember 2022-07-01 2022-09-30 0001356576 supn:GOCOVRIMember 2021-07-01 2021-09-30 0001356576 supn:GOCOVRIMember 2022-01-01 2022-09-30 0001356576 supn:GOCOVRIMember 2021-01-01 2021-09-30 0001356576 supn:QelbreeMember 2022-07-01 2022-09-30 0001356576 supn:QelbreeMember 2021-07-01 2021-09-30 0001356576 supn:QelbreeMember 2022-01-01 2022-09-30 0001356576 supn:QelbreeMember 2021-01-01 2021-09-30 0001356576 supn:APOKYNMember 2022-07-01 2022-09-30 0001356576 supn:APOKYNMember 2021-07-01 2021-09-30 0001356576 supn:APOKYNMember 2022-01-01 2022-09-30 0001356576 supn:APOKYNMember 2021-01-01 2021-09-30 0001356576 us-gaap:ManufacturedProductOtherMember 2022-07-01 2022-09-30 0001356576 us-gaap:ManufacturedProductOtherMember 2021-07-01 2021-09-30 0001356576 us-gaap:ManufacturedProductOtherMember 2022-01-01 2022-09-30 0001356576 us-gaap:ManufacturedProductOtherMember 2021-01-01 2021-09-30 0001356576 supn:TrokendiXrMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2022-07-01 2022-09-30 0001356576 supn:TrokendiXrMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001356576 supn:CardinalHealthMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001356576 supn:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001356576 supn:McKessonMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001356576 supn:AmerisourceBergenDrugCorporationMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001356576 supn:CardinalHealthMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001356576 supn:McKessonMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001356576 supn:ThreeMajorCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001356576 supn:ThreeMajorCustomersMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001356576 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember supn:NavitorPharmaceuticalsIncMember 2020-04-01 2020-04-30 0001356576 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember supn:NavitorPharmaceuticalsIncMember 2020-04-30 0001356576 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember supn:NavitorPharmaceuticalsIncMember 2021-03-31 0001356576 2021-12-01 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2022-09-30 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2022-09-30 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2022-09-30 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2022-09-30 0001356576 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001356576 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember supn:CorporateAndMunicipalDebtSecuritiesMember 2021-12-31 0001356576 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001356576 us-gaap:FairValueInputsLevel2Member 2022-09-30 0001356576 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001356576 2020-06-09 2020-06-09 0001356576 supn:SPN830RegulatoryAndCommercialActivitiesMember 2020-06-09 2020-06-09 0001356576 supn:SPN830FDAAcceptanceMilestoneMember 2020-06-09 2020-06-09 0001356576 supn:SPN830NDAApprovalMilestoneMember 2020-06-09 2020-06-09 0001356576 supn:SPN830NDAApprovalMilestoneTimeBasedMember 2020-06-09 2020-06-09 0001356576 supn:SPN830NDAApprovalMilestoneApprovalBasedMember 2022-01-01 2022-09-30 0001356576 supn:SPN830FutureSalesPerformanceMember 2020-06-09 2020-06-09 0001356576 supn:SPN830FirstCommercialAndSaleMember 2020-06-09 2020-06-09 0001356576 supn:APOKYNMember 2020-06-09 2020-06-09 0001356576 supn:APOKYNAndSPN830Member 2020-06-09 2020-06-09 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2022-07-01 2022-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2022-01-01 2022-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2021-07-01 2021-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2021-01-01 2021-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2021-04-01 2021-06-30 0001356576 supn:AdamasPharmaceuticalsMember 2022-07-01 2022-09-30 0001356576 supn:AdamasPharmaceuticalsMember 2022-01-01 2022-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2021-12-31 0001356576 supn:AdamasMember 2021-12-31 0001356576 supn:AdamasMember 2022-01-01 2022-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember 2022-09-30 0001356576 supn:AdamasMember 2022-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember 2022-09-30 0001356576 supn:AdamasMember supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember 2022-09-30 0001356576 supn:RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember 2022-09-30 0001356576 supn:MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember supn:SalesBasedContingentConsiderationLiabilityMember 2022-09-30 0001356576 supn:AdamasMember supn:SalesBasedContingentConsiderationLiabilityMember 2022-09-30 0001356576 supn:SalesBasedContingentConsiderationLiabilityMember 2022-09-30 0001356576 us-gaap:InProcessResearchAndDevelopmentMember 2022-09-30 0001356576 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001356576 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-09-30 0001356576 us-gaap:DevelopedTechnologyRightsMember 2022-09-30 0001356576 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001356576 supn:PatentDefenseCostsMember 2022-01-01 2022-09-30 0001356576 supn:PatentDefenseCostsMember 2022-09-30 0001356576 supn:PatentDefenseCostsMember 2021-12-31 0001356576 supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember 2022-07-01 2022-09-30 0001356576 supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember 2022-01-01 2022-09-30 0001356576 supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember 2021-07-01 2021-09-30 0001356576 supn:DevelopedTechnologyRightsAndPatentDefenseCostsMember 2021-01-01 2021-09-30 0001356576 us-gaap:ConvertibleDebtMember 2018-03-31 0001356576 us-gaap:ConvertibleDebtMember 2022-09-30 0001356576 supn:ConversionCircumstanceOneMember us-gaap:ConvertibleDebtMember 2018-03-01 2018-03-31 0001356576 supn:ConversionCircumstanceTwoMember us-gaap:ConvertibleDebtMember 2018-03-01 2018-03-31 0001356576 us-gaap:ConvertibleDebtMember 2018-03-01 2018-03-31 0001356576 2018-03-31 0001356576 us-gaap:ConvertibleDebtMember 2021-12-31 0001356576 us-gaap:ConvertibleDebtMember 2021-12-31 2021-12-31 0001356576 us-gaap:ConvertibleDebtMember 2022-09-30 2022-09-30 0001356576 us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001356576 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001356576 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0001356576 supn:StockOptionStockAppreciationRightsMember 2021-12-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2021-01-01 2021-12-31 0001356576 supn:StockOptionStockAppreciationRightsMember 2022-01-01 2022-09-30 0001356576 supn:StockOptionStockAppreciationRightsMember 2022-09-30 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001356576 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001356576 supn:PerformanceBasedUnitsMember 2021-12-31 0001356576 supn:MarketBasedUnitsMember 2021-12-31 0001356576 us-gaap:PerformanceSharesMember 2021-12-31 0001356576 supn:PerformanceBasedUnitsMember 2022-01-01 2022-09-30 0001356576 supn:MarketBasedUnitsMember 2022-01-01 2022-09-30 0001356576 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0001356576 supn:PerformanceBasedUnitsMember 2022-09-30 0001356576 supn:MarketBasedUnitsMember 2022-09-30 0001356576 us-gaap:PerformanceSharesMember 2022-09-30 0001356576 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0001356576 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2021-09-30 0001356576 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0001356576 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-09-30 0001356576 us-gaap:StockCompensationPlanMember 2022-07-01 2022-09-30 0001356576 us-gaap:StockCompensationPlanMember 2021-07-01 2021-09-30 0001356576 us-gaap:StockCompensationPlanMember 2022-01-01 2022-09-30 0001356576 us-gaap:StockCompensationPlanMember 2021-01-01 2021-09-30 0001356576 us-gaap:AccountingStandardsUpdate202006Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001356576 2019-02-01 0001356576 2021-11-24 0001356576 supn:AdamasPharmaceuticalsMember 2022-01-01 2022-03-31 0001356576 supn:LabEquipmentAndFurnitureMember 2022-09-30 0001356576 supn:LabEquipmentAndFurnitureMember 2021-12-31 0001356576 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001356576 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001356576 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-09-30 0001356576 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-12-31 0001356576 us-gaap:ComputerEquipmentMember 2022-09-30 0001356576 us-gaap:ComputerEquipmentMember 2021-12-31 0001356576 us-gaap:ConstructionInProgressMember 2022-09-30 0001356576 us-gaap:ConstructionInProgressMember 2021-12-31 0001356576 2014-09-30 0001356576 supn:MDDSubsidiariesMember 2019-03-01 2019-03-31 0001356576 supn:NAMENDAXRNamzaricQuiTamLitigationMember 2019-04-01 2019-04-01 shares iso4217:USD iso4217:USD shares supn:marketedProduct supn:segment supn:right pure supn:day utr:Rate supn:renewalOption iso4217:EUR 0001356576 false --12-31 2022 Q3 http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member 0.0168545 http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent 10-Q true 2022-09-30 false 001-35518 SUPERNUS PHARMACEUTICALS, INC. DE 20-2590184 9715 Key West Avenue Rockville MD 20850 301 838-2500 Yes Yes Large Accelerated Filer false false false Common Stock, $0.001 par value per share 54058138 SUPN NASDAQ 111492000 203434000 280297000 136246000 164086000 148932000 83165000 85959000 24846000 27019000 663886000 601590000 131937000 119166000 15872000 16955000 722761000 784693000 117383000 117516000 41290000 49232000 1693129000 1689152000 110302000 117683000 158470000 132724000 47590000 44840000 401438000 0 8187000 20132000 725987000 315379000 0 379252000 9781000 35637000 36028000 41298000 58164000 85355000 10371000 16380000 840331000 873301000 0.001 0.001 130000000 130000000 54053513 54053513 53256094 53256094 54000 53000 401026000 434337000 -4046000 1539000 455764000 379922000 852798000 815851000 1693129000 1689152000 172724000 145532000 485647000 412541000 4629000 2932000 14263000 8184000 177353000 148464000 499910000 420725000 25878000 18085000 64267000 58067000 19554000 19654000 56778000 69389000 112314000 72032000 303249000 203024000 20644000 6009000 61932000 17964000 486000 80000 1894000 -7650000 178876000 115860000 488120000 340794000 -1523000 32604000 11790000 79931000 1724000 5925000 5476000 17489000 2803000 2281000 19289000 8682000 1079000 -3644000 13813000 -8807000 -444000 28960000 25603000 71124000 -2193000 7398000 -9627000 20142000 1749000 21562000 35230000 50982000 0.03 0.41 0.66 0.96 0.03 0.40 0.62 0.94 53789674 53187764 53517838 53053441 55034838 54334794 61543121 54301461 1749000 21562000 35230000 50982000 -1826000 -1224000 -5585000 -4766000 -1826000 -1224000 -5585000 -4766000 -77000 20338000 29645000 46216000 53256094 53000 434337000 1539000 379922000 815851000 -56212000 40612000 -15600000 53256094 53000 378125000 1539000 420534000 800251000 4025000 4025000 130211 866000 866000 25616000 25616000 -2312000 -2312000 53386305 53000 383016000 -773000 446150000 828446000 4297000 4297000 106081 2273000 2273000 7865000 7865000 -1447000 -1447000 53492386 53000 389586000 -2220000 454015000 841434000 4985000 4985000 561127 1000 6455000 6456000 1749000 1749000 -1826000 -1826000 54053513 54000 401026000 -4046000 455764000 852798000 52868482 53000 409332000 8975000 326498000 744858000 4371000 4371000 125655 2247000 2247000 5694000 5694000 -2726000 -2726000 52994137 53000 415950000 6249000 332192000 754444000 5476000 5476000 150622 2749000 2749000 23726000 23726000 -816000 -816000 53144759 53000 424175000 5433000 355918000 785579000 4027000 4027000 35884 524000 524000 21562000 21562000 -1224000 -1224000 53180643 53000 428726000 4209000 377480000 810468000 35230000 50982000 64694000 19888000 0 15000000 12888000 0 1582000 13037000 14000 221000 -3215000 845000 1894000 -7650000 -7983000 22000 13307000 13874000 -18564000 -479000 14958000 -7352000 6304000 9331000 -3098000 13351000 25746000 5856000 -12659000 -15726000 -2100000 0 89262000 78364000 340665000 307634000 173189000 152546000 422000 2005000 0 950000 -167898000 -158043000 22900000 0 9594000 5520000 0 800000 -13306000 6320000 -91942000 -73359000 203434000 288640000 111492000 215281000 2516000 1887000 14558000 25111000 9547000 7613000 973000 4120000 144000 186000 580000 0 Business Organization<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Products</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trokendi XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (topiramate) is the first once-daily extended-release topiramate product indicated for the treatment of epilepsy in patients 6 years of age and older in the United States (U.S.) market. It is also indicated for the prophylaxis of migraine headache in adults and adolescents 12 years and older. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Oxtellar XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (oxcarbazepine) is indicated as therapy for the treatment of partial onset seizures in patients 6 years of age and older. It is also the first once-daily extended-release oxcarbazepine product indicated for the treatment of epilepsy in the U.S.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Qelbree</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (viloxazine extended-release capsules) is a novel non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older. On April 2, 2021, the U.S. Food and Drug Administration (FDA) approved Qelbree for the treatment of ADHD in pediatric patients 6 to 17 years of age. In May 2021, the Company launched Qelbree for pediatric patients in the U.S. On April 29, 2022, the FDA approved Qelbree for treatment of ADHD in adult patients. The Company launched Qelbree for adult patients in May 2022.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">GOCOVRI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amantadine) extended-release capsules is the first and only FDA approved medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa/carbidopa with PD experiencing "off" episodes. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">APOKYN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced PD. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XADAGO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (safinamide) is a once-daily product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Osmolex ER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amantadine) extended-release is a once-daily product for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MYOBLOC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rimabotulinumtoxinB injection) is a product indicated for the treatment of cervical dystonia and chronic sialorrhea in adults. It is the only botulinum toxin type B available on the market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Candidates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing a pipeline of novel CNS product candidates for the treatment of various CNS conditions. The Company's product candidates in clinical development include the following: </span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.27pt">SPN-830 (apomorphine infusion device) is a late-stage drug/device combination product candidate for the continuous treatment of motor fluctuations ("off" episodes) in PD patients that are not adequately controlled with oral levodopa and one or more adjunct PD medications. In October 2022, the FDA issued a Complete Response Letter (CRL) regarding the NDA for SPN-830. Refer to Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-820 (NV-5138) is a first-in-class product candidate for treatment-resistant depression, currently in Phase II development. It is an orally active small molecule that directly activates brain mechanistic target of rapamycin complex 1 (mTORC1).</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SPN-817 (huperzine A) is a novel product candidate for treatment-resistant seizures, currently in Phase I development.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Adamas Acquisition and Reorganization</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2021, the Company entered into an Agreement and Plan of Merger by and among the Company, Adamas Pharmaceuticals, Inc. (Adamas) and Supernus Reef, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (Purchaser) (Adamas Agreement). On November 24, 2021 (the Closing Date), the Company completed its purchase of all of the outstanding equity of Adamas, pursuant to the Adamas Agreement dated October 10, 2021, and the Purchaser was merged with and into Adamas (the Merger), with Adamas continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (Adamas Acquisition). On the Closing Date, Adamas owned two marketed products: GOCOVRI (amantadine) extended-release capsules, the first and only FDA approved medicine indicated for the treatment of both "off" episodes and dyskinesia in patients with PD receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing "off" episodes; and Osmolex ER (amantadine) extended-release tablets, approved for the treatment of PD and drug-induced extrapyramidal reactions in adult patients. Adamas also owns the right to receive royalties from Allergan plc for sales of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) in the U.S.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2022 and subsequent to the Adamas Acquisition, the Company completed a reorganization of the Adamas legal entities in an effort to obtain operational, legal and other benefits that also resulted in certain state tax efficiencies. The reorganization had no effect on the condensed consolidated financial statements other than certain state tax efficiencies. (See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Tax (Benefit) Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business operations and has assessed the impact of the COVID-19 pandemic on its condensed consolidated financial statements as of September 30, 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the situation surrounding the COVID-19 pandemic remains fluid and the duration uncertain, the long-term nature and extent of the impacts of the pandemic on the Company's business operations and financial position cannot be reasonably estimated at this time.</span></div> 2 Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, which is primarily located in the U.S., operates in one operating segment. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the fair values of financial instruments and the recoverability of intangible assets, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expense includes the cost of promotional materials and activities, such as television, print media, digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $52.0 million and $112.8 million in advertising expense for the three and nine months ended September 30, 2022, respectively, and approximately $22.6 million and $59.7 million for the three and nine months ended September 30, 2021, respectively. These expenses are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of earnings.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific U.S. GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with the requirements of the U.S. Securities and Exchange Commission (SEC) for interim financial information. As permitted under Generally Accepted Accounting Principles in the United States (U.S. GAAP), certain notes and other information have been omitted from the interim unaudited condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q. Therefore, these condensed consolidated financial statements should be read in conjunction with the Company’s most recent Annual Report on Form 10-K, for the year ended December 31, 2021, filed with the SEC.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management’s opinion, the condensed consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position, results of operations, and cash flows. The results of operations for any interim period are not necessarily indicative of the Company’s future quarterly or annual results.</span></div>The Company, which is primarily located in the U.S., operates in one operating segment. 1 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's condensed consolidated financial statements include the accounts of Supernus Pharmaceuticals, Inc. and its wholly owned subsidiaries. These are collectively referred to herein as "Supernus" or "the Company." All significant intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements reflect the consolidation of entities in which the Company has a controlling financial interest. In determining whether there is a controlling financial interest, the Company considers if it has a majority of the voting interests of the entity, or if the entity is a variable interest entity (VIE) and if the Company is the primary beneficiary. In determining the primary beneficiary of a VIE, the Company evaluates whether it has both: the power to direct the activities of the VIE that most significantly impact the VIE's economic performance; and the obligation to absorb losses of, or the right to receive benefits from the VIE that could potentially be significant to that VIE. The Company's judgment with respect to its level of influence or control of an entity involves the consideration of various factors, including the form of an ownership interest; representation in the entity's governance; the size of the investment; estimates of future cash flows; the ability to participate in policymaking decisions; and the rights of the other investors to participate in the decision making process, including the right to </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liquidate the entity, if applicable. If the Company is not the primary beneficiary of the VIE, and an ownership interest is maintained in the entity, the interest is accounted for under the equity or cost methods of accounting, as appropriate. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously assesses whether it is the primary beneficiary of a VIE as changes to existing relationships or future transactions may affect its conclusions.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on: historical experience; forecasts; information received from its service providers; information from other sources, including public and proprietary sources; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company periodically evaluates the methodologies employed in making its estimates.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may directly or indirectly impact our business, financial condition and results of operations is highly uncertain and subject to change. As a result, certain of our estimates and assumptions, including the provision for sales deductions, the fair values of financial instruments and the recoverability of intangible assets, require increased judgment and carry a higher degree of variability and volatility that could result in material changes to our estimates in future periods.</span></div> <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expense</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising expense includes the cost of promotional materials and activities, such as television, print media, digital marketing, marketing programs and speaker programs. The cost of the Company's advertising efforts are expensed as incurred.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred approximately $52.0 million and $112.8 million in advertising expense for the three and nine months ended September 30, 2022, respectively, and approximately $22.6 million and $59.7 million for the three and nine months ended September 30, 2021, respectively. These expenses are recorded as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of earnings.</span></div> 52000000 112800000 22600000 59700000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Adopted</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in August 2020, simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible debt instruments with cash conversion and beneficial conversion features. ASU 2020-06 eliminates requirements to separately account for liability and equity components of such convertible debt instruments and eliminates the ability to use the treasury stock method for calculating diluted earnings per share for convertible instruments whose principal amount may be settled in whole or in part with equity. Instead, ASU 2020-06 requires (i) the entire amount of the security to be presented as a liability on the balance sheet and (ii) application of the “if-converted” method for calculating diluted earnings per share. This new standard also removes certain settlement conditions required for equity contracts to qualify for the derivative scope exception.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the new guidance as of January 1, 2022 using the modified retrospective method of transition which allows for a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. As a result, the cumulative effect of the accounting change increased the carrying amount of the convertible notes, net by $20.6 million, increased retained earnings by $40.6 million, reduced additional paid-in capital by $56.2 million, and decreased deferred tax liabilities by $5.0 million as of January 1, 2022. In addition, the Company had an increase of 6.8 million in dilutive shares included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share under the if-converted method. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The new standard, issued in November 2021, requires the disclosure of information about transactions with a government that are accounted for by applying a grant or contribution model by analogy. This could include various forms of government assistance, but excludes transactions in the scope of specific U.S. GAAP, such as tax incentives accounted for under Accounting Standards Codification (ASC) 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For transactions in the scope of the new standard, information about the nature of the transaction, including significant terms and conditions, as well as the amounts and specific financial statement line items affected by the transaction are required to be disclosed. This guidance is effective for fiscal years beginning after December 15, 2021 on a prospective basis. The adoption of the new standard as of January 1, 2022 did not have a material impact to the financial statements.</span></div> 20600000 40600000 -56200000 -5000000 6800000 Acquisition<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adamas Acquisition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Adamas Acquisition (see Note 1), the Company paid the Adamas shareholders $400.8 million and transferred two non-tradable contingent value rights (CVRs). Each CVR represents the contractual right to receive a contingent payment of $0.50 per share in cash, less any applicable withholding taxes and without interest, upon the achievement of the applicable milestone (each such amount, a Milestone Payment) in accordance with the terms of a Contingent Value Rights Agreement entered into between the Company and American Stock Transfer &amp; Trust Company, LLC, as rights agent (CVR Agreement). One Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $150 million during any consecutive 12-month period ending on or before December 31, 2024 (Milestone 2024). Another Milestone Payment is payable (subject to certain terms and conditions) upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive 12-month period ending on or before December 31, 2025 (Milestone 2025 and, together with Milestone 2024, the Milestones). Each Milestone may only be achieved once.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the two CVRs, the Company recorded contingent consideration liabilities of $10.3 million as of the date of the acquisition, to reflect the estimated fair value of the contingent consideration. The estimated fair values of the contingent consideration liabilities were determined using Monte Carlo simulations. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs and thus represent Level 3 fair value measurements. The key assumptions considered include the estimated amount and timing of projected revenues, volatility, estimated discount rates and the risk-free interest rate. In each reporting period after the acquisition, the Company will revalue the contingent consideration liabilities and will record increases or decreases in the fair value of the liabilities in its consolidated statements of earnings. Changes in fair value will result from actual milestone achievement, as well as changes to forecasts. The inputs and assumptions may not be observable in the market, but they reflect the assumptions the Company believes would be made by a market participant. The possible outcomes for the contingent consideration range from $0 to $50.9 million on an undiscounted basis.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as a business combination under the acquisition method of accounting, in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill. The estimated fair values of the assets acquired and liabilities assumed, including goodwill, have been included in the Company's consolidated financial statements since the acquisition Closing Date. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to finalize its purchase price allocation within one year of the Closing Date. In addition, the Company continues to analyze and assess relevant information necessary to determine, recognize and record at fair value the assets acquired and liabilities assumed. The activities the Company is currently undertaking include review and evaluation of the tax positions, and other tax-related matters. Accordingly, the preliminary recognition and measurement of assets acquired and liabilities assumed as of the Closing Date are subject to change.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Initially Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,293 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,673 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,733)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,980)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Measurement period adjustments reflect changes for the nine months ended September 30, 2022 based on information related to the facts and circumstances that existed as of the Closing Date. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease recorded in the first quarter of 2022. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents tax impact for the changes in fair value estimate of the right of use asset and changes made to finalize the accounting of certain state tax attributes which existed at the opening balance sheet date.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Inventory</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the inventory was determined using the comparative sales method, which estimated the expected sales price of the product, reduced by all costs expected to be incurred to complete or dispose of the inventory, as well as a profit on the sale.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangible Assets</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired intangible assets include the acquired developed technology and product rights to GOCOVRI and Osmolex ER, as well as the right to receive royalties from Allergan plc for sales of Namzaric. The Company determined the estimated fair values for the acquired intangible assets as of the Closing Date using the income approach. This is a valuation technique that provides an estimate of fair value of the assets, based on the market participant's expectations of the cash flows that the assets are forecasted to generate. The cash flows were discounted at a rate commensurate with the level of risk associated with its projected cash flows. The Company believes the assumptions are representative of those a market participant would use in estimating fair value.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the acquired intangible assets were determined based on significant unobservable inputs and thus represent Level 3 fair value measurement. Some of the more significant inputs and assumptions used in the intangible assets valuation includes: the estimated future cash flows from product sales, the timing and projection of costs and expenses, discount rates and tax rates. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets consist of developed technology and product rights and are amortized over their estimated useful lives on a straight-line basis. The following table summarizes the preliminary purchase price allocation and the average remaining useful lives for identifiable intangible assets (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life as of Closing Date (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 - 8.1</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acquired that could not be individually identified and separately recognized. Goodwill is primarily attributable to the anticipated cost synergies, additional growth platforms, and an expanded revenue base with the addition of the assets from the Adamas Acquisition. The goodwill is not expected to be deductible for tax purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired Deferred Income Tax Liabilities, net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred income tax liabilities, net relates to the difference between the financial statement carrying amount and the tax basis of acquired intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences. The acquired federal and state net operating loss carryforwards are reduced by a valuation allowance for amounts that are not expected to be realizable in the future. The reported measurement period adjustment of $1.8 million for the nine months ended September 30, 2022 consisted of a reduction to deferred tax liabilities of $3.7 million recorded in the first quarter of 2022 and an increase to deferred tax liabilities of $1.9 million recorded in the third quarter of 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Net Earnings of Adamas</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of Adamas and its subsidiaries have been included in the Company's consolidated statements of earnings for the periods subsequent to the Closing Date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.009%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information is based on historical financial information and the Company's preliminary allocation of purchase price; therefore, it is subject to subsequent adjustment upon finalization of the purchase price allocation. In order to reflect the occurrence of the acquisition on January 1, 2020, the unaudited pro forma combined financial information reflects the recognition of additional amortization expense on intangible assets and estimated additional cost of products sold related to the inventory step-up adjustment; the estimated reduction in the Company's interest income generated from marketable securities that were liquidated to fund the purchase price of the Adamas Acquisition, and the estimated tax impact of the pro forma adjustments.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited pro forma combined financial information should not necessarily be considered indicative of the results that would have occurred if the acquisition had been consummated on the assumed completion date, nor are they indicative of future results.</span></div> 400800000 2 0.50 150000000 225000000 2 10300000 0 50900000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company's preliminary estimates of the fair value of assets acquired and liabilities assumed as of the Closing Date and subsequent measurement period adjustments recorded (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Initially Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Measurement Period Adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,064 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,293 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582,673 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,592)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,014)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,224)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212,733)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,753 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,980)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,560 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371,693 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,420 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,806 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase price</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,113 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Measurement period adjustments reflect changes for the nine months ended September 30, 2022 based on information related to the facts and circumstances that existed as of the Closing Date. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refinement of the estimate of fair value of the right of use asset associated with the acquired Adamas headquarters lease recorded in the first quarter of 2022. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents tax impact for the changes in fair value estimate of the right of use asset and changes made to finalize the accounting of certain state tax attributes which existed at the opening balance sheet date.</span></div> 90064000 90064000 11156000 11156000 20200000 20200000 5077000 5077000 1254000 1254000 450100000 450100000 6442000 -1620000 4822000 584293000 -1620000 582673000 4592000 4592000 8014000 8014000 138315000 138315000 5224000 5224000 56588000 -1753000 54835000 212733000 -1753000 210980000 371560000 133000 371693000 39553000 -133000 39420000 411113000 411113000 400806000 400806000 10307000 10307000 411113000 411113000 The following table summarizes the preliminary purchase price allocation and the average remaining useful lives for identifiable intangible assets (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.302%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.913%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Life as of Closing Date (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 - 8.1</span></div></td></tr></table> 450100000 P3Y1M6D P8Y1M6D -1800000 -3700000 1900000 <div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the unaudited pro forma combined financial information for each of the periods presented, as if the Adamas Acquisition had occurred on January 1, 2020 (dollars in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.009%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.011%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma total revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,905)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 174360000 487904000 -10405000 -30905000 Disaggregated Revenues <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,724 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,532 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,647 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,353 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,464 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,910 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes net product sales of MYOBLOC, XADAGO and Osmolex ER. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trokendi XR accounted for more than 40% of the Company’s total net product sales for both the three and nine months ended September 30, 2022, and 56% of the Company's total net product sales for both the three and nine months ended September 30, 2021, respectively. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of our three major customers, AmerisourceBergen Drug Corporation, Cardinal Health, Inc. and McKesson Corporation, individually accounted for more than 25% of our total net product sales for both the nine months ended September 30, 2022 and 2021, and collectively accounted for more than 80% and 85% of our total net product sales for the nine months ended September 30, 2022 and 2021, respectively.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenues include noncash royalty revenues. The Company recognized noncash royalty revenue of $2.5 million and $7.2 million, for the three and nine months ended September 30, 2022, respectively. The Company recognized noncash royalty revenue of $2.4 million and $6.8 million, for the three and nine months ended September 30, 2021, respectively. Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span>. <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the disaggregation of revenues by product or source (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,872 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,724 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,532 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,647 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,353 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,464 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,910 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,725 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div>(1) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER. 69599000 80935000 204033000 231531000 30528000 29728000 88007000 82120000 27878000 0 75179000 0 18326000 2370000 37708000 2685000 18261000 24627000 57156000 73338000 8132000 7872000 23564000 22867000 172724000 145532000 485647000 412541000 4629000 2932000 14263000 8184000 177353000 148464000 499910000 420725000 420725000 0.40 0.56 0.25 0.25 0.25 0.25 0.25 0.25 0.80 0.85 2500000 7200000 2400000 6800000 Investments <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and U.S. government agency and municipal debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,234 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years to 3 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years to 4 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,234 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there was no impairment due to credit loss on any available-for-sale marketable securities. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Navitor</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Development Agreement </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a development agreement (the Development Agreement) with Navitor Pharmaceuticals, Inc. (Navitor Inc.). The Company can terminate the Development Agreement upon 30 days' notice. Under the terms of the Development Agreement, the Company and Navitor Inc. will jointly conduct a Phase II clinical program for NV-5138 (SPN-820) for treatment-resistant depression. The Company will bear all of the Phase I and Phase II development costs incurred by either party, up to a maximum of $50 million. In addition, the Company will incur certain other research and development support costs. There are certain additional payment amounts which could be incurred by the Company. These costs are contingent upon Navitor Inc. achieving defined development milestones. The Company has an option to acquire or license NV-5138 (SPN-820), for which additional payments would be required.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity investment</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to entering into the Development Agreement in April 2020, the Company acquired Series D Preferred Shares of Navitor Inc. for $15 million, representing an approximately 13% ownership position in Navitor Inc. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Navitor Inc. underwent a legal restructuring. In the restructuring, Navitor Inc. became a wholly owned subsidiary of a newly formed limited liability company, Navitor Pharmaceuticals LLC (Navitor LLC), and the outstanding shares of stock in Navitor Inc. were exchanged for units of membership in Navitor LLC having equivalent rights and preferences (Navitor Restructuring). As part of the Navitor Restructuring, the Series D Preferred Shares previously held by the Company were exchanged for Series D Preferred Units in Navitor LLC. In addition, certain assets that did not relate to NV-5138 (SPN-820) were transferred from Navitor Inc. to a newly formed entity that became a separate, wholly owned subsidiary of Navitor LLC.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had determined that Navitor LLC is a VIE. The Company does not consolidate this VIE because the Company lacks the power to direct the activities that most significantly impact Navitor’s economic performance. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Navitor Restructuring, the investment was accounted for under the practical expedient allowed for equity securities without readily determinable fair value, which is cost minus impairment plus any changes in observable price changes from an orderly transaction of similar investments in Navitor Inc. Following the legal restructuring and exchange of the preferred shares for member equity units of Navitor LLC, the investment was accounted for under the equity method of accounting due to the Company's ability to exert significant influence over but not control the financial and operating decisions of Navitor LLC. As a result of the change from a cost method investment to an equity method investment, the Company was required to measure its investment initially in accordance with the guidance in ASC 805. The majority of the assets and liabilities recorded in Navitor LLC's financial statements represent working capital items and cash that are being used for research and development purposes and are significantly lower than the Company's investment in Navitor LLC, which created a significant basis difference for the Company's investment in the underlying net assets. The Company determined that substantially all of the fair value of the investment was attributable to a single in-process research and development (IPR&amp;D) asset. As a result, Navitor LLC was not considered a business as defined in ASC 805. In the first quarter of 2021, the $15 million investment, which was previously recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated balance sheets, was expensed and recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the condensed consolidated statements of earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records its share of the results of Navitor LLC, a private company, on a quarter lag as the financial information of Navitor LLC is not available on a sufficiently timely basis for the Company to apply the equity method of accounting. In December 2021, Navitor LLC sold one of its subsidiaries and distributed cash to its members in accordance with each member's share of the proceeds from the sale. The Company received $12.9 million in December 2021 from Navitor LLC in connection with this sale. As the Company's policy is to record its share of the results in its equity method investment on a quarter lag as previously indicated, the Company recorded the cash amount received in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets as of December 31, 2021. In the first quarter of 2022, the Company determined its estimated share of Navitor LLC's year-end 2021 earnings and recorded a gain of $12.9 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the condensed consolidated statement of earnings. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum exposure to losses related to Navitor LLC is approximately $50 million for Phase I and Phase II development of NV-5138 (SPN-820), and the cost of other development and formulation activities provided by the Company.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Subsequent to the Development Agreement entered into in 2020, no additional equity investment has been made or financing has been provided to Navitor LLC.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrestricted available-for-sale marketable securities held by the Company are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and U.S. government agency and municipal debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,301 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,234 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 417576000 253301000 0 2349000 5342000 238000 412234000 255412000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the unrestricted available-for-sale marketable securities held by the Company are as follows, (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.268%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1 year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year to 2 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,346 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years to 3 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years to 4 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 4 years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,234 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 280297000 104346000 27591000 0 0 412234000 0 P30D 50000000 15000000 0.13 15000000 12900000 12900000 50000000 Fair Value of Financial Instruments<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an asset or liability represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between unrelated market participants.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports the fair value of assets and liabilities using a three level measurement hierarchy that prioritizes the inputs used to measure fair value. The fair value hierarchy consists of the following three levels: </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Valuations based on unadjusted quoted prices in active markets that are accessible at measurement date for identical assets. </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and model-based valuations in which all significant inputs are observable in the market, either directly or indirectly (e.g., interest rates; yield curves). </span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Valuations using significant inputs that are unobservable in the market and inputs that reflect the Company’s own assumptions. These are based on the best information available, including the Company’s own data. </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the restricted marketable securities which are classified as Level 2 financial assets are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated balance sheets. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Recorded at Fair Value on a Recurring Basis</span></div><div style="margin-top:10pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2022 (unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value at September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value at December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other financial instruments, including accounts receivable, accounts payable, and accrued expenses, approximate fair value due to their short-term maturities. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Financial Liabilities Recorded at Carrying Value</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value has been estimated based on actual trading information, and quoted prices, both provided by bond traders. As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further discussion of the accounting standard adoption.</span></div> <div style="margin-top:10pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis are as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2022 (unaudited)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value at September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,937 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524,190 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412,689 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fair Value at December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,863 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities - restricted (SERP)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,692 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,784 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 111087000 111087000 0 0 405000 405000 0 0 280297000 0 280297000 0 131937000 0 131937000 0 464000 9000 455000 0 524190000 111501000 412689000 0 57371000 0 0 57371000 57371000 0 0 57371000 148863000 148863000 0 0 54571000 54571000 0 0 136246000 251000 135995000 0 119166000 0 119166000 0 630000 7000 623000 0 459476000 203692000 255784000 0 80477000 0 0 80477000 80477000 0 0 80477000 The following table sets forth the carrying value and fair value of the Company's financial liabilities that are not carried at fair value (dollars in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value (Level 2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,438 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,236 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 401438000 392438000 379252000 400236000 20600000 Contingent Consideration<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contingent consideration liabilities are related to the USWM Acquisition (as defined below) and the Adamas Acquisition. The contingent consideration liabilities are measured at fair value on a recurring basis using either a Monte Carlo simulation or the income approach. The Company classifies its contingent consideration liabilities as Level 3 fair value measurements based on the significant unobservable inputs used to estimate fair value. These reflect the inputs and assumptions the Company believes would be made by market participants. Changes in any of those inputs together or in isolation may result in significantly lower or higher fair value measurement. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Contingent Consideration</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020 (the USWM Closing Date), the Company completed its acquisition of all the outstanding equity of USWM Enterprises, LLC (USWM Enterprises) (USWM Acquisition). The USWM Acquisition included potential additional contingent consideration payments of up to $230 million comprised of the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory and developmental milestones - gross contingent consideration of up to $130 million contingent upon achievement of regulatory and developmental milestones.</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This includes a $25 million milestone due upon the FDA acceptance of the SPN-830 NDA for review, which was paid in the first quarter of 2022. This milestone payment is reported under both financing and operating activities in the condensed consolidated statements of cash flows. Of the $25 million payment, $22.9 million represents the acquisition date fair value of the contingent consideration liability and was reported under cash flows from financing activities. The remaining $2.1 million represents the excess of the acquisition date fair value and was reported under cash flows from operating activities.</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $105 million is comprised of amounts due upon achievement of certain FDA's regulatory approval and commercial launch of SPN-830. This includes a $50 million milestone which has a time-based mechanism for full or partial payment. As of September 30, 2022, the achievement of this milestone is remote. The remaining $55 million, which does not have a time-based mechanism for payment, relates to the FDA's approval of the SPN-830 NDA and the subsequent commercial product launch. Refer to Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sales-based milestones consist of gross contingent consideration payments of up to $100 million related to future sales performance of the acquired USWM products. Of the $100 million sales-based contingent consideration, a $35 million milestone due upon the achievement of certain U.S. net product sales of APOKYN in 2021 was not achieved. The remaining $65 million relates to the achievement of certain net product sales of the acquired USWM products in 2022 and 2023. As of September 30, 2022, the Company assessed that the remaining sales-based milestones will not be achieved based on net sales projections.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value is reported on the condensed consolidated statement of earnings in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration expense (gain)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The key assumptions considered in estimating the fair value include the estimated probability and timing of milestone achievement, such as the probability and timing of obtaining regulatory approval, discount rate, the estimated revenue volatility and the estimated amount and timing of projected revenues from the acquired USWM products.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a $0.4 million expense and a $2.4 million expense due to the change in fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2022, respectively. The change in the fair value of contingent consideration for USWM milestones was primarily driven by the increase in estimated fair value of regulatory and developmental milestones due to passage of time and the accretion to the payout amount related to the milestone achieved in the first quarter of 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a $0.1 million expense and a $7.7 million gain due to the change in fair value of the contingent consideration liabilities for the USWM milestones for the three and nine months ended September 30, 2021, respectively. In the second quarter of 2021, the Company recorded a change in fair value of $7.7 million, which was primarily due to the write-down of the sales-based contingent consideration. The Company assessed that the sales-based milestones will not be achieved based on the revised net sales projections.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adamas Contingent Consideration</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Adamas Acquisition included payment of two non-tradable contingent value rights (CVRs) each of which represents the contractual right to receive a contingent payment upon the achievement of the applicable aggregate worldwide net product sales of GOCOVRI. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the measurement period, changes in the fair value of contingent consideration related to the Adamas Acquisition are recorded against goodwill if such changes are related to facts and circumstances that existed at the acquisition date. In each reporting period after the acquisition, the Company remeasures the fair value of contingent consideration liabilities and records in its consolidated statements of earnings the increases or decreases in the fair value of the liabilities. The Company recorded a $0.1 million expense and a $0.5 million gain due to the change in fair value of the contingent consideration liabilities for the three and nine months ended September 30, 2022, respectively. The change in fair value was reported on the condensed consolidated statement of earnings in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent consideration expense (gain)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in estimated fair value of contingent consideration for the sales-based Adamas milestones was primarily due to changes in market data and the passage of time. The key assumptions considered in estimating the fair value of the Adamas sales-based milestones include the estimated amount and timing of projected revenues, volatility, estimated discount rates and risk-free interest rate. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of significant inputs and assumptions used in the valuation of the contingent consideration for the Adamas Acquisition.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and developmental contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported under the following captions in the condensed consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 230000000 130000000 25000000 25000000 22900000 2100000 105000000 50000000 55000000 100000000 100000000 35000000 65000000 400000 -2400000 -100000 -7700000 -7700000 2 -100000 500000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the beginning and ending balances related to the contingent consideration liabilities for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.647%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USWM Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adamas Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recognized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,894 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and developmental contingent consideration liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales-based contingent consideration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2022 (unaudited)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides the current and long-term portions related to the contingent consideration for the USWM Acquisition and Adamas Acquisition (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported under the following captions in the condensed consolidated balance sheets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 70170000 10307000 80477000 25000000 0 25000000 2420000 -526000 1894000 47590000 9781000 57371000 47590000 0 47590000 0 9781000 9781000 47590000 9781000 57371000 47590000 44840000 9781000 35637000 57371000 80477000 Goodwill and Intangible Assets, Net<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments related to the acquisition of Adamas (see Note 3)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022 (unaudited)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets and goodwill (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Weighted<br/>Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent defense costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,159)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,227)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent defense costs are deferred legal fees incurred in conjunction with defending patents for Oxtellar XR and Trokendi XR. U.S. patents covering Oxtellar XR and Trokendi XR will expire no earlier than 2027. In regards to Trokendi XR, the Company entered into settlement agreements that allow third parties to enter the market by January 1, 2023, or earlier under certain circumstances. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was approximately $20.6 million and $61.9 million for the three and nine months ended September 30, 2022, respectively, and approximately $6.0 million and $18.0 million for the three and nine months ended September 30, 2021, respectively. The increase in expense is primarily due to amortization of the acquired developed technology and product rights from the Adamas Acquisition. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anticipated annual amortization expense for intangible assets is estimated at $79.8 million each in both 2023 and 2024, $75.1 million in 2025, $74.9 million in 2026, and $73.2 million in 2027.</span></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,516 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Measurement period adjustments related to the acquisition of Adamas (see Note 3)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022 (unaudited)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 117516000 -133000 117383000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the gross carrying amounts and related accumulated amortization of intangibles assets and goodwill (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.823%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Weighted<br/>Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Gross</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount, Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets subject to amortization:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired developed technology and product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">645,550 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized patent defense costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,677)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,159)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,761 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848,920 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,227)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784,693 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 124000000 124000000 124000000 124000000 P8Y7D 681100000 93642000 587458000 681100000 35550000 645550000 P4Y2M26D 43820000 32517000 11303000 43820000 28677000 15143000 P7Y11M12D 848920000 126159000 722761000 848920000 64227000 784693000 20600000 61900000 6000000 18000000 79800000 79800000 75100000 74900000 73200000 Convertible Senior Notes Due 2023<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 0.625% Convertible Senior Notes Due 2023 (2023 Notes), which were issued in March 2018, bear interest at an annual rate of 0.625%, payable semi-annually in arrears on April 1 and October 1 of each year. The 2023 Notes will mature on April 1, 2023, unless earlier converted or repurchased by the Company. The Company may not redeem the 2023 Notes at its option before maturity. The total principal amount of 2023 Notes is $402.5 million. We have reclassified the debt from long-term to current liabilities on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as the debt matures in less than twelve months as of September 30, 2022. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes were issued pursuant to an Indenture between the Company and Wilmington Trust, National Association, as trustee. The Indenture includes customary terms and covenants, including certain events of default upon which the 2023 Notes may be due and payable immediately. The Indenture does not contain any financial or operating covenants, or any restrictions on the payment of dividends, the issuance of other indebtedness, or the issuance or repurchase of securities by the Company.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noteholders may convert their 2023 Notes at their option only in the following circumstances: (1) during any calendar </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter, if the last reported sale price per share of the Company's common stock for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including the last trading day of the immediately preceding calendar quarter, exceeds 130% of the conversion price, or a price of approximately $77.13 per share on such trading day; (2) during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company's common stock on such trading day and the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on the Company's common stock, as specified in the Indenture; and (4) at any time from and including October 1, 2022, until the close of business on the second scheduled trading day immediately before the maturity date. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At its election, the Company will settle conversions by paying or delivering, as applicable, cash, shares of the Company’s common stock, or a combination of cash and shares of the Company’s common stock, based on the applicable conversion rate. The initial conversion rate is 16.8545 shares per $1,000 principal amount of the 2023 Notes, which represents an initial conversion price of approximately $59.33 per share and is subject to adjustment as specified in the Indenture. In the event of conversion, if converted in cash, the holders would forgo all future interest payments, any unpaid accrued interest, and the possibility of further stock price appreciation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a “make-whole fundamental change,” as defined in the Indenture occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. If a “fundamental change,” as defined in the Indenture occurs, then noteholders may require the Company to repurchase their 2023 Notes at a cash repurchase price equal to the principal amount of the 2023 Notes to be repurchased, plus accrued and unpaid interest, if any.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneous with the issuance of the 2023 Notes, the Company also entered into separate privately negotiated convertible note hedge transactions (collectively, the Convertible Note Hedge Transactions) with each of the call spread counterparties. The Company issued 402,500 convertible note hedge options. In the event that shares or cash are deliverable to holders of the 2023 Notes upon conversion at limits defined in the Indenture, counterparties to the convertible note hedges will be required to deliver up to approximately 6.8 million shares of the Company’s common stock, or to pay cash to the Company in a similar amount as the value that the Company delivers to the holders of the 2023 Notes, based on a conversion price of $59.33 per share.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with entering into the Convertible Note Hedge Transactions, the Company also entered into separate privately negotiated warrant transactions (collectively, the Warrant Transactions) with each of the call spread counterparties. The Company issued a total of 6,783,939 warrants. The warrants entitle the holder to one share per warrant. The strike price of the Warrant Transactions will initially be $80.91 per share of the Company’s common stock, and is subject to adjustment.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Note Hedge Transactions are expected to reduce the potential dilution of the Company’s common stock upon conversion of the 2023 Notes, and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2023 Notes, as the case may be. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant Transactions were intended to partially offset the cost to the Company of the purchased Convertible Note Hedge Transactions; however, the Warrant Transactions could have a dilutive effect with respect to the Company’s common stock, to the extent that the market price per share of the Company’s common stock, as measured under the terms of the Warrant Transactions, exceeds the strike price of the warrants.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability component of the 2023 Notes consists of the following (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,438 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, the Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition resulting in an increase in the carrying amount of the debt by $20.6 million as of the adoption date. Refer to Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the accounting standard adoption. No 2023 Notes were converted as of September 30, 2022 or December 31, 2021.</span></div> 0.00625 0.00625 402500000 20 30 1.30 77.13 5 10 10 0.98 59.33 402500 6800000 59.33 6783939 1 80.91 <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liability component of the 2023 Notes consists of the following (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total carrying value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,438 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 402500000 402500000 1062000 23248000 401438000 379252000 20600000 0 0 Share-Based Payments<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,027 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,307 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,874 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option and Stock Appreciation Rights </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option and stock appreciation rights (SAR) activities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options &amp; SARs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>(per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,002,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2022 (unaudited):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,002,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit (RSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September 30, 2022 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,460 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no forfeited RSU awards during the nine months ended September 30, 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Share Units </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit (PSU) activities:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total PSUs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,250)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,250)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,375</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is as follows (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,985 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,027 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,307 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,874 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 825000 615000 2284000 1909000 4160000 3412000 11023000 11965000 4985000 4027000 13307000 13874000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option and stock appreciation rights (SAR) activities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Options &amp; SARs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price<br/>(per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2022 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,002,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774,076 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651,824 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2022 (unaudited):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,002,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83</span></td></tr></table> 5774076 24.15 P5Y11M12D 1046785 31.95 673120 12.79 145473 30.06 6002268 26.64 P6Y3M14D 5774076 24.15 P5Y11M12D 3651824 21.29 P4Y6M10D 6002268 26.64 P6Y3M14D 3682170 24.61 P4Y9M29D <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restricted stock unit (RSU) activities:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September 30, 2022 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,460 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no forfeited RSU awards during the nine months ended September 30, 2022.</span></div> 21110 29.61 134460 32.17 21110 29.61 134460 32.17 0 <div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes performance share unit (PSU) activities:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market-Based Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total PSUs </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of PSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.43 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,250)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,250)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.08 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,375</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 53500 29.82 35625 26.34 89125 28.43 155000 28.93 0 0 155000 28.93 22250 29.69 0 0 22250 29.69 1500 30.45 0 0 1500 30.45 184750 29.08 35625 26.34 220375 28.64 Earnings per Share<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, whereas the Company previously calculated diluted earnings per share under the treasury stock method. Basic earnings per share (EPS) is calculated using the weighted average number of common shares outstanding. Diluted EPS is calculated using the weighted average number of common shares outstanding, including the dilutive effect of the Company’s stock option grants, SARs, RSUs, employee stock purchase plan (ESPP) awards, and the 2023 Notes, as determined per the if-converted method for the three and nine months ended September 30, 2022 in connection with the adoption of ASU 2020-06 and the treasury stock method for the three and nine months ended September 30, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of Convertible Notes and Related Convertible Note Hedges and Warrants </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, the Company entered into Convertible Note Hedge and Warrant Transactions as described further in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes Due 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The expected collective impact of the Convertible Note Hedge and Warrant Transactions is to reduce the potential dilution that would occur if the price of the Company's common stock was between the conversion price of $59.33 per share and the strike price of the warrants of $80.91 per share.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted EPS related to the 2023 Notes in the current year is calculated using the if-converted method. The number of dilutive shares is based on the initial conversion rate associated with the 2023 Notes. The Convertible Note Hedge and Warrant Transactions are excluded in the calculation of diluted EPS because inclusion would be anti-dilutive. Specifically, the denominator of the diluted EPS calculation excludes the additional shares related to the warrants because the average price of the Company's common stock was less than the strike price of the warrants of $80.91 per share. Prior to actual conversion, the Convertible Note Hedge Transactions are not considered in calculating diluted earnings per share, as their impact would be anti-dilutive. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards and shares associated with the conversion of the 2023 Notes in the calculation of diluted EPS, because their inclusion would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs, PSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,904 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,816 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,822 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397,424 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As mentioned in Note 2, as a result of the adoption of ASU 2020-06 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are not included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended September 30, 2022 because their inclusion would be anti-dilutive. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net earnings per share for the three and nine months ended September 30, 2022 under the if-converted method and for the three and nine months ended September 30, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax interest expense for 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for dilutive earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,562 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,894 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,982 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,789,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,187,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,517,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,053,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and SARs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,034,838 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,334,794 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,543,121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,301,461 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 59.33 80.91 80.91 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above described effect of the 2023 Notes and the related Convertible Note Hedge and Warrant Transactions, the Company also excluded the common stock equivalents of the following outstanding stock-based awards and shares associated with the conversion of the 2023 Notes in the calculation of diluted EPS, because their inclusion would be anti-dilutive: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs, PSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792,904 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,816 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470,822 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397,424 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>As mentioned in Note 2, as a result of the adoption of ASU 2020-06 on January 1, 2022 the Company calculated diluted earnings per share using the if-converted method. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are not included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the three months ended September 30, 2022 because their inclusion would be anti-dilutive. The 6.8 million in dilutive shares associated with the conversion of the 2023 Notes are included in diluted weighted average shares of common stock outstanding for the purposes of calculating diluted earnings per share for the nine months ended September 30, 2022. For the three and nine months ended September 30, 2021, the Company calculated diluted earnings per share using the treasury stock method wherein the shares associated with the conversion of the 2023 Notes were excluded as the Company assumed the 2023 Notes would be settled entirely or partly in cash. 6783936 0 0 0 792904 1654816 470822 1397424 6800000 6800000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth the computation of basic and diluted net earnings per share for the three and nine months ended September 30, 2022 under the if-converted method and for the three and nine months ended September 30, 2021 under the treasury stock method (dollars in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax interest expense for 2023 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator for dilutive earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,562 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,894 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,982 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,789,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,187,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,517,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,053,441 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options, RSUs and SARs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,241,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,020 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,783,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,034,838 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,334,794 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,543,121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,301,461 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1749000 21562000 35230000 50982000 0 0 2664000 0 1749000 21562000 37894000 50982000 53789674 53187764 53517838 53053441 1245164 1147030 1241347 1248020 0 0 6783936 0 55034838 54334794 61543121 54301461 0.03 0.41 0.66 0.96 0.03 0.40 0.62 0.94 Income Tax (Benefit) Expense<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the Company’s income tax (benefit) expense for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in income tax expense for the three months ended September 30, 2022 compared to the same period in prior year was primarily due to lower earnings before income taxes. The change in effective tax rate for the three months ended September 30, 2022 compared to the same period in prior year was primarily due to larger excess tax benefits of stock-based awards in 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in income tax (benefit) expense and effective tax rate for the nine months ended September 30, 2022 compared to the same period in the prior year was primarily due to tax benefits associated with the Adamas legal entities reorganization in the first quarter of 2022.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding the Company’s income tax (benefit) expense for the three and nine months ended September 30, 2022 and 2021 (dollars in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table> -2193000 7398000 -9627000 20142000 4.939 0.255 -0.376 0.283 Leases<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Office Space and Fleet Vehicle Leases</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its headquarters lease, certain other office space, and its fleet vehicles. With respect to the fleet vehicle leases, given the volume of individual leases involved in the overall arrangement, the Company applies a portfolio approach to effectively account for the operating lease assets and liabilities. The Company also elected to combine the lease and non-lease components for the fleet vehicles and headquarters leases. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's headquarters lease commenced on February 1, 2019 (the Commencement Date) and will continue until April 30, 2034, unless earlier terminated in accordance with the terms of the lease. The lease includes options to extend the lease for up to 10 years. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Adamas Acquisition, the Company acquired a lease for office space. Adamas' operating lease for the office space term will continue until April 30, 2025. The lease contains an option to extend the term for one additional five-year period. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During a measurement period, changes in fair value due to measurement period adjustments are recorded against goodwill. The Company recorded in the first quarter of 2022 a measurement period adjustment associated with the valuation of the acquired Adamas lease which decreased the fair value estimate of the operating lease right of use asset by $1.6 million. Refer to Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Lease </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a contract manufacturing agreement with Merz Pharma GmbH &amp; Co. KGaA (Merz), for the manufacture and supply of rimabotulinumtoxinB finished products (Merz Agreement). The Merz Agreement will expire in July 2027 unless the Company and Merz mutually agree to extend the terms. The Merz Agreement may not be terminated for convenience.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is required to purchase a minimum quantity of MYOBLOC finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated manufacturing facility which the Company accounts for as an embedded lease. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made an accounting policy election, by class of underlying asset, to not combine lease and non-lease components for the manufacturing facility. A portion of the in-substance fixed contract consideration was allocated to the lease component based on the stand-alone selling price. Accordingly, the Company classifies and accounts for the embedded lease as an operating lease.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMy0xLTEtMS0xMDQ3NTg_14960eb4-031e-4473-8dac-6c9c082095ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMy0xLTEtMS0xMDQ3NTg_e6bc3657-30a8-42ee-ac2e-ed4c3b0d04ad">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,663 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfOC0xLTEtMS0xMDQ3NTg_2843e78d-ef4c-4d6c-9c5d-6a9f559a518b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfOC0xLTEtMS0xMDQ3NTg_44b3375a-a9cc-460c-841a-fe98a7bfd5b4">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMTAtMS0xLTEtMTA0NzU4_3540b484-4054-4a8e-8a47-763ac8ddc6bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMTAtMS0xLTEtMTA0NzU4_b21bad92-f29e-4c89-b4c9-ed876b6102ce">Operating lease liabilities, long-term</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,785 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P10Y 1 P5Y 1600000 <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.641%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMy0xLTEtMS0xMDQ3NTg_14960eb4-031e-4473-8dac-6c9c082095ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMy0xLTEtMS0xMDQ3NTg_e6bc3657-30a8-42ee-ac2e-ed4c3b0d04ad">Other assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,663 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,365 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfOC0xLTEtMS0xMDQ3NTg_2843e78d-ef4c-4d6c-9c5d-6a9f559a518b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfOC0xLTEtMS0xMDQ3NTg_44b3375a-a9cc-460c-841a-fe98a7bfd5b4">Accounts payable and accrued liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMTAtMS0xLTEtMTA0NzU4_3540b484-4054-4a8e-8a47-763ac8ddc6bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUwMDBhYzdmNGViMjQwZjg4ZDQ1MTdkOTMyNDI0MjRhL3NlYzplMDAwYWM3ZjRlYjI0MGY4OGQ0NTE3ZDkzMjQyNDI0YV83My9mcmFnOmVhYzc4ZDQxYjNiYjQ5MjJiZjhiNmM3YTk4NjgzMDRlL3RhYmxlOjM4MTUzODM2NDA2OTRkYTNiNDUxYjFmYzY4Y2YzMDhmL3RhYmxlcmFuZ2U6MzgxNTM4MzY0MDY5NGRhM2I0NTFiMWZjNjhjZjMwOGZfMTAtMS0xLTEtMTA0NzU4_b21bad92-f29e-4c89-b4c9-ed876b6102ce">Operating lease liabilities, long-term</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,028 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,785 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,775 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 29663000 35365000 29663000 35365000 6757000 6477000 36028000 41298000 42785000 47775000 Composition of Other Balance Sheet ItemsThe following details the composition of other balance sheet items (dollars in thousands for amounts in tables):<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivables, Net </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the Company has recorded allowances reducing accounts receivable by approximately $12.8 million and $13.5 million, respectively. These allowances represent prompt pay discounts and contractual service fees, which were originally recorded as a reduction to revenues, representing estimated amounts not expected to be paid by our customers. The Company's customers are primarily pharmaceutical wholesalers and distributors and specialty pharmacies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,165 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories as of September 30, 2022 include acquired inventory from the Adamas Acquisition. Refer to Note 3,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the acquisition.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:3pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment and furniture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,872 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense on property and equipment was approximately $0.8 million and $2.2 million for the three and nine months ended September 30, 2022, respectively, and approximately $0.6 million and $1.9 million for the three and nine months ended September 30, 2021, respectively. The Company retired certain fully depreciated property and equipment in the nine months ended September 30, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional &amp; marketing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes preclinical and all clinical trial-related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Product Returns and Rebates</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,470 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,724 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrecourse liability related to sale of future royalties, long-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12800000 13500000 <div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventories, Net </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,012 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,692 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,165 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,959 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11012000 7325000 25461000 45711000 46692000 32923000 83165000 85959000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net </span></div><div style="margin-bottom:3pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment and furniture</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,409 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,872 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,955 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12207000 12287000 14023000 14369000 1007000 4776000 1282000 1944000 291000 33000 28810000 33409000 12938000 16454000 15872000 16955000 800000 2200000 600000 1900000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Payable and Accrued Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,015 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional &amp; marketing fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,302 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes preclinical and all clinical trial-related costs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> 16015000 9331000 31269000 26728000 16748000 28068000 11129000 18460000 11671000 13821000 6823000 9125000 6757000 6477000 9890000 5673000 110302000 117683000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Product Returns and Rebates</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product rebates</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,470 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,724 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 119162000 97597000 39308000 35127000 158470000 132724000 <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Liabilities</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.270%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonrecourse liability related to sale of future royalties, long-term</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,371 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,380 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 5977000 10371000 10403000 10371000 16380000 Interest Expense <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of interest expense (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,488)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on nonrecourse liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,724)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,925)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,476)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,489)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, interest expense includes noncash interest expense related to amortization of deferred financing costs of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.5 million and $1.6 million. For the three and nine months ended September 30, 2021, interest expense includes noncash interest expense related to amortization of deferred financing costs and amortization of the debt discount on the 2023 Notes of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.4 million and $13.0 million. As discussed in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company adopted ASU 2020-06 on January 1, 2022. As a result, interest expense for the three and nine months ended September 30, 2022 significantly decreased compared to the three and nine months ended September 30, 2021 due to the Company no longer recording interest expense on the previously recorded discount for the embedded conversion feature on the 2023 Notes.</span></div> <div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details the composition of interest expense (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,033)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,488)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on nonrecourse liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,724)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,925)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,476)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,489)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1158000 5033000 3488000 14593000 566000 892000 1988000 2896000 1724000 5925000 5476000 17489000 500000 1600000 4400000 13000000 Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Licenses</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has obtained exclusive licenses from third parties for proprietary rights to support the product candidates in the Company's CNS portfolio. Under these license agreements, the Company may be required to pay certain amounts upon the achievement of defined milestones. If these products are ultimately commercialized, the Company is also obligated to pay royalties to third parties, computed as a percentage of net product sales, for each respective product under a license agreement.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Through the USWM Acquisition, the Company acquired licensing agreements with other pharmaceutical companies for APOKYN, XADAGO, and MYOBLOC. The Company is obligated to pay royalties to third parties, computed as a percentage of net product sales, for each of the products under the respective license agreements. The royalty expense incurred for these acquired products is recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the condensed consolidated statements of earnings. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Agreement</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2014, the Company received $30 million pursuant to a Royalty Interest Acquisition Agreement related to the purchase by HC Royalty of certain of the Company's rights under the Company's agreement with United Therapeutics related to the commercialization of Orenitram (treprostinil) Extended-Release Tablets. Full ownership of the royalty rights will revert to the Company if and when a certain cumulative payment threshold is reached (see Note 4, Note 14, and Note 15).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">USWM Enterprises Commitments Assumed</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the USWM Acquisition, the Company assumed the remaining commitments of USWM Enterprises and its subsidiaries, which are discussed below. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assumed the annual minimum purchase requirement of MYOBLOC, amounting to an estimated €3.9 million annually, under the contract manufacturing agreement with Merz for manufacture and supply. Refer to Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion related to the Merz Agreement in connection with the MYOBLOC annual minimum purchase requirement. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, USWM Enterprises had an existing license and distribution agreement for XADAGO. This included an annual minimum promotional spend to support the marketing of XADAGO for the first five years of the agreement which will end in 2022. As of September 30, 2022, there is no remaining contractual commitment. </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, MDD US Operations, LLC (formerly US WorldMeds, LLC) and its subsidiary, Solstice Neurosciences, LLC (US) (collectively, the MDD Subsidiaries) entered into a Corporate Integrity Agreement (CIA) with the Office of Inspector </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General of the U.S. Department of Health and Human Services. Under the CIA, the MDD Subsidiaries agreed to and paid $17.5 million to resolve U.S. Department of Justice allegations that it violated the False Claims Act and committed to the establishment and ongoing maintenance of an effective compliance program. The fine was paid by the MDD Subsidiaries prior to closing of the USWM Acquisition. As part of the USWM Acquisition, the Company assumed the obligations of the CIA and could become liable for payment of certain stipulated monetary penalties in the event of any CIA violations. In addition, the Company will continue to maintain a broad array of processes, policies and procedures necessary to comply with the CIA through March 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data Breach-related Contingency</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 24, 2021, the Company announced that it was the target of a ransomware attack. The attack had no significant impact on our business and did not cause any long-term disruption to our operations. Based on its internal investigation, the Company believes the criminal ransomware groups ("criminal groups") copied certain data from the Company's systems, encrypted certain data on the Company's systems, and then deployed malware designed to impede access to the Company's systems. Thereafter the criminal groups contacted the Company and threatened to publish certain data copied from the Company's systems. Upon detection of the ransomware attack, the Company notified government authorities, engaged third-party cybersecurity experts through our outside counsel, and commenced its recovery process. The Company maintains redundant off-site data backups, which were verified to have not been compromised by the ransomware attack and were utilized to restore the data encrypted by the criminal groups. In the fourth quarter of 2021, the Company had successfully recovered the impacted files and took additional steps designed to further protect its networks and files.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, while the Company has not been the subject of any legal proceedings involving the attack, the likelihood that the Company could be the subject of claims from persons alleging they suffered damages from the incident or actions by governmental authorities is possible, but the amount of such fines, penalties or costs, if any, cannot be estimated at this time. The Company continues to monitor the situation. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Claims and Litigation</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in various claims, litigation and legal proceedings. These matters may involve patent litigation, product liability and other product-related litigation, commercial and other matters, and government investigations, among others. On a quarterly basis, the Company reviews the status of each significant matter and assesses its potential financial exposure. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated, the Company will accrue a liability for the estimated loss. Because of uncertainties related to claims, legal proceedings and litigation, accruals will be based on the Company's best estimates based on available information. The Company does not believe that any of these matters will have a material adverse effect on our financial position. The Company may reassess the potential liability related to these matters and may revise these estimates. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters will adversely affect the Company, its results of operations, financial condition and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NAMENDA XR/Namzaric Qui Tam Litigation </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Adamas was served with a complaint filed in the United States District Court for the Northern District of California (the District Court) (Case No. 3:18-cv-03018-JCS) against it and several Allergan entities alleging violations of federal and state false claims acts (FCA) in connection with the commercialization of NAMENDA XR and Namzaric by Allergan. The lawsuit is a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint brought by an individual, asserting rights of the federal government and various state governments. The lawsuit was originally filed in May 2018 under seal, and Adamas became aware of the lawsuit when it was served. The complaint alleges that patents held by Allergan and Adamas covering NAMENDA XR and Namzaric were procured through fraud on the United States Patent and Trademark Office and that these patents were asserted against potential generic manufacturers of NAMENDA XR and Namzaric to prevent the generic manufacturers from entering the market, thereby wrongfully excluding generic competition resulting in artificially high price being charged to government payors. Adamas' patents in question were licensed exclusively to Forest Laboratories Holdings Limited. The complaint includes a claim for damages of "potentially more than $2.5 billion dollars," treble damages and statutory penalties. To date the federal and state governments have declined to intervene in this action. This case is currently stayed pending Adamas's and Allergan's interlocutory appeal of the District Court's December 11, 2020 order denying Adamas's and Allergan's motion to dismiss the complaint. The appeal is pending in the United States Court of Appeals for the Ninth Circuit (Case No. 21-80005). Argument was held on January 10, 2022. On August 25, 2022, the Ninth Circuit sided with the defendants by reversing the District Court’s public disclosure bar rulings and remanding the case back to the District Court to decide certain issues in the first instance. On October 11, 2022, the plaintiff filed a petition for rehearing with the Ninth Circuit. The petition remains pending. No decision has been reached as of the date of this filing. The Company intends to defend itself vigorously. However, the Company can offer no assurances that it will be successful in a litigation.</span></div> 30000000 3900000 P5Y 0 17500000 2500000000 Subsequent Events<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPN-830 Regulatory Development</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we resubmitted the NDA for SPN-830 to the FDA. In February 2022, we received a notice from the FDA that the resubmission of the NDA for SPN-830 is considered as a Standard Review, thereby was assigned a PDUFA target action date in early October 2022. In October 2022, the FDA issued a CRL regarding the NDA for SPN-830. The CRL requires additional information and analysis related to the infusion device and drug product across several areas of the NDA including, but not limited to, labeling, product quality and manufacturing, device performance and risk analysis. In addition, the FDA mentions that approval of the NDA requires inspections that could not be completed in a timely manner due to COVID-19 travel restrictions. The CRL does not request additional efficacy and safety clinical studies. The FDA has made an initial determination that the amendment to the Company’s application in response to the CRL will be subject to a Class 2, or six-month, review timeline.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of analyzing the CRL and determining next steps for the resubmission of the NDA. While it is too early to ascertain the full impact to our financial statements, we anticipate that we may identify indicators of impairment for the IPR&amp;D asset that represents an estimate of the fair value of SPN-830, the product candidate, that could result from the non-approval of the NDA. The potential adjustment to the IPR&amp;D asset that may be necessary as a result of any required interim impairment analysis may be material. Additionally, the Company also expects to assess adjustments to the fair value of the contingent consideration arrangements which includes milestones payments due upon achievement of certain FDA's regulatory approval and commercial launch of SPN-830. While we are unable to estimate the anticipated financial impact at this time, we expect potential adjustments, which may be material, will be recognized and reported within the fourth quarter of 2022. These adjustments could impact the Company’s future results of operations and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:102%">APOKYN Litigation </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     On October 3, 2022, Sage Chemical, Inc. and TruPharma, LLC filed a lawsuit in the United States District Court for the District of Delaware (Case No. 22-cv-1302) alleging that Supernus Pharmaceuticals, Inc., Britannia Pharmaceuticals Limited, and US WorldMeds Partners, LLC violated state and federal antitrust law in connection with APOKYN. The Company is currently reviewing the details of the complaint and will respond as appropriate.</span></div> Excludes amortization of acquired intangible assets EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 274 330 1 true 71 0 false 11 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.supernus.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.supernus.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Earnings Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings Condensed Consolidated Statements of Earnings Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings Condensed Consolidated Statements of Comprehensive Earnings Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity Condensed Consolidated Statements of Changes in Stockholder's Equity Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 0000008 - Disclosure - Business Organization Sheet http://www.supernus.com/role/BusinessOrganization Business Organization Notes 8 false false R9.htm 0000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Acquisition Sheet http://www.supernus.com/role/Acquisition Acquisition Notes 10 false false R11.htm 0000011 - Disclosure - Disaggregated Revenues Sheet http://www.supernus.com/role/DisaggregatedRevenues Disaggregated Revenues Notes 11 false false R12.htm 0000012 - Disclosure - Investments Sheet http://www.supernus.com/role/Investments Investments Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value of Financial Instruments Sheet http://www.supernus.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Contingent Consideration Sheet http://www.supernus.com/role/ContingentConsideration Contingent Consideration Notes 14 false false R15.htm 0000015 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNet Goodwill and Intangible Assets, Net Notes 15 false false R16.htm 0000016 - Disclosure - Convertible Senior Notes Due 2023 Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023 Convertible Senior Notes Due 2023 Notes 16 false false R17.htm 0000017 - Disclosure - Share-Based Payments Sheet http://www.supernus.com/role/ShareBasedPayments Share-Based Payments Notes 17 false false R18.htm 0000018 - Disclosure - Earnings per Share Sheet http://www.supernus.com/role/EarningsperShare Earnings per Share Notes 18 false false R19.htm 0000019 - Disclosure - Income Tax (Benefit) Expense Sheet http://www.supernus.com/role/IncomeTaxBenefitExpense Income Tax (Benefit) Expense Notes 19 false false R20.htm 0000020 - Disclosure - Leases Sheet http://www.supernus.com/role/Leases Leases Notes 20 false false R21.htm 0000021 - Disclosure - Composition of Other Balance Sheet Items Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItems Composition of Other Balance Sheet Items Notes 21 false false R22.htm 0000022 - Disclosure - Interest Expense Sheet http://www.supernus.com/role/InterestExpense Interest Expense Notes 22 false false R23.htm 0000023 - Disclosure - Commitments and Contingencies Sheet http://www.supernus.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 0000024 - Disclosure - Subsequent Events Sheet http://www.supernus.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 0000025 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.supernus.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 0000026 - Disclosure - Acquisition (Tables) Sheet http://www.supernus.com/role/AcquisitionTables Acquisition (Tables) Tables http://www.supernus.com/role/Acquisition 26 false false R27.htm 0000027 - Disclosure - Disaggregated Revenues (Tables) Sheet http://www.supernus.com/role/DisaggregatedRevenuesTables Disaggregated Revenues (Tables) Tables http://www.supernus.com/role/DisaggregatedRevenues 27 false false R28.htm 0000028 - Disclosure - Investments (Tables) Sheet http://www.supernus.com/role/InvestmentsTables Investments (Tables) Tables http://www.supernus.com/role/Investments 28 false false R29.htm 0000029 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.supernus.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.supernus.com/role/FairValueofFinancialInstruments 29 false false R30.htm 0000030 - Disclosure - Contingent Consideration (Tables) Sheet http://www.supernus.com/role/ContingentConsiderationTables Contingent Consideration (Tables) Tables http://www.supernus.com/role/ContingentConsideration 30 false false R31.htm 0000031 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) Tables http://www.supernus.com/role/GoodwillandIntangibleAssetsNet 31 false false R32.htm 0000032 - Disclosure - Convertible Senior Notes Due 2023 (Tables) Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Tables Convertible Senior Notes Due 2023 (Tables) Tables http://www.supernus.com/role/ConvertibleSeniorNotesDue2023 32 false false R33.htm 0000033 - Disclosure - Share-Based Payments (Tables) Sheet http://www.supernus.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) Tables http://www.supernus.com/role/ShareBasedPayments 33 false false R34.htm 0000034 - Disclosure - Earnings per Share (Tables) Sheet http://www.supernus.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.supernus.com/role/EarningsperShare 34 false false R35.htm 0000035 - Disclosure - Income Tax (Benefit) Expense (Tables) Sheet http://www.supernus.com/role/IncomeTaxBenefitExpenseTables Income Tax (Benefit) Expense (Tables) Tables http://www.supernus.com/role/IncomeTaxBenefitExpense 35 false false R36.htm 0000036 - Disclosure - Leases (Tables) Sheet http://www.supernus.com/role/LeasesTables Leases (Tables) Tables http://www.supernus.com/role/Leases 36 false false R37.htm 0000037 - Disclosure - Composition of Other Balance Sheet Items (Tables) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables Composition of Other Balance Sheet Items (Tables) Tables http://www.supernus.com/role/CompositionofOtherBalanceSheetItems 37 false false R38.htm 0000038 - Disclosure - Interest Expense (Tables) Sheet http://www.supernus.com/role/InterestExpenseTables Interest Expense (Tables) Tables http://www.supernus.com/role/InterestExpense 38 false false R39.htm 0000039 - Disclosure - Business Organization (Details) Sheet http://www.supernus.com/role/BusinessOrganizationDetails Business Organization (Details) Details http://www.supernus.com/role/BusinessOrganization 39 false false R40.htm 0000040 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails Summary of Significant Accounting Policies - Basis of Presentation (Details) Details 40 false false R41.htm 0000041 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails Summary of Significant Accounting Policies - Advertising Expense (Details) Details 41 false false R42.htm 0000042 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) Sheet http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details) Details 42 false false R43.htm 0000043 - Disclosure - Acquisition - Narrative (Details) Sheet http://www.supernus.com/role/AcquisitionNarrativeDetails Acquisition - Narrative (Details) Details 43 false false R44.htm 0000044 - Disclosure - Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) Sheet http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) Details 44 false false R45.htm 0000045 - Disclosure - Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) Sheet http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details) Details 45 false false R46.htm 0000046 - Disclosure - Acquisition - Pro Forma Information (Details) Sheet http://www.supernus.com/role/AcquisitionProFormaInformationDetails Acquisition - Pro Forma Information (Details) Details 46 false false R47.htm 0000047 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details) Sheet http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails Disaggregated Revenues - Summary of Revenues (Details) Details 47 false false R48.htm 0000048 - Disclosure - Disaggregated Revenues - Narrative (Details) Sheet http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails Disaggregated Revenues - Narrative (Details) Details 48 false false R49.htm 0000049 - Disclosure - Investments - Unrestricted Marketable Securities (Details) Sheet http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails Investments - Unrestricted Marketable Securities (Details) Details 49 false false R50.htm 0000050 - Disclosure - Investments - Contractual Maturities (Details) Sheet http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails Investments - Contractual Maturities (Details) Details 50 false false R51.htm 0000051 - Disclosure - Investments - Narrative (Details) Sheet http://www.supernus.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 51 false false R52.htm 0000052 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 52 false false R53.htm 0000053 - Disclosure - Fair Value of Financial Instruments - Carrying Value (Details) Sheet http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails Fair Value of Financial Instruments - Carrying Value (Details) Details 53 false false R54.htm 0000054 - Disclosure - Fair Value of Financial Instruments- Financial Instruments (Details) Sheet http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails Fair Value of Financial Instruments- Financial Instruments (Details) Details 54 false false R55.htm 0000055 - Disclosure - Contingent Consideration - Narrative (Details) Sheet http://www.supernus.com/role/ContingentConsiderationNarrativeDetails Contingent Consideration - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) Sheet http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) Details 56 false false R57.htm 0000057 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) Details 57 false false R58.htm 0000058 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details) Details 58 false false R59.htm 0000059 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) Sheet http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails Goodwill and Intangible Assets, Net - Narrative (Details) Details 59 false false R60.htm 0000060 - Disclosure - Convertible Senior Notes Due 2023 - Narrative (Details) Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails Convertible Senior Notes Due 2023 - Narrative (Details) Details 60 false false R61.htm 0000061 - Disclosure - Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) Notes http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details) Details 61 false false R62.htm 0000062 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails Share-Based Payments - Share-based Compensation Expense (Details) Details 62 false false R63.htm 0000063 - Disclosure - Share-Based Payments - SAR Activity (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails Share-Based Payments - SAR Activity (Details) Details 63 false false R64.htm 0000064 - Disclosure - Share-Based Payments - Restricted Stock Units (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails Share-Based Payments - Restricted Stock Units (Details) Details 64 false false R65.htm 0000065 - Disclosure - Share-Based Payments - Performance Stock Units (Details) Sheet http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails Share-Based Payments - Performance Stock Units (Details) Details 65 false false R66.htm 0000066 - Disclosure - Earnings per Share (Details) Sheet http://www.supernus.com/role/EarningsperShareDetails Earnings per Share (Details) Details http://www.supernus.com/role/EarningsperShareTables 66 false false R67.htm 0000067 - Disclosure - Income Tax (Benefit) Expense (Details) Sheet http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails Income Tax (Benefit) Expense (Details) Details http://www.supernus.com/role/IncomeTaxBenefitExpenseTables 67 false false R68.htm 0000068 - Disclosure - Leases - Narrative (Details) Sheet http://www.supernus.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 68 false false R69.htm 0000069 - Disclosure - Leases - Leases Balance Sheet Information (Details) Sheet http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails Leases - Leases Balance Sheet Information (Details) Details 69 false false R70.htm 0000070 - Disclosure - Composition of Other Balance Sheet Items - Accounts Receivables (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsReceivablesDetails Composition of Other Balance Sheet Items - Accounts Receivables (Details) Details 70 false false R71.htm 0000071 - Disclosure - Composition of Other Balance Sheet Items - Inventories (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails Composition of Other Balance Sheet Items - Inventories (Details) Details 71 false false R72.htm 0000072 - Disclosure - Composition of Other Balance Sheet Items - Property and Equipment (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails Composition of Other Balance Sheet Items - Property and Equipment (Details) Details 72 false false R73.htm 0000073 - Disclosure - Composition of Other Balance Sheet Items - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails Composition of Other Balance Sheet Items - Accounts Payable and Accrued Liabilities (Details) Details 73 false false R74.htm 0000074 - Disclosure - Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details) Details 74 false false R75.htm 0000075 - Disclosure - Composition of Other Balance Sheet Items - Other Liabilities (Details) Sheet http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails Composition of Other Balance Sheet Items - Other Liabilities (Details) Details 75 false false R76.htm 0000076 - Disclosure - Interest Expense (Details) Sheet http://www.supernus.com/role/InterestExpenseDetails Interest Expense (Details) Details http://www.supernus.com/role/InterestExpenseTables 76 false false R77.htm 0000077 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.supernus.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.supernus.com/role/CommitmentsandContingencies 77 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1 - supn-20220930.htm 4 supn-20220930.htm supn-20220930.xsd supn-20220930_cal.xml supn-20220930_def.xml supn-20220930_lab.xml supn-20220930_pre.xml supn-20220930x10qxex311.htm supn-20220930x10qxex312.htm supn-20220930x10qxex321.htm supn-20220930x10qxex322.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 95 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "supn-20220930.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 274, "dts": { "calculationLink": { "local": [ "supn-20220930_cal.xml" ] }, "definitionLink": { "local": [ "supn-20220930_def.xml" ] }, "inline": { "local": [ "supn-20220930.htm" ] }, "labelLink": { "local": [ "supn-20220930_lab.xml" ] }, "presentationLink": { "local": [ "supn-20220930_pre.xml" ] }, "schema": { "local": [ "supn-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 544, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 8, "http://xbrl.sec.gov/dei/2022": 5, "total": 13 }, "keyCustom": 42, "keyStandard": 288, "memberCustom": 34, "memberStandard": 36, "nsprefix": "supn", "nsuri": "http://www.supernus.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.supernus.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Acquisition", "role": "http://www.supernus.com/role/Acquisition", "shortName": "Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Disaggregated Revenues", "role": "http://www.supernus.com/role/DisaggregatedRevenues", "shortName": "Disaggregated Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Investments", "role": "http://www.supernus.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.supernus.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "supn:ContingentConsiderationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Contingent Consideration", "role": "http://www.supernus.com/role/ContingentConsideration", "shortName": "Contingent Consideration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "supn:ContingentConsiderationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Goodwill and Intangible Assets, Net", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNet", "shortName": "Goodwill and Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Convertible Senior Notes Due 2023", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023", "shortName": "Convertible Senior Notes Due 2023", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Share-Based Payments", "role": "http://www.supernus.com/role/ShareBasedPayments", "shortName": "Share-Based Payments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Earnings per Share", "role": "http://www.supernus.com/role/EarningsperShare", "shortName": "Earnings per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Income Tax (Benefit) Expense", "role": "http://www.supernus.com/role/IncomeTaxBenefitExpense", "shortName": "Income Tax (Benefit) Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Leases", "role": "http://www.supernus.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Composition of Other Balance Sheet Items", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItems", "shortName": "Composition of Other Balance Sheet Items", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Interest Expense", "role": "http://www.supernus.com/role/InterestExpense", "shortName": "Interest Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Commitments and Contingencies", "role": "http://www.supernus.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Subsequent Events", "role": "http://www.supernus.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Acquisition (Tables)", "role": "http://www.supernus.com/role/AcquisitionTables", "shortName": "Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Disaggregated Revenues (Tables)", "role": "http://www.supernus.com/role/DisaggregatedRevenuesTables", "shortName": "Disaggregated Revenues (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Investments (Tables)", "role": "http://www.supernus.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.supernus.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Contingent Consideration (Tables)", "role": "http://www.supernus.com/role/ContingentConsiderationTables", "shortName": "Contingent Consideration (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Goodwill and Intangible Assets, Net (Tables)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables", "shortName": "Goodwill and Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Convertible Senior Notes Due 2023 (Tables)", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Tables", "shortName": "Convertible Senior Notes Due 2023 (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Share-Based Payments (Tables)", "role": "http://www.supernus.com/role/ShareBasedPaymentsTables", "shortName": "Share-Based Payments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Earnings per Share (Tables)", "role": "http://www.supernus.com/role/EarningsperShareTables", "shortName": "Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Income Tax (Benefit) Expense (Tables)", "role": "http://www.supernus.com/role/IncomeTaxBenefitExpenseTables", "shortName": "Income Tax (Benefit) Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Leases (Tables)", "role": "http://www.supernus.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Composition of Other Balance Sheet Items (Tables)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables", "shortName": "Composition of Other Balance Sheet Items (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Interest Expense (Tables)", "role": "http://www.supernus.com/role/InterestExpenseTables", "shortName": "Interest Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i58dc84af1ba449cda489de9e861e41b7_D20211124-20211124", "decimals": "INF", "first": true, "lang": "en-US", "name": "supn:NumberOfEstablishedMarketedProducts", "reportCount": 1, "unique": true, "unitRef": "marketedproduct", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Business Organization (Details)", "role": "http://www.supernus.com/role/BusinessOrganizationDetails", "shortName": "Business Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i58dc84af1ba449cda489de9e861e41b7_D20211124-20211124", "decimals": "INF", "first": true, "lang": "en-US", "name": "supn:NumberOfEstablishedMarketedProducts", "reportCount": 1, "unique": true, "unitRef": "marketedproduct", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Condensed Consolidated Statements of Earnings", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "shortName": "Condensed Consolidated Statements of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails", "shortName": "Summary of Significant Accounting Policies - Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Advertising Expense (Details)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails", "shortName": "Summary of Significant Accounting Policies - Advertising Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:AdvertisingCostsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i8d1e6a1c126f42fcb146758e0be6c8af_I20220101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DeferredTaxLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Acquisition - Narrative (Details)", "role": "http://www.supernus.com/role/AcquisitionNarrativeDetails", "shortName": "Acquisition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisition - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i5a996ae75f094e849db325e4d0494c4d_I20211124", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i5a996ae75f094e849db325e4d0494c4d_I20211124", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details)", "role": "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "shortName": "Acquisition - Components of Intangible Assets and Estimated Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ib430dedf6e024d38a4350b89903790f0_I20211124", "decimals": "-5", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i24641b45743247559c7101137c9051fb_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Acquisition - Pro Forma Information (Details)", "role": "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "shortName": "Acquisition - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i24641b45743247559c7101137c9051fb_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Disaggregated Revenues - Summary of Revenues (Details)", "role": "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails", "shortName": "Disaggregated Revenues - Summary of Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i737bfa2058df444396fdafa9e359692a_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:RevenueFromRoyaltyAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Disaggregated Revenues - Narrative (Details)", "role": "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "shortName": "Disaggregated Revenues - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:RevenueFromRoyaltyAgreement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Investments - Unrestricted Marketable Securities (Details)", "role": "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails", "shortName": "Investments - Unrestricted Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Earnings", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings", "shortName": "Condensed Consolidated Statements of Comprehensive Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Investments - Contractual Maturities (Details)", "role": "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails", "shortName": "Investments - Contractual Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Investments - Narrative (Details)", "role": "http://www.supernus.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i8d1e6a1c126f42fcb146758e0be6c8af_I20220101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "role": "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Fair Value of Financial Instruments - Carrying Value (Details)", "role": "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "shortName": "Fair Value of Financial Instruments - Carrying Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "iafeb756a3828467e8f3bd20b7e9e4019_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i9996a014ad6545929732be162f5d0e62_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleLongTermNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Fair Value of Financial Instruments- Financial Instruments (Details)", "role": "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments- Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i9996a014ad6545929732be162f5d0e62_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleLongTermNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "iffec4c8362a5432db44203b63d9f28d6_D20200609-20200609", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Contingent Consideration - Narrative (Details)", "role": "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "shortName": "Contingent Consideration - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "supn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i1c741d8384894c5186428efef3b0a9fc_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details)", "role": "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "shortName": "Contingent Consideration - Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i1c741d8384894c5186428efef3b0a9fc_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i1c741d8384894c5186428efef3b0a9fc_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "shortName": "Goodwill and Intangible Assets, Net - Goodwill and Intangible Assets Gross Carrying Amount and Related Accumulated Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)", "role": "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails", "shortName": "Goodwill and Intangible Assets, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i88bf87d0d6dc43bd9a04fd0ff6b3e1b5_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "iaab76aace3cb4a6c9e58a94095480be1_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Stockholder's Equity", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "shortName": "Condensed Consolidated Statements of Changes in Stockholder's Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i117f875b5d2b4caca696e43ea17940ec_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Convertible Senior Notes Due 2023 - Narrative (Details)", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "shortName": "Convertible Senior Notes Due 2023 - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i54dfe5bfbbd2486f92dac70c751c7bed_I20180331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ic64d65ca3a3347298ce40324ffaafee7_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details)", "role": "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "shortName": "Convertible Senior Notes Due 2023 - Summary of liability component of 2023 Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ic64d65ca3a3347298ce40324ffaafee7_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Share-Based Payments - Share-based Compensation Expense (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails", "shortName": "Share-Based Payments - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751132504d6a4a749f33bac7a970bac1_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Share-Based Payments - SAR Activity (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails", "shortName": "Share-Based Payments - SAR Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ia801d6feb6c44d458c2af8710b8b051b_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i2ee8265febba4f6d8758db339de1937f_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Share-Based Payments - Restricted Stock Units (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "shortName": "Share-Based Payments - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i2ee8265febba4f6d8758db339de1937f_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i992fca004c4141fc92bd07d287f04e7c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Share-Based Payments - Performance Stock Units (Details)", "role": "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "shortName": "Share-Based Payments - Performance Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i992fca004c4141fc92bd07d287f04e7c_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Earnings per Share (Details)", "role": "http://www.supernus.com/role/EarningsperShareDetails", "shortName": "Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:InterestOnConvertibleDebtNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Income Tax (Benefit) Expense (Details)", "role": "http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails", "shortName": "Income Tax (Benefit) Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ia4ffdff26e884179ad97ae14fa8232c8_I20211124", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Leases - Narrative (Details)", "role": "http://www.supernus.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ia4ffdff26e884179ad97ae14fa8232c8_I20211124", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Leases - Leases Balance Sheet Information (Details)", "role": "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails", "shortName": "Leases - Leases Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:AllowanceForExpectedSalesDeductions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Composition of Other Balance Sheet Items - Accounts Receivables (Details)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsReceivablesDetails", "shortName": "Composition of Other Balance Sheet Items - Accounts Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:AllowanceForExpectedSalesDeductions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Composition of Other Balance Sheet Items - Inventories (Details)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails", "shortName": "Composition of Other Balance Sheet Items - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryWorkInProcessAndRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Composition of Other Balance Sheet Items - Property and Equipment (Details)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails", "shortName": "Composition of Other Balance Sheet Items - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i1c741d8384894c5186428efef3b0a9fc_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Composition of Other Balance Sheet Items - Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails", "shortName": "Composition of Other Balance Sheet Items - Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:AccruedRebates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails", "shortName": "Composition of Other Balance Sheet Items - Accrued Product Returns and Rebates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "supn:ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:AccruedRebates", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:NonRecourseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Composition of Other Balance Sheet Items - Other Liabilities (Details)", "role": "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails", "shortName": "Composition of Other Balance Sheet Items - Other Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i751b086a4be443cdb21bac970c5c89c5_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "supn:NonRecourseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Interest Expense (Details)", "role": "http://www.supernus.com/role/InterestExpenseDetails", "shortName": "Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i67c266b5cc64497e9ba4c584f31d2ac4_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ia3f8789b47b9486fa6ce126ed2f63f25_I20140930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "ia3f8789b47b9486fa6ce126ed2f63f25_I20140930", "decimals": "-5", "first": true, "lang": "en-US", "name": "supn:NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Business Organization", "role": "http://www.supernus.com/role/BusinessOrganization", "shortName": "Business Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.supernus.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "supn-20220930.htm", "contextRef": "i370bd506faa543f0b3416ece458e1b90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r642" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r629" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r98", "r258", "r262", "r267", "r445", "r446", "r450", "r451", "r526", "r625" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r98", "r258", "r262", "r267", "r445", "r446", "r450", "r451", "r526", "r625" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": { "auth_ref": [ "r2", "r103", "r112", "r197", "r382", "r383", "r384", "r404", "r405", "r462", "r467", "r468", "r523" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]", "terseLabel": "Balance, January 1, 2022" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r103", "r112", "r119", "r197", "r382", "r383", "r384", "r404", "r405", "r462", "r465", "r467", "r468", "r523" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect of adoption of ASU 2020-06" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r103", "r112", "r119", "r197", "r382", "r383", "r384", "r404", "r405", "r462", "r465", "r467", "r468", "r523" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r103", "r112", "r119", "r197", "r382", "r383", "r384", "r404", "r405", "r462", "r465", "r467", "r468", "r523" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r174", "r315", "r319", "r607" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r251", "r253", "r254", "r255", "r273", "r297", "r338", "r340", "r538", "r539", "r540", "r541", "r542", "r543", "r565", "r605", "r608", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r251", "r253", "r254", "r255", "r273", "r297", "r338", "r340", "r538", "r539", "r540", "r541", "r542", "r543", "r565", "r605", "r608", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r174", "r315", "r319", "r607" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r172", "r253", "r254", "r315", "r317", "r567", "r604", "r606" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r172", "r253", "r254", "r315", "r317", "r567", "r604", "r606" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r244", "r251", "r253", "r254", "r255", "r273", "r297", "r328", "r338", "r340", "r372", "r373", "r374", "r538", "r539", "r540", "r541", "r542", "r543", "r565", "r605", "r608", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r244", "r251", "r253", "r254", "r255", "r273", "r297", "r328", "r338", "r340", "r372", "r373", "r374", "r538", "r539", "r540", "r541", "r542", "r543", "r565", "r605", "r608", "r626", "r627" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r3", "r100", "r101", "r102", "r104", "r105", "r109", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r138", "r198", "r199", "r405", "r463", "r467", "r468", "r469", "r510", "r524", "r525", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "terseLabel": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r3", "r100", "r101", "r102", "r104", "r105", "r109", "r110", "r111", "r112", "r114", "r115", "r116", "r117", "r118", "r119", "r138", "r198", "r199", "r405", "r463", "r467", "r468", "r469", "r510", "r524", "r525", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r3", "r100", "r102", "r104", "r105", "r109", "r110", "r111", "r112", "r114", "r115", "r117", "r118", "r138", "r198", "r199", "r405", "r463", "r467", "r468", "r469", "r510", "r524", "r525", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]", "terseLabel": "As Initially Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "supn_APOKYNAndSPN830Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "APOKYN And SPN-830", "label": "APOKYN And SPN-830 [Member]", "terseLabel": "APOKYN and SPN-830" } } }, "localname": "APOKYNAndSPN830Member", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_APOKYNMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "APOKYN", "label": "APOKYN [Member]", "terseLabel": "APOKYN" } } }, "localname": "APOKYNMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_AccruedClinicalTrialAndClinicalSupplyCostsCurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of clinical trial and clinical supply costs accrued.", "label": "Accrued Clinical Trial and Clinical Supply Costs Current", "terseLabel": "Accrued clinical trial costs" } } }, "localname": "AccruedClinicalTrialAndClinicalSupplyCostsCurrent", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AccruedProductCostsCurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Product Costs, Current", "label": "Accrued Product Costs, Current", "terseLabel": "Accrued product costs" } } }, "localname": "AccruedProductCostsCurrent", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AccruedProductReturns": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "order": 2.0, "parentTag": "supn_AccruedProductReturnsAndRebates", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued product returns.", "label": "Accrued Product Returns", "terseLabel": "Accrued product returns" } } }, "localname": "AccruedProductReturns", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AccruedProductReturnsAndRebates": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued product returns and rebates.", "label": "Accrued Product Returns and Rebates.", "terseLabel": "Accrued product returns and rebates", "totalLabel": "Total" } } }, "localname": "AccruedProductReturnsAndRebates", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "supn_AccruedRebates": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails": { "order": 1.0, "parentTag": "supn_AccruedProductReturnsAndRebates", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of accrued rebates.", "label": "Accrued Rebates", "terseLabel": "Accrued product rebates" } } }, "localname": "AccruedRebates", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccruedProductReturnsandRebatesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AdamasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adamas", "label": "Adamas [Member]", "terseLabel": "Adamas Acquisition" } } }, "localname": "AdamasMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_AdamasPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adamas Pharmaceuticals", "label": "Adamas Pharmaceuticals [Member]", "terseLabel": "Adamas Pharmaceuticals" } } }, "localname": "AdamasPharmaceuticalsMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/BusinessOrganizationDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_AllowanceForExpectedSalesDeductions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the allowance for sales discounts related to prompt-pay discounts and contractual fee for service arrangements to wholesalers and distributors.", "label": "Allowance for Expected Sales deductions", "terseLabel": "Allowance for expected sales discounts and allowances" } } }, "localname": "AllowanceForExpectedSalesDeductions", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AmerisourceBergenDrugCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmerisourceBergen Drug Corporation", "label": "AmerisourceBergen Drug Corporation [Member]", "terseLabel": "AmerisourceBergen Drug Corporation" } } }, "localname": "AmerisourceBergenDrugCorporationMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing after the first year through the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value", "terseLabel": "1 year to 2 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securities Debt Maturities, Thereafter, Fair Value", "label": "Available For Sale Securities Debt Maturities, Thereafter, Fair Value", "terseLabel": "Greater than 4 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the third fiscal year through the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value", "terseLabel": "3 years to 4 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of available-for-sale debt securities maturing in the second fiscal year through the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value", "terseLabel": "2 years to 3 years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Excess Acquisition Date Fair Value", "terseLabel": "Fair value of excess of the acquisition" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationExcessAcquisitionDateFairValue", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One", "label": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period One", "terseLabel": "Additional cash payments upon milestone achievements minimum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodOne", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two", "label": "Business Combination, Contingent Consideration Arrangements, Consecutive Twelve-Month Net Sales Threshold, Period Two", "terseLabel": "Additional cash payments upon milestone achievements maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsConsecutiveTwelveMonthNetSalesThresholdPeriodTwo", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationContingentConsiderationNumberOfContingentValueRightsPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share", "label": "Business Combination, Contingent Consideration, Number Of Contingent Value Rights Per Common Share", "terseLabel": "Contingents value rights" } } }, "localname": "BusinessCombinationContingentConsiderationNumberOfContingentValueRightsPerCommonShare", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "integerItemType" }, "supn_BusinessCombinationContingentConsiderationRightsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Rights Per Share", "label": "Business Combination, Contingent Consideration, Rights Per Share", "terseLabel": "Rights per share (in dollars per share)" } } }, "localname": "BusinessCombinationContingentConsiderationRightsPerShare", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "perShareItemType" }, "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets (Liabilities), Net", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Assets (Liabilities), Net", "totalLabel": "Total identifiable net assets, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsLiabilitiesNet", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Income Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredIncomeTaxLiabilities", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "supn_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets", "terseLabel": "Change in fair value of operating lease acquired" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses And Other Current Liabilities", "negatedTerseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Acquired", "totalLabel": "Total fair value of assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIncomeTaxLiabilities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Deferred Income Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredIncomeTaxLiabilities", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Liability, Noncurrent", "negatedLabel": "Operating lease liabilities, long-term" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNoncurrent", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "supn_CardinalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardinal Health", "label": "Cardinal Health [Member]", "terseLabel": "Cardinal Health" } } }, "localname": "CardinalHealthMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_ClassOfWarrantOrRightNumberOfSharesInWhichHolderCanBeEntitledPerWarrantsAtStrikePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the shares per warrant entitled to holders at strike price.", "label": "Class of Warrant or Right, Number of Shares in Which Holder Can be Entitled per Warrants at Strike Price", "terseLabel": "Number of shares per warrant entitled to holder (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSharesInWhichHolderCanBeEntitledPerWarrantsAtStrikePrice", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "supn_CollaborativeArrangementThresholdForDevelopmentCostsPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Threshold For Development Costs Payments", "label": "Collaborative Arrangement, Threshold For Development Costs Payments", "terseLabel": "Threshold for development costs payments" } } }, "localname": "CollaborativeArrangementThresholdForDevelopmentCostsPayments", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_ContingentConsiderationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Disclosure", "label": "Contingent Consideration Disclosure [Text Block]", "terseLabel": "Contingent Consideration Disclosure" } } }, "localname": "ContingentConsiderationDisclosureTextBlock", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsideration" ], "xbrltype": "textBlockItemType" }, "supn_ConversionCircumstanceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Circumstance One", "label": "Conversion Circumstance One [Member]", "terseLabel": "Conversion Circumstance One" } } }, "localname": "ConversionCircumstanceOneMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_ConversionCircumstanceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Circumstance Two", "label": "Conversion Circumstance Two [Member]", "terseLabel": "Conversion Circumstance Two" } } }, "localname": "ConversionCircumstanceTwoMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_CorporateAndMunicipalDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate And Municipal Debt Securities", "label": "Corporate And Municipal Debt Securities [Member]", "terseLabel": "Corporate and Municipal Debt Securities" } } }, "localname": "CorporateAndMunicipalDebtSecuritiesMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "supn_DeferredLegalFeesAndFixedAssetsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Legal Fees and Fixed Assets Included in Accounts Payable and Accrued Expenses", "label": "Deferred Legal Fees and Fixed Assets Included in Accounts Payable and Accrued Expenses", "terseLabel": "Deferred legal fees and fixed assets included in accounts payable and accrued expenses" } } }, "localname": "DeferredLegalFeesAndFixedAssetsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_DevelopedTechnologyRightsAndPatentDefenseCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed Technology Rights And Patent Defense Costs", "label": "Developed Technology Rights And Patent Defense Costs [Member]", "terseLabel": "Developed Technology Rights and Patent Defense Costs" } } }, "localname": "DevelopedTechnologyRightsAndPatentDefenseCostsMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_EPSBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EPS Basic And Diluted", "label": "EPS Basic And Diluted [Abstract]", "verboseLabel": "Earnings per share" } } }, "localname": "EPSBasicAndDilutedAbstract", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "supn_GOCOVRIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GOCOVRI", "label": "GOCOVRI [Member]", "terseLabel": "GOCOVRI" } } }, "localname": "GOCOVRIMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_IncreaseDecreaseInAccruedProductReturnsAndRebates": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in product returns and rebates.", "label": "Increase (Decrease) In Accrued Product Returns And Rebates", "terseLabel": "Accrued product returns and rebates" } } }, "localname": "IncreaseDecreaseInAccruedProductReturnsAndRebates", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_IncreaseDecreaseInContingentConsideration": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Contingent Consideration", "label": "Increase (Decrease) In Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "IncreaseDecreaseInContingentConsideration", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_LabEquipmentAndFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to lab equipment and furniture.", "label": "Lab Equipment And Furniture [Member]", "terseLabel": "Lab equipment and furniture" } } }, "localname": "LabEquipmentAndFurnitureMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "supn_LeaseLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities, Current", "label": "Lease Liabilities, Current [Abstract]", "terseLabel": "Lease liabilities, current" } } }, "localname": "LeaseLiabilitiesCurrentAbstract", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "supn_LeaseLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Liabilities, Noncurrent", "label": "Lease Liabilities, Noncurrent [Abstract]", "terseLabel": "Lease liabilities, long-term" } } }, "localname": "LeaseLiabilitiesNoncurrentAbstract", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "supn_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Liability", "label": "Lease, Liability", "totalLabel": "Total lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "supn_LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating and Finance Lease, Balance Sheet Disclosure", "label": "Lessee, Operating and Finance Lease, Balance Sheet Disclosure [Table Text Block]", "terseLabel": "Schedule of balance sheet information related to leases" } } }, "localname": "LesseeOperatingAndFinanceLeaseBalanceSheetDisclosureTableTextBlock", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "supn_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Lessee, Operating Lease, Number Of Renewal Options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "supn_MDDSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MDD Subsidiaries", "label": "MDD Subsidiaries [Member]", "terseLabel": "MDD Subsidiaries" } } }, "localname": "MDDSubsidiariesMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "supn_MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MDD US Enterprises LLC (Formerly USWM Enterprises)", "label": "MDD US Enterprises LLC (Formerly USWM Enterprises) [Member]", "terseLabel": "USWM Enterprises" } } }, "localname": "MDDUSEnterprisesLLCFormerlyUSWMEnterprisesMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_MarketBasedUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Based Units", "label": "Market Based Units [Member]", "terseLabel": "Market-Based Units" } } }, "localname": "MarketBasedUnitsMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "supn_McKessonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McKesson", "label": "McKesson [Member]", "terseLabel": "McKesson" } } }, "localname": "McKessonMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_NAMENDAXRNamzaricQuiTamLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NAMENDA XR/Namzaric Qui Tam Litigation", "label": "NAMENDA XR/Namzaric Qui Tam Litigation [Member]", "terseLabel": "NAMENDA XR/Namzaric Qui Tam Litigation" } } }, "localname": "NAMENDAXRNamzaricQuiTamLitigationMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "supn_NavitorPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Navitor Pharmaceuticals, Inc.", "label": "Navitor Pharmaceuticals, Inc. [Member]", "terseLabel": "Navitor Pharmaceuticals, Inc." } } }, "localname": "NavitorPharmaceuticalsIncMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of debt, net of the amount due within one year or the normal operating cycle, if longer, related to the sale of future royalties, for which the creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property.", "label": "Non Recourse Debt Sale of Future Royalties Noncurrent", "terseLabel": "Nonrecourse liability related to sale of future royalties, long term" } } }, "localname": "NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "supn_NonRecourseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-Recourse Liability, Noncurrent", "label": "Non-Recourse Liability, Noncurrent", "terseLabel": "Nonrecourse liability related to sale of future royalties, long-term" } } }, "localname": "NonRecourseLiabilityNoncurrent", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "supn_NumberOfEstablishedMarketedProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Established Marketed Products", "label": "Number Of Established Marketed Products", "terseLabel": "Number of established marketed products" } } }, "localname": "NumberOfEstablishedMarketedProducts", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/BusinessOrganizationDetails" ], "xbrltype": "integerItemType" }, "supn_OxtellarXRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Oxtellar XR product.", "label": "Oxtellar X R [Member]", "terseLabel": "Oxtellar XR" } } }, "localname": "OxtellarXRMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_PatentDefenseCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information concerning the capitalized patent defense costs related to the Watson litigation.", "label": "Patent Defense Costs [Member]", "terseLabel": "Capitalized patent defense costs" } } }, "localname": "PatentDefenseCostsMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "supn_PaymentsForProceedsFromCollaborativeArrangementInvestment": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For (Proceeds From) Collaborative Arrangement, Investment", "label": "Payments For (Proceeds From) Collaborative Arrangement, Investment", "negatedLabel": "Other income from Navitor (see Note 5)" } } }, "localname": "PaymentsForProceedsFromCollaborativeArrangementInvestment", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees", "label": "Payments To Acquire Property, Plant, And Equipment, And Deferred Legal Fees", "negatedTerseLabel": "Purchase of property and equipment and deferred legal fees paid" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipmentAndDeferredLegalFees", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_PerformanceBasedUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Based Units", "label": "Performance Based Units [Member]", "terseLabel": "Performance-Based Units" } } }, "localname": "PerformanceBasedUnitsMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "supn_ProceedsFromGovernmentalLoanAndGrant": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Governmental Loan and Grant", "label": "Proceeds from Governmental Loan and Grant", "terseLabel": "Proceeds from governmental loan and grant" } } }, "localname": "ProceedsFromGovernmentalLoanAndGrant", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_PurchaseCommitmentAnnualMinimumAmountCommitted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase Commitment, Annual Minimum Amount Committed", "label": "Purchase Commitment, Annual Minimum Amount Committed", "terseLabel": "Annual minimum purchase quantity requirement amount" } } }, "localname": "PurchaseCommitmentAnnualMinimumAmountCommitted", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "supn_QelbreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qelbree", "label": "Qelbree [Member]", "terseLabel": "Qelbree" } } }, "localname": "QelbreeMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory And Developmental Contingent Consideration Liability", "label": "Regulatory And Developmental Contingent Consideration Liability [Member]", "terseLabel": "Regulatory and developmental contingent consideration liabilities" } } }, "localname": "RegulatoryAndDevelopmentalContingentConsiderationLiabilityMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_RevenueFromRoyaltyAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents revenue from the sale of certain royalty and milestone rights.", "label": "Revenue From Royalty Agreement", "terseLabel": "Non-cash royalty revenue" } } }, "localname": "RevenueFromRoyaltyAgreement", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "supn_RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability", "label": "Right-of-Use Asset Obtained In Exchange For Operating And Finance Lease Liability", "terseLabel": "Lease assets obtained for new operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "supn_SPN830FDAAcceptanceMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 FDA Acceptance Milestone", "label": "SPN-830 FDA Acceptance Milestone [Member]", "terseLabel": "SPN-830 FDA Acceptance Milestone" } } }, "localname": "SPN830FDAAcceptanceMilestoneMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830FirstCommercialAndSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 First Commercial And Sale", "label": "SPN-830 First Commercial And Sale [Member]", "terseLabel": "SPN-830 First Commercial And Sale" } } }, "localname": "SPN830FirstCommercialAndSaleMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830FutureSalesPerformanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 Future Sales Performance", "label": "SPN-830 Future Sales Performance [Member]", "terseLabel": "SPN-830 Future Sales Performance" } } }, "localname": "SPN830FutureSalesPerformanceMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830NDAApprovalMilestoneApprovalBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 NDA Approval Milestone, Approval-Based", "label": "SPN-830 NDA Approval Milestone, Approval-Based [Member]", "terseLabel": "SPN-830 NDA Approval Milestone, Approval-Based" } } }, "localname": "SPN830NDAApprovalMilestoneApprovalBasedMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830NDAApprovalMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 NDA Approval Milestone", "label": "SPN-830 NDA Approval Milestone [Member]", "terseLabel": "SPN-830 NDA Approval Milestone" } } }, "localname": "SPN830NDAApprovalMilestoneMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830NDAApprovalMilestoneTimeBasedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 NDA Approval Milestone, Time-Based", "label": "SPN-830 NDA Approval Milestone, Time-Based [Member]", "terseLabel": "SPN-830 NDA Approval Milestone, Time-Based" } } }, "localname": "SPN830NDAApprovalMilestoneTimeBasedMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SPN830RegulatoryAndCommercialActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPN-830 Regulatory And Commercial Activities", "label": "SPN-830 Regulatory And Commercial Activities [Member]", "terseLabel": "SPN-830 Regulatory and Commercial Activities" } } }, "localname": "SPN830RegulatoryAndCommercialActivitiesMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_SalesBasedContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales-Based Contingent Consideration Liability", "label": "Sales-Based Contingent Consideration Liability [Member]", "terseLabel": "Sales-based contingent consideration liabilities" } } }, "localname": "SalesBasedContingentConsiderationLiabilityMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "supn_ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the accrued product returns and rebates.", "label": "Schedule of Accrued Product Returns and Rebates [Table Text Block]", "terseLabel": "Schedule of accrued product returns and rebates" } } }, "localname": "ScheduleOfAccruedProductReturnsAndRebatesTableTextBlock", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "supn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term\u00a0(in\u00a0years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "supn_StockOptionStockAppreciationRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to stock option awards for employees and non-employees as well as stock appreciation rights.", "label": "Stock Option Stock Appreciation Rights [Member]", "terseLabel": "Stock option and Stock Appreciation Rights" } } }, "localname": "StockOptionStockAppreciationRightsMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "domainItemType" }, "supn_ThreeMajorCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Major Customers", "label": "Three Major Customers [Member]", "terseLabel": "Three Major Customers" } } }, "localname": "ThreeMajorCustomersMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "supn_TrokendiXrMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Trokendi XR patent litigation.", "label": "Trokendi Xr [Member]", "terseLabel": "Trokendi XR" } } }, "localname": "TrokendiXrMember", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "supn_VariableInterestEntityAgreementTerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entity, Agreement Termination Notice, Period", "label": "Variable Interest Entity, Agreement Termination Notice, Period", "terseLabel": "Agreement termination notice period" } } }, "localname": "VariableInterestEntityAgreementTerminationNoticePeriod", "nsuri": "http://www.supernus.com/20220930", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r104", "r105", "r106", "r107", "r178", "r179", "r194", "r195", "r196", "r197", "r198", "r199", "r382", "r383", "r384", "r404", "r405", "r428", "r429", "r430", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r499", "r500", "r507", "r508", "r509", "r520", "r521", "r522", "r523", "r524", "r525", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible Enumeration]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37", "r529" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r175", "r176" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional & marketing fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r10", "r40" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r15", "r241" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r49", "r50", "r51", "r595", "r616", "r620" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive earnings (loss), net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r48", "r51", "r58", "r59", "r60", "r100", "r101", "r102", "r449", "r525", "r611", "r612" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated\u00a0Other Comprehensive Earnings\u00a0(Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r529" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r100", "r101", "r102", "r382", "r383", "r384", "r467" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional\u00a0 Paid-in\u00a0Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r104", "r105", "r106", "r107", "r119", "r178", "r179", "r194", "r195", "r196", "r197", "r198", "r199", "r382", "r383", "r384", "r402", "r403", "r404", "r405", "r428", "r429", "r430", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r499", "r500", "r507", "r508", "r509", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r569", "r570", "r571", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r342", "r386", "r387" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expense" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r83", "r286", "r294", "r295", "r504" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing costs and debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r83", "r226", "r233" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded in the calculation of diluted income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Income per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r19", "r94", "r161", "r164", "r170", "r193", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r445", "r450", "r483", "r527", "r529", "r577", "r592" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r36", "r94", "r193", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r445", "r450", "r483", "r527", "r529" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r471" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Total assets at fair value", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r182" ], "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r183" ], "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r184", "r185", "r587" ], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r181", "r205" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Corporate and municipal debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r13", "r181", "r205" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Corporate and municipal debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r346", "r347", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r337", "r339", "r424" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/BusinessOrganizationDetails", "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r337", "r339", "r419", "r420", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/BusinessOrganizationDetails", "http://www.supernus.com/role/CommitmentsandContingenciesDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/BusinessOrganizationDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business acquisition, pro forma information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r417", "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Pro forma net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r417", "r418" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Pro forma total revenues" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r432", "r433", "r436" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r82", "r440" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration", "verboseLabel": "Contingent consideration expense (gain)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r441" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "terseLabel": "Fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Additional cash payments upon milestone achievements maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Additional cash payments upon milestone achievements minimum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r431", "r434", "r438" ], "calculation": { "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration", "totalLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r431", "r435" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration, current portion" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r431", "r435" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration, long-term" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r425", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/Acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "negatedLabel": "Current debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangibles", "verboseLabel": "Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total fair value of liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "supn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r422" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r87", "r88", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment additions from utilization of tenant improvement allowance" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r6", "r12", "r85" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r79", "r85", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r79", "r492" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Strike price of the warrant transactions (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants issued (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r246", "r247", "r248", "r256", "r624" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r100", "r101", "r467" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r529" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common Stock, Value, Issued" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r54", "r56", "r57", "r64", "r583", "r600" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive earnings (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r227", "r231", "r426" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r149", "r150", "r174", "r481", "r482", "r623" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r149", "r150", "r174", "r481", "r482", "r621", "r623" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r149", "r150", "r174", "r481", "r482", "r621", "r623" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r149", "r150", "r174", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage (more than)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r149", "r150", "r174", "r481", "r482", "r623" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r92", "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction-in-progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails", "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Fair\u00a0Value (Level\u00a02)" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r269", "r270", "r271", "r273", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "2023 Notes" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "Convertible Debt [Table Text Block]", "verboseLabel": "Summary of liability component of 2023 Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Carrying\u00a0Value" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r69", "r567" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r68" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r147", "r174" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r87", "r89" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]", "terseLabel": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r87", "r89" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "verboseLabel": "Common stock issued upon conversion of notes (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r87", "r89" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Convertible note hedge options issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r87", "r89" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]", "terseLabel": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r87", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "verboseLabel": "Conversion of debt to equity" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r272", "r290" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price, per share of common stock (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r43", "r272", "r300", "r301", "r303" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion rate for the notes (in shares per $1,000 principal amount)" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.", "label": "Debt Instrument, Convertible, Stock Price Trigger", "terseLabel": "Conversion option stock price trigger (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading day period (in days)" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Conversion rate of the notes on trading day (as percent)" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days (whether or not consecutive)" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r270", "r292", "r293", "r503", "r505", "r506" ], "calculation": { "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "2023 Notes", "verboseLabel": "Principal amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42", "r271" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "verboseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r93", "r98", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r292", "r293", "r294", "r295", "r300", "r302", "r303", "r304", "r502", "r503", "r505", "r506", "r590" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r277", "r288", "r292", "r293", "r504" ], "calculation": { "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt discount and deferred financing costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent": { "auth_ref": [ "r205" ], "calculation": { "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current", "totalLabel": "Amortized cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": { "auth_ref": [ "r205" ], "calculation": { "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLossCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "terseLabel": "Total fair value", "totalLabel": "Total" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsContractualMaturitiesDetails", "http://www.supernus.com/role/InvestmentsUnrestrictedMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding accrued interest, of credit loss expense on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with no credit loss previously recorded.", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Allowance for Credit Loss, Not Previously Recorded", "terseLabel": "Debt securities, available-for-sale, excluding accrued interest, allowance for credit loss, not previously recorded" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecorded", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Current [Abstract]", "terseLabel": "Marketable securities" } } }, "localname": "DebtSecuritiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Noncurrent [Abstract]", "terseLabel": "Long term marketable securities" } } }, "localname": "DebtSecuritiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r83", "r95", "r400", "r408", "r409", "r410" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r392", "r393" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r393", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTerseLabel": "Deferred tax liabilities, net" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r325", "r326", "r327", "r336", "r576", "r591" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "verboseLabel": "Marketable securities - restricted (SERP)" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r83", "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r83", "r159" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology and product rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of disaggregation of revenues by nature" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r345", "r346", "r378", "r379", "r380", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r65", "r109", "r110", "r112", "r113", "r114", "r120", "r123", "r132", "r133", "r134", "r138", "r139", "r468", "r469", "r584", "r601" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r65", "r109", "r110", "r112", "r113", "r114", "r123", "r132", "r133", "r134", "r138", "r139", "r468", "r469", "r584", "r601" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r135", "r136", "r137", "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based payments" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r58", "r59", "r60", "r100", "r101", "r102", "r105", "r115", "r118", "r141", "r197", "r299", "r305", "r382", "r383", "r384", "r404", "r405", "r467", "r493", "r494", "r495", "r496", "r497", "r498", "r525", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Investments" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r471", "r472", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value of the financial assets and liabilities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r279", "r292", "r293", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r472", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r471", "r472", "r473", "r474", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments and Contingent Consideration" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r279", "r329", "r330", "r335", "r336", "r472", "r535" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r279", "r292", "r293", "r329", "r330", "r335", "r336", "r472", "r536" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r279", "r292", "r293", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r472", "r537" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of financial liabilities that are not carried at fair value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r475", "r479" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of the beginning and ending balances related to the contingent consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value recognized in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Milestone payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r475" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at September 30, 2022 (unaudited)", "periodStartLabel": "Balance at December 31, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r279", "r292", "r293", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r535", "r536", "r537" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsFinancialInstrumentsDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r478", "r480" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]", "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ContingentConsiderationReconciliationoftheBeginningandEndingBalancesRelatedtotheContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r186", "r187", "r189", "r190", "r191", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r209", "r210", "r287", "r298", "r458", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r634", "r635", "r636", "r637", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-lived and indefinite-lived intangible assets acquired as part of business combination" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r17", "r232" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r227", "r229", "r232", "r236", "r568", "r572" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r232", "r572" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Carrying Amount, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "verboseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r227", "r231" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r232", "r568" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Carrying Amount, Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining Weighted Average\u00a0Life (Years)" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r16", "r212", "r213", "r220", "r224", "r529", "r575" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance as of September 30, 2022 (unaudited)", "periodStartLabel": "Balance as of December\u00a031, 2021", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets, Net" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r219", "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill, adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Acquired in-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r62", "r161", "r163", "r166", "r169", "r171", "r573", "r581", "r586", "r602" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings (Loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r243", "r245" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r96", "r396", "r397", "r399", "r406", "r411", "r413", "r414", "r415" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax (Benefit) Expense" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/IncomeTaxBenefitExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r97", "r117", "r118", "r160", "r394", "r407", "r412", "r603" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/IncomeTaxBenefitExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": { "auth_ref": [ "r401" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.", "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability", "negatedTerseLabel": "Income tax expense (benefit), adjustment of deferred tax (asset) liability" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r82" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r82" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r82" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r82" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r128", "r129", "r134" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Convertible notes (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r124", "r125", "r126", "r134", "r344" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Stock options, RSU and SAR (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r228", "r235" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r235" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Acquired in-process research and development" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r228", "r235" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r16" ], "calculation": { "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total intangible assets, carrying amount, gross" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r225", "r230" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r61", "r158", "r501", "r504", "r585" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.supernus.com/role/InterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "negatedTotalLabel": "Total" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r72", "r284", "r291", "r294", "r295" ], "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/InterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedLabel": "Interest expense on nonrecourse liability related to sale of future royalties" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of interest expense" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InterestExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "auth_ref": [ "r122", "r127", "r134" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.", "label": "Interest on Convertible Debt, Net of Tax", "terseLabel": "After-tax interest expense for 2023 Notes" } } }, "localname": "InterestOnConvertibleDebtNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r78", "r80", "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest on convertible notes" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r30", "r211" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r7", "r35", "r529" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterialsNetOfReserves": { "auth_ref": [ "r35", "r211" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of items which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryWorkInProcessAndRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r31", "r211" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r72" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedLabel": "Amortization of premium/discount on marketable securities" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "verboseLabel": "Schedule of contractual maturities of the unrestricted available-for-sale marketable securities held" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r188", "r574", "r588", "r622", "r641" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Optional lease renewal term (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r94", "r165", "r193", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r446", "r450", "r451", "r483", "r527", "r528" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r94", "r193", "r483", "r529", "r580", "r597" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r9", "r41", "r94", "r193", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r446", "r450", "r451", "r483", "r527", "r528", "r529" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r471" ], "calculation": { "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Payment to resolve U.S. Department of Justice allegations" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r278", "r289", "r292", "r293", "r579", "r594" ], "calculation": { "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total carrying value" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Convertible notes, net" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r20" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Convertible notes, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Convertible Senior Notes Due 2023" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Long-term purchase commitment, amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-Term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-Term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r44", "r257" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023Summaryofliabilitycomponentof2023NotesDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Commitment period" } } }, "localname": "LongtermPurchaseCommitmentPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r249", "r250", "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss contingency, damages sought, value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturedProductOtherMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by labor or machinery, classified as other.", "label": "Manufactured Product, Other [Member]", "terseLabel": "Other" } } }, "localname": "ManufacturedProductOtherMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "negatedTerseLabel": "Realized gains from sales of marketable securities" } } }, "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r142", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Business Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/BusinessOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r79" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r79", "r81", "r84" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r52", "r55", "r60", "r63", "r84", "r94", "r104", "r109", "r110", "r112", "r113", "r117", "r118", "r130", "r161", "r163", "r166", "r169", "r171", "r193", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r469", "r483", "r582", "r599" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/EarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings", "totalLabel": "Net earnings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r109", "r110", "r112", "r113", "r120", "r121", "r131", "r134", "r161", "r163", "r166", "r169", "r171" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Numerator for dilutive earnings per share" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r103", "r104", "r105", "r106", "r107", "r108", "r112", "r119", "r138", "r178", "r179", "r194", "r195", "r196", "r197", "r198", "r199", "r382", "r383", "r384", "r402", "r403", "r404", "r405", "r428", "r429", "r430", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r499", "r500", "r507", "r508", "r509", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r569", "r570", "r571", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesBasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r161", "r163", "r166", "r169", "r171" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating earnings (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r512" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "supn_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails", "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r512" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "supn_LeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term", "verboseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r514", "r518" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r511" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/LeasesLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsAccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r443", "r444", "r448" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized loss on marketable securities, net of tax", "verboseLabel": "Unrealized loss on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r53", "r56", "r443", "r444", "r448" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofComprehensiveEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r40", "r529" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other noncash adjustments, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Other liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": { "auth_ref": [ "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Other Nonoperating Income and Expense [Text Block]", "terseLabel": "Interest Expense" } } }, "localname": "OtherNonoperatingIncomeAndExpenseTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InterestExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Interest and other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r21", "r578", "r593" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsOtherLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payment of contingent consideration", "terseLabel": "Payment of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r75", "r437" ], "calculation": { "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r75" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of USWM, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r180" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "verboseLabel": "Total PSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prior Period Adjustment [Abstract]", "terseLabel": "Measurement Period Adjustments" } } }, "localname": "PriorPeriodAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Cash distributions received" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r76" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Net product sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r242", "r517" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r14", "r240" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r242", "r529", "r589", "r598" ], "calculation": { "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r391", "r566", "r628" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Navitor investment R&D expense (see Note 5)" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r305", "r529", "r596", "r615", "r620" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r100", "r101", "r102", "r105", "r115", "r118", "r197", "r382", "r383", "r384", "r404", "r405", "r467", "r611", "r613" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r156", "r157", "r162", "r167", "r168", "r172", "r173", "r174", "r314", "r315", "r567" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r149", "r174" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer Benchmark" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenuesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r324" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Disaggregated Revenues" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/DisaggregatedRevenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "Revenues" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty revenues" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/DisaggregatedRevenuesSummaryofRevenuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accounts payable and accrued liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of common stock equivalents excluded in the calculation of diluted earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of unrestricted available-for-sale marketable securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r419", "r420", "r424" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionComponentsofIntangibleAssetsandEstimatedUsefulLivesDetails", "http://www.supernus.com/role/AcquisitionNarrativeDetails", "http://www.supernus.com/role/AcquisitionProFormaInformationDetails", "http://www.supernus.com/role/AcquisitionScheduleofRecognizedIdentifiedAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.supernus.com/role/BusinessOrganizationDetails", "http://www.supernus.com/role/ContingentConsiderationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted earnings per share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of income tax expense at the U.S Federal statutory income tax rate to the entity's effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/IncomeTaxBenefitExpenseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r376", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r227", "r231", "r568" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails", "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r235", "r237" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetGoodwillandIntangibleAssetsGrossCarryingAmountandRelatedAccumulatedAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of intangible assets and goodwill" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/GoodwillandIntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r32", "r33", "r34" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItemsPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of recognized identified assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r341", "r343", "r346", "r347", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r350", "r365", "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock options and SAR activities" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of restricted stock units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r445", "r446", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r70" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSharebasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r82" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, ending balance (in shares)", "periodStartLabel": "Nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number\u00a0of RSUs", "verboseLabel": "Number of PSUs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "periodStartLabel": "Nonvested, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-Based Payments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number\u00a0of Options & SARs" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise\u00a0Price (per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r346", "r347", "r348", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsPerformanceStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsRestrictedStockUnitsDetails", "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Summary of performance stock unit" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the end of the period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r91", "r99" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r46", "r58", "r59", "r60", "r100", "r101", "r102", "r105", "r115", "r118", "r141", "r197", "r299", "r305", "r382", "r383", "r384", "r404", "r405", "r467", "r493", "r494", "r495", "r496", "r497", "r498", "r525", "r611", "r612", "r613" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement", "verboseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r100", "r101", "r102", "r141", "r567" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]", "terseLabel": "Stock options, RSUs, PSUs" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r299", "r305" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r299", "r305", "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ShareBasedPaymentsSARActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r299", "r305" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in connection with the Company\u2019s equity award plans" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r94", "r177", "r193", "r483", "r529" ], "calculation": { "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "negatedTerseLabel": "Stockholders' equity attributable to parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedBalanceSheets", "http://www.supernus.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r530", "r531" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Composition of Other Balance Sheet Items" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CompositionofOtherBalanceSheetItems" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r186", "r187", "r189", "r190", "r191", "r287", "r298", "r458", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r634", "r635", "r636", "r637", "r638", "r639", "r640" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/FairValueofFinancialInstrumentsCarryingValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r104", "r105", "r106", "r107", "r119", "r178", "r179", "r194", "r195", "r196", "r197", "r198", "r199", "r382", "r383", "r384", "r402", "r403", "r404", "r405", "r428", "r429", "r430", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r499", "r500", "r507", "r508", "r509", "r510", "r520", "r521", "r522", "r523", "r524", "r525", "r569", "r570", "r571", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/ConvertibleSeniorNotesDue2023NarrativeDetails", "http://www.supernus.com/role/EarningsperShareDetails", "http://www.supernus.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesRecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r143", "r144", "r145", "r146", "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "VIE, qualitative or quantitative information, ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r122", "r134" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r120", "r134" ], "calculation": { "http://www.supernus.com/role/EarningsperShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/CondensedConsolidatedStatementsofEarnings", "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.supernus.com/role/EarningsperShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r415": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r519": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r531": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r574": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r588": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r622": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r629": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r632": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r633": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r634": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r635": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r636": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r637": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r638": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r639": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r640": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r641": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r642": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" } }, "version": "2.1" } ZIP 96 0001356576-22-000076-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356576-22-000076-xbrl.zip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�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end